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Abstract 
Peroxisome Proliferators (PPs) are a class of chemicals that cause a programme of augmentative
liver growth, however, the mechanism which regulates the induction of hepatic DNA synthesis
as a result of exposure to peroxisome proliferators is currently uncharacterized. This study sets
out to characterise the induction of DNA synthesis in mouse by peroxisome proliferators, as a
prerequisite for investigating and identifying the genes that are responsible for induction of
DNA synthesis to control liver growth.
Administration of BrdU in drinking water can reduce mouse body weight; an optimized proto-
col was devised, which does not lead to body weight loss, and which enables reliable measure-
ment of DNA synthesis.
Male 129S4/SvJae mice were treated with a single dose of ciprofibrate (100-400 mg kg-1) or
methylclofenapate (25 mg kg-1) for two days. Although liver to body weight ratios increased
significantly at all doses, no induction in DNA synthesis was observed within 2 days. Subse-
quent time course studies with ciprofibrate (100 mg kg-1day-1) or methylclofenapate (25 mg kg-
1day-1) showed that liver-to-body weight ratio was significantly increased in treated groups by
day 2, but that the induction of DNA synthesis was increased significantly only after three days
of treatment, for both compounds. No induction of hepatic DNA synthesis was observed in
PPARD null mice after treatment with ciprofibrate (100mg kg-1day-1) for 2 or 6 days, showing
that the effect required the PPARD.
A dose-response study with 0,1,3,10,30,100 or 200 mg kg-1 day-1 ciprofibrate for 3 days, or with
0,10,30,100 mg kg-1 day-1 ciprofibrate for 4 days revealed that liver to body weight ratios were
significantly increased in 129S4/SvJae mice treated with 10mg kg-1day-1 and greater ciprofi-
brate at 3 and 4 days, whereas hepatic labelling index was significantly increased at 100 mg kg-
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1 day-1 ciprofibrate at 3 days after dosing, with progressive increases at doses of 30 and 100 mg
kg-1 day-1 ciprofibrate at 4 days after dosing. 
In order to explain the early time course of induction of DNA synthesis reported by Styles [113]
[164] in Alderley Park mice, a time course study was performed between 1-4 days in Alderley
park mice using methylclofenapate (25mg kg-1day-1). The study showed that liver growth was
induced by day 2, but DNA synthesis was significantly induced only after 3 days of dosing. 
To evaluate species differences, the time-course of induction of DNA synthesis was examined
in F-344 rats treated with ciprofibrate (50mg kg-1day-1) for 1-4 days. The liver-to-body weight
ratio was significantly increased in all time points, but DNA synthesis was significantly in-
creased after 2 days of dosing.
These finding demonstrate that there was a delay in induction of DNA synthesis by peroxisome
proliferators in mouse by at least 48 hours. This delay in response is not due to strain differenc-
es. Moreover, induction of DNA synthesis in rat was earlier than those in mouse, which makes
rats a feasible experimental model to study the immediate early genes/ proteins induced by per-
oxisome proliferators to induce liver growth.
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Chapter 1 Introduction
Section 1.1 Liver
Liver is the largest mass of glandular tissue and the second largest organ after skin in the body
[1]. It represents about 2-5% of the body weight in man and other mammals such as the rat and
mouse (human liver: 2%; rat liver 4%; mouse liver 5%) [2] [3] [4] [5]. The liver has the ability
to regulate its growth in humans and animals The liver is the main detoxifying organ of the body
and may be injured by ingested toxins. Loss of hepatic tissue by surgical removal (partial hepa-
tectomy), or liver cell loss caused by viral or chemical injury triggers a mechanism by which
hepatocytes begin to divide, continuing until the original mass of tissue is restored; text; indi-
cates, that liver knows when to start and when to stop growing during liver regeneration. This
is mediated via activation of several genes such as c-fos, c-jun and c-myc or and inhibition the
process by other factors such as TGFE [6]. The set point for liver growth is the ratio between
liver mass and body mass. This ratio enables the liver to perform the amount of metabolic work
needed to meet the functional requirements of the body. Thus, any surgical removal of tissue or
hepatic functional deficiency will induce sequential changes in gene expression in the hepato-
cyte to restore the liver mass/body mass ratio. This condition induces the liver cell to move from
quiescent state to the replicative state. On the other hand, when liver mass exceeds the bodys
functional needs, in the case of drug-induced liver growth, the liver loses mass to restore the
optimal liver mass/body mass ratio upon cessation of drug treatment [7]. 
Section 1.1.1 Physiology of the liver 
In mammals, the liver is composed of different cell types; parenchymal cells or hepatocytes
which constitute about 90% of the liver by volume and nonparenchymal cells which constitute
mainly sinusoidal lining cells and hemopoietic, bile duct and blood vessels wall cells. The sinu-
soidal lining cells consist of four types of cells: endothelial, Kupffer, fat-storing and pit (like
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natural killer) cells [2]. Unlike most organs, the liver receives blood from two sources, the he-
patic portal vein from the gastrointestinal tract which accounts for 75% of the liver's blood sup-
ply and the hepatic artery, which supplies 25% of the liver's blood. The liver consists of several
lobes and each lobe contains thousands of six-sided units called a lobule, which is a structural
and functional unit of the liver [2]. Liver has a number of essential roles in the body including
glycogen storage, plasma protein synthesis and it plays an important role in metabolism of pro-
tein and lipid [4]. The liver also has an important role in detoxification and breaking down sub-
stances such as xenobiotic chemicals and metabolic waste; there are two types of metabolism,
phase I, whereby the liver is using Cytochrome P-450 mixed function oxidase enzyme pathway
to oxidise the potential toxicant and phase II, the conjugation pathway, whereby the hepatocytes
add another substance (e.g. glutathione or a sugar) to a toxic chemical or drug to make it water-
soluble, so it can then be excreted from the body via watery fluids such as bile or urine [9]. 
There are three alternative ways to describe the structure of the liver in terms of a functional
unit: the classic lobule, the portal lobule, and the liver acinus. The classic lobule is the traditional
way that explains the structural organization of the liver (Figure 1.1). It is based on the concept
that blood flows from the periphery (portal triads) to the centre of the lobule (central vein). In
the portal lobule concept, the major exocrine function of the liver is bile secretion. Thus, this
concept defined the portal lobule as a triangular region with the portal triad as the centre and the
central veins as the apices of the triangle (Figure 1.1). Recently, the hepatic acinus unit has been
used to describe the structure of liver (Figure 1.1). It is the structural unit that provides the best
correlation between blood perfusion, metabolic activity, and liver pathology [10]. However, the
liver acinus, unlike the classic lobule, is difficult to visualize, but represents a unit that is of
more relevance to hepatic function because it is oriented around the afferent vascular system.
The hepatocytes in each liver acinus are arranged in three ellipsoidal zones: Zone 1, 2 and 3.
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Those hepatocytes closest to the arterioles (zone 1or periportal, PP) are best oxygenated because
they encircle the portal canals where the oxygenated blood from hepatic arteries enters the liver.
Oxygen tension decreases toward the centrolobular region, zone 3 [4]. Moreover, zone 1 shows
higher E-oxidation of fatty acids than zone 3. Zone 2 has no sharp boundaries, but is intermedi-
ate to both zones 1 and zone 3. Zone 3 is the region surrounding the central vein, so called cen-
trilobular or perivenous (PV). Zone 3 is characterised by higher basal levels of cytochrome
P450, ATP-citrate lyase, acetyl-CoA carboxylase and fatty acid synthase, the key enzymes of
lipogenesis as compared to zone 1 [11]. This arrangement also means that cells in the centre of
the acinus (zone 1) are the first to be exposed to, and potentially absorb, blood-borne toxins ab-
sorbed into portal blood from the small intestine
.
Section 1.1.2 Liver growth
Living cells have the ability to multiply by replication of genetic material. This multiplication
of a single cell can be divided into two essential processes: (1) the replication of DNA which
Central vein
Portal triad
The classic lobule The portal lobule The liver acinus
1 2 33 2 1 
Figure 1.1 Schematic drawing illustrating the different organization of liver lobule. Liver lobule can be
defined by three different ways. The classic lobule, which is hexagon-shaped and the lobule is filled by cords of hepatocytes
that radiate the central vein (left). The portal lobule has a portal triad in the centre and the central veins at the peripheral
angles of the lobule (center). The liver acinus, which was described as diamond or elliptical shaped, divided into three zones;
zone 1 (periportal, PP) is the closest to the axis (is the short axis between two portal triad); zone 3 (perivenous, PV) is the
furthest from the short axis; zone 2 is the area between zone 1 and 3. (Modified from Michael, 2003 [10])
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involves the incorporation of nucleotide precursors into DNA that can be detected by exposing
the cell to a DNA analogue, such as bromodeoxyuridine (BrdU); and (2) the cell splitting itself
into two daughter cells by the cell division process which consist of nuclear division (mitosis)
and cytoplasmic division (cytokinesis) [12]. In general, the cycle of proliferating cells is divided
into four stages G1, S, G2, and M phase. S phase is characterised by DNA synthesis and the
amount of DNA in the cell doubles. At the end of the S-phase, the number of chromosomes have
been replicated to 4n in diploid organisms and 2n in haploid organisms [13]. M (mitotic) phase
is characterised by two processes; mitosis (prophase, metaphase, anaphase, telophase) and cy-
tokinesis to generate two identical daughter cells. G1(first gap) is the period between the M-
phase and the S-phase. In the middle of G1, cyclin-CDKs start to prepare cells for DNA repli-
cation in the S-phase. G2 (second gap) is the phase between S- and M-phase. In G2 stage, sig-
nificant protein synthesis occurs notably the proteins for remodeling of microtubules to form
the spindle apparatus [13]. There is another stage which is the non-proliferating state of cells,
the G0 phase [14]. In normal rat liver, hepatocytes are in the G0 phase, or quiescent phase, of
the cell cycle [15]. When induced to regenerate (for example, by partial hepatectomy), hepato-
cytes enter G1 phase, which is the initial stage in the cell cycle. They proceed through the cell
cycle (G1-S-G2-M), and at the end of M phase, cell division occurs. Normally, hepatocytes may
have one or two nuclei which contain 2n, 4n, 8n and even greater DNA amounts. The existence
of binucleated hepatocytes is a consequences of DNA synthesis and mitosis with no of cell di-
vision [16]. There is a large proportion of polyploid nuclei in hepatocytes, and they are tetra-
ploid or occasionally octaploid (8n) at G0 phase [14]. For example, normal adult rat liver is
constituted from 85-90% tetraploid, 8-10% diploid and 1-3% octaploid cells. Among the tetra-
ploid cells, 65% of the cells are mononucleate and 20% are binucleate hepatocytes [17]. Since
cell division is rarely seen in hepatocytes and DNA synthesis activity in young adult rodent is
infrequent (1% of the nuclei were in the S phase), then liver regeneration, (resection of the liver)
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becomes a useful model for studying liver growth [18] [19]. Liver growth can be induced in two
different patterns: compensatory regeneration (compensatory) and primary or direct hyperplasia
(mitogen-induced liver growth). In compensatory regeneration, the DNA synthesis in the liver
is induced by a loss of liver cells such as that seen during partial hepatectomy or cell necrosis,
whereas in direct hyperplasia, DNA synthesis is induced without preceding cell loss [17] [20]
[19]. The regenerative capacity of the liver was first clearly described by the two-thirds partial
hepatectomy model in rodents by Higgins and Anderson (1931). They showed that when two
thirds of the liver is surgically removed, the remaining liver enlarges until the original liver mass
is restored at approximately 1 week after surgery when the regenerative process stops. Two
main distinct changes happened during liver regeneration. Adaptive changes, where dramatic
metabolic and circulatory perturbations were enforced due to liver mass loss and mitogenic
changes, where the 95% of hepatic cell, which are normally quiescent, rapidly re-enter a repli-
cative state [19]. In rat liver, the rate of DNA synthesis in parenchymal cells begins to increase
after about 12 hours and peaks around 24 hours, whereas in non-parenchymal cells such as
Kupffer and biliary epithelial cells it begins around 48 hours, and at ~96 hours for endothelial
cells. The onset of DNA synthesis is synchronized in hepatocytes, starting in cells that surround
the portal triad (periportal hepatocytes) of the liver lobule and then proceeding towards the cen-
tral vein, pericentral hepatocytes [21]. However, the incidence of mitotic figures (M phase) is
lower than the number of hepatocytes that undergo DNA synthesis during liver regeneration
[19]. This is because partial hepatectomy leads to hepatic polyploidy, which increase nuclear
DNA content. Moreover, cells with greater ploidy exhibit reduced  mitogenic activity and in-
crease the probability of cell death [22], and the ploidy of hepatocytes and percentage of binu-
cleate cells increases with successive rounds of DNA synthesis, which ultimately limits further
regeneration [22].
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Section 1.1.3 Control of liver cell growth
Liver has the ability to regulate its growth through controlling a complex array of signal and
transcription factors and on interaction of hepatocytes with non-parenchymal cells. Studies of
liver growth in hepatocyte culture have limited relevance to in vivo, since in vitro study fre-
quently does not mimic the liver: this may be because in vitro studies do not take into account
the extracellular growth factors or systemic factors which might be crucial for liver growth [6].
For this reason, much of the investigation on the mechanism of hepatic growth has been done
in partially hepatectomised animals. After partial hepatectomy (PH), a large number of genes
are either newly expressed or increase their expression. These genes are believed to be respon-
sible for the transit of quiescent hepatic cells into replicative cells through to two stages: the
competence stage where the cell gets the ability to enter cell cycle (G0 to G1 phase) and the
progression stage where liver cell progresses from G1 phase to undergo DNA synthesis (G1
to S phase). The G0/G1 transition involves the activation of certain genes termed immediate ear-
ly genes (primary response), whereas during the G1/S phase transition, another set of genes is
involved termed delayed response genes [6] [18] [23]. The priming phase, characterised by the
expression of immediate early genes, takes up 4 hours after partial hepatectomy, whereas in the
second phase (G1/S), hepatic cells are less synchronized than in the priming phase, since the
variation in the length of G1 time varies in cells located in different areas of liver lobule [7]. The
mechanism of liver growth during liver regeneration is quite complex. Several potential signal-
ing stimuli are released in the liver or in circulation after the loss of hepatic cells. These signals
can be classified into two main pathways: cytokine-dependent and a cytokine-independent path-
way. Cytokines such as tumor necrosis factor (TNF), interleukin-6 (IL-6), norepinephrine, are
not mitogens, but they do enable activation of an intracellular signaling cascade in the hepato-
cytes to allow the cell to passage from G0 to G1 of the cell cycle [24] [19]. In the cytokine de-
pendent pathway, after partial hepatectomy (PHx) or liver injury, immune system components
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such as lipopolysaccharide (LPS), complement factors C3a and C5a and intercellular adhesion
molecules (ICAMs,) activate kupffer cells to produce tumour necrosis factor-D (TNF-D) [25]
[26] [27] [19], which in turn up-regulates interleukin-6 (IL-6) transcription by the nuclear factor
(NF)-kB pathway [19]. TNF-D and IL-6 activate neighbouring hepatocytes to produce the tran-
scription factors, signal transducer and activator of transcription-3 (STAT3). NF-kB and
STAT3 are proteins that bind to target genes in specific recognition sites to initiate or enhance
their transactivation after partial hepatectomy within 30 min for NF-kB and 1-2 h for STAT3.
STAT3 activates transcription of ~ 36% of immediate early genes [19]. In addition to the cy-
tokine-dependent pathway, the growth-factor-mediated pathway is a second pathway involved
in liver regeneration. It has been reported that IL-6 is not a powerful hepatocyte mitogen in the
absence of partial hepatectomy [28] [19]. So, growth factors play a crucial role to drive the cell
from G1- to S-phase. Transforming growth factor (TGFD) and hepatocyte growth factor (HGF)
are considered to be the most important growth factors [29]. HGF is a paracrine factor synthe-
sised by non-parenchymal cells, particularly stellate cells. TGFD is an autocrine growth factor
produced from an active hepatocyte [30]. Both factors HGF and TGFD regulate various process-
es in the liver, as well as being direct stimulants of hepatocyte proliferation [7]. It has been re-
ported that neither of these growth factors are capable of increasing DNA synthesis in quiescent
hepatocytes in vivo [6]. In contrast, HGF and TGF increase DNA replication during the progres-
sion phase and help cells to move beyond a restriction point in G1 phase [7]. Many genes were
identified and defined as immediate early genes. By using DNA microarray analysis, there are
more than 100 immediate early genes which have been identified during liver regeneration [31]
[19]. Some of these genes show transient up-regulation, whereas others were involved in protein
synthesis and cell growth such as fos and jun family, egr-1, LRF-1, c-myc [7] [32]. Finally,
when liver is restored and restructured, the liver growth and DNA synthesis eventually stop. The
size of the liver is highly regulated and controlled, but, the signals that are controlling these
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events are poorly understood. However, the most well-known inhibitor of hepatocyte prolifer-
ation is transforming growth factor-E (TGFE) and related TNFE-family member such as activin
[33]. TNFE is produced mainly by hepatic stellate cells and it is upregulated during liver regen-
eration. It has been reported that TNFE mRNA increase within 3 to 4 hours after PHx, reaching
a plateau in the liver at 48 to 72 hours [24]. Therefore, it has been postulated that the increased
concentration of TGFE is responsible for the termination of DNA synthesis.
Section 1.2 Peroxisome proliferators
Section 1.2.1 Peroxisomes 
Peroxisomes are single-membrane bound organelles with peroxidative function. The term per-
oxisome was introduced by de Duve and Baudhuin in 1965 [34]. They are present in most
mammalian cells specially tissues active in lipid metabolism such as the liver. Peroxisomes con-
tain oxidases and catalase enzymes and oxidise a variety of substances in the liver [35]. In rat
hepatocytes, peroxisomes are normally an oval shape and comprise around 2% of the total cy-
toplasmic volume and cellular protein [36]. These organelles are easily identifiable in several
species of animal, but not human, due to the presence of urate oxidase crystalline deposits in the
matrix of these organelles. Peroxisomes have important metabolic functions, including catabol-
ic pathways such as a breakdown of polyunsaturated medium-, long- and very long-chain fatty
acids and some xenobiotics [37] and anabolic pathways such as cholesterol synthesis and
dolichol synthesis [38]. Certain chemicals are capable of increasing the size and number of per-
oxisomes, and are designated as peroxisome proliferators [36] [35] [39] [5].
Section 1.2.2 Peroxisome proliferators
Reddy and Krishnakantha were the first people who used peroxisome proliferators to describe
the hypolipidemic drug clofibrate and other structurally diverse chemicals causing hepatic per-
oxisome proliferation [39]. Peroxisome proliferators are a diverse group of chemicals that do
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not necessarily have similar structure but all induce characteristic effects in the liver of treated
rats and mice. The initial hepatic response in rodents is a dramatic increase in the size and num-
ber of peroxisomes up to 25% of hepatocyte cytoplasmic volume in association with the induc-
tion of some enzymes such as Cytochrome P450 4A [35]. In addition, these compounds cause
a marked increase in liver weight (hepatomegaly) of susceptible species in the form of both hy-
perplasia and hypertrophy. Hepatocyte hypertrophy is a result of an increase in the size of liver
cells with an increase in the numbers and size of subcellular organelles such as peroxisomes,
mitochondria and smooth endoplasmic reticulum [36]. In contrast, hyperplasia is an increase of
in the number of liver cells due to replicative DNA synthesis. Peroxisome proliferators include
hypolipidemic drugs, plasticizers and organic solvents used in the chemical industry, herbi-
cides, and naturally occurring hormones such as dehydroepiandrosterone. Peroxisome prolifer-
ators are excellent models for the study of liver growth and liver tumorigenesis because the liver
is a target organ of many non-genotoxic compounds including PP and these chemicals regulate
gene transcription through a receptor, PPARD, which is expressed in hepatocytes [40] [41].
Section 1.2.3 Chemical structure of peroxisome proliferators
Efforts have been made to reveal the structure-activity relationship of compounds causing pro-
liferation of peroxisomes. For example, many peroxisome proliferators contain an acidic func-
tion [36]. This acidic function is normally a carboxyl group, either present in the parent structure
or generated by metabolism such as clofibrate, which is metabolized to clofibric acid. On the
other hand, Reddy and Lalwai (1983) classified these compounds into several groups; clofibrate
and its analogues, plasticizers, other compounds, and dietary and other factors [5]. Bentley re-
ported that compounds and physiological factors, which have been shown to induce peroxisome
proliferation can be arranged into groups based on chemical structure (Table 1.1). Recently, it
has been concluded that a lipophilic anion is the ultimate structure to induce peroxisome prolif-
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eration [42].
 
Group Example Structure
2-Phenoxyacetic acids Ciprofibrate
2-Phenoxyacetic acid 
and analogues
WY-14,643
n-alkylcarboxylic acids Palmitic acid
n-alkylcarboxylic acids 
and their precursors
Di-(2-ethylhexyl)adipate
Long-chain aklyldicar-
boxylic acid and their 
precursors
Hexadecanedioic acid 
Table 1.1 Classification of peroxisome proliferators based on chemical structure. 
HOOC-(CH2)14-COOH
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Section 1.2.4 Effects of non-genotoxic agents
Chemical carcinogens can be classified into two classes based on their mechanisms of action:
genotoxic carcinogens and non-genotoxic (epigenetic) carcinogens. Genotoxic carcinogens are
either immediately electrophilic or are metabolically activated by endogenous enzymes to high-
ly reactive electrophilic compounds that will covalently interact with DNA to cause mutation,
and ultimately cell transformation [43]. In contrast, non-genotoxic (epigenetic) carcinogens
cause cell transformation through mechanisms that do not involve direct DNA damage [43].
Alkyl-aryl carboxy-
lic acids and their pre-
cursors
Gemfibrozil
O-substituted benzoic 
acids and their precur-
sors
Aspirin
Non-carboxylic acids 
and their precursors
Thyroid hormone (T4)
Other compound and 
physiological factors
Dihydroepiandrosterone 
acetate
Group Example Structure
Table 1.1 Classification of peroxisome proliferators based on chemical structure. 
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Non-genotoxic agents constitute a diverse group of chemicals. Some of these group cause acute
liver injury followed by regenerative hyperplasia such as carbon tetrachloride [44], whereas
other groups cause cell proliferation without tissue damage such as peroxisome proliferators
class [45]. In the liver, tissue damage is indicated by an increase in liver-specific enzyme such
as alanine aminotransferase (ALT), in the serum [46]. Other examples of non-genotoxic hepa-
tocarcinogens are phenobarbital and TCPOBOP (1,4-bis[2-(3,5-dichloropyridyloxy)] benzene).
These compounds are ligands of the constitutive androstane receptor (CAR), a member of the
nuclear hormone receptor superfamily [47] [48]. Phenobarbital and TCPOBOP have been re-
ported to increase DNA synthesis in hepatocytes [206] [49].
Section 1.2.5 Peroxisome proliferators are non-genotoxic carcinogen
Peroxisome proliferators (PPs) are one of the most widespread of non-genotoxic (non-mutagen-
ic) class of carcinogen. Unlike genotoxic carcinogens, peroxisome proliferators do not give a
positive result with mutagenicity tests but are still able to perturb hepatocyte proliferation
through altered gene expression or interruption of growth-regulatory signal transduction path-
ways [50]. In addition, several years ago, data has been generated to support the concept that a
large fraction of carcinogens are not mutagenic and do not directly damage DNA [51]. Current
estimates are that about half of all rodent carcinogens are mutagens and that the other half is not
mutagenic [52]. Several tests for genotoxicity of peroxisome proliferators have failed to detect
any damage to DNA. In vivo, the peroxisome proliferator, WY 14,643, failed to induce unsched-
uled DNA synthesis in rat hepatocytes following treatment at a dose which induces liver cancer
[53]. Galloway et al. (2000) reported no evidence of chromosome aberration induction with
nafenopin in Chinese hamster ovary (CHO) cells at dose up to the level that are toxic to CHO
cells. Moreover, an extensive literature review for 18 peroxisome proliferators concluded that
peroxisome proliferators are predominantly non genotoxic [51]. Some peroxisome proliferators
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show a weak positive response in the genotoxicity test. For example, ciprofibrate shows a pos-
itive effect with genotoxicity tests, sister chromatid exchange (SCE), chromosomal aberration
(CA), and micronuclei (MN) in rat hepatocytes [54]. However, ciprofibrate gave negative result
with unscheduled DNA synthesis (UDS) and Ames tests [55]. Nilsson et al. (1991) who exam-
ined the ability of ciprofibrate to induce chromosomal damage in Wistar rats after treatment
with 750 mg kg-1day-1 ciprofibrate for 14 days. Hepatocyte were then isolated and examined
for micronuclei and chromosomal aberration. Ciprofibrate did not show any increase in chro-
mosomal damage as compared to control [56]. The highly sensitive 32P-postlabeling assay was
employed to detect peroxisome proliferator-DNA adducts in male F-344 rats treated with clofi-
brate, ciprofibrate, Wy-14643 or di(2-ethylhexyl)phthalate in vivo and in vitro. No adducts were
detected by this assay in the DNA isolated from the livers of rats treated in vivo or in vitro with
any of the peroxisome proliferators [57]. 
Section 1.3 The nuclear receptor superfamily
Nuclear receptors are a class of proteins located inside cells that are responsible for mediating
the action of hormones and certain other molecules. They have the ability to directly bind to
DNA at specific sites and regulate the expression of adjacent genes, hence these receptors are
classified as transcription factors. So they serve as on-off switches for transcription within the
cell nucleus. The nuclear receptor superfamily includes nuclear hormone receptors (NHRs) and
orphan nuclear receptors. NHRs are receptors for which hormonal ligands have been identified,
whereas orphan receptors have a similar structure to other identified receptors but their ligands
are unknown, at least at the time the receptor is identified [58]. Manglesdorf et al. (1995) pro-
posed four categories of nuclear receptors; Class I receptors, which are located in the cytosol
when ligands bind to it before they translocate from the cytosol to nucleus. They work as ho-
modimers binding to half-site hormone response elements (HREs) inverted repeats. Class I has
subfamily estrogen-like receptors, that include estrogen receptor (ER) group. Class II receptors,
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in contrast to class I, exist in the nucleus before binding to ligands, and bind as heterodimers
with RXR receptor partners and function in a ligand dependent manner. Class II has subfamily
thyroid hormone receptor-like that include different receptors such as thyroid hormone receptor
(THR), and retinoic acid receptors (RAR), constitutive androstane receptor (CAR), and perox-
isome proliferator receptors (PPAR). Class III nuclear receptors are similar to class I receptors
in that both classes bind to DNA as homodimers, but class III in contrast to class I nuclear re-
ceptors, bind to direct repeat instead of inverted repeat HREs. Class III has subfamily retinoid
X receptor-like which include Retinoid X receptor (RXR). Class IV are the nuclear receptors
that bind either as monomers or dimers, but only a single DNA binding domain of the receptor
binds to a single half site HRE. The last two classes are considered to be orphan receptors [59]. 
The regulation of gene expression by nuclear receptors is ligand dependent. In other words, nu-
clear receptors normally are only active in the presence of ligand. More specifically, ligand
binding to a nuclear receptor results in a conformational change in the receptor which in turn
activates the receptor resulting in up-regulation of gene expression [60] 
Section 1.4 Mechanism of Peroxisome proliferation: receptor-mediated 
mechanism
It was hypothesized that effects induced by peroxisome proliferators were the result of a recep-
tor-mediated mechanism [5]. This hypothesis remained until the receptor was cloned from
mouse liver by Issemann and Green in 1990 and called peroxisome proliferator-activated recep-
torD (PPARD[61]. To date, three different isoforms of PPAR were cloned: PPARD, PPARE/
G and PPARJ. The different PPARs appear to perform distinct physiological functions. PPARJ
was cloned from several mammalian species including human. PPARJis expressed at high lev-
els in adipose tissue, and is an important regulator of adipocyte differentiation and lipid metab-
olism [62]. In mouse, there are two PPARJisoforms have been described, that is, J1 and J2[63].
PPARJ is found mainly in liver, whereas PPARJ is expressed exclusively in adipose tissue
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[64]. PPAREG is widely expressed in a wide range of tissues and cells, with relatively higher
levels expression in adipose tissues, brain, skin, heart, kidney, and digestive tract [62]. PPARD
has critical roles in regulation of fatty acid metabolism. It mediates the expression of genes en-
coding both peroxisomal and mitochondrial fatty acid metabolizing enzymes at both the consti-
tutive and inducible level in tissues such as liver, kidney, heart, and intestinal mucosa [43] [61]. 
PPAR isoforms Action
PPARD - Serve as receptor for diverse compounds,
e.g. fibrates that induce hepatic peroxisome
proliferation, hepatomegaly, hepatocarcino-
genesis, and activate expression of several
enzymes such as CYP4A in rodent.
- Plays a critical roles in the E-oxidation fatty
acid and lipid metabolism.
- Induce expression of the fatty acid transport
protein.
- Upregulates transcription of long chain fatty
acid acetyl-CoA synthase [65].
- Regulation of inflammation [64]
PPAREG - Developmental and physiological roles in 
adipose tissues, brain, skin, heart, kidney, 
and digestive tract tissues [62]
- Play a critical role in the control of keratino-
cyte proliferation and helping in rapid heal-
ing of a skin wound in mouse [66]
- Play an important role in adipocyte prolifer-
ation and differentiation [67] [62]
Table 1.2 The physiological actions of PPAR isoforms . 
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PPARD target genes encodes for the microsomal CYP4A family (CYP4A1 and 4A3) and sev-
eral cell recognition surface proteins including CD24 and CD39 [35]. After murine PPARD was
cloned, several PPARs have been cloned from different species such as frog [68], rat [69], rabbit
[70], and human [40]. 
Section 1.4.1 Mode of action of PPARs 
PPAR receptors, like other nuclear receptors, have four functional domains: the ligand-indepen-
dent transcriptional activation function domain (AF-1) that works in a cell-specific manner; the
highly conserved DNA-binding domain (DBD) holding two zinc finger DNA binding motifs
that target the receptor to specific DNA sequences called PP response elements PPRE in respon-
sive genes; the ligand-binding domain (LBD), is responsible for interacting with a broad range
of ligands and responsible for conversion of PPAR from an inactive form to a form that can bind
DNA.[64]. Ligand-dependent activation function domain (AF-2) is involved in the generation
of the receptorcoactivator binding site Figure 1.2. In rodents, PPARD regulates transcription of
a number of genes by binding to a specific DNA regulatory element located in the upstream pro-
moter region of these genes. In the beginning, a peroxisome proliferator binds to a specific site
in PPARD which then heterodimerises with an other receptor, the retinoid X receptor, the re-
PPARJ - Regulates the expression of numerous genes 
involved in lipid metabolism, including 
acyl-CoA synthase and lipoprotein lipase 
[65]
- Plays an important role in the differentiation, 
proliferation, and programmed cell death of 
adipocytes.
- Participating in the regulation of glucose and 
lipid homeostasis, immune function, and cell 
growth regulation [62].
PPAR isoforms Action
Table 1.2 The physiological actions of PPAR isoforms . 
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ceptor for 9-cis-retinoic acid (9c-RA). The ligand induces allosteric changes within the LBD
that regulate interactions with coactivator and corepressor complexes, which can further control
the transcriptional activities of the nuclear receptors [71]. The heterodimer, PPARRXR, binds
to the consensus PPRE as a direct repeat of two AGGTCA X AGGTCA. Interaction between
the PPARRXR heterodimer and other transcription factors such as coactivators or corepressors
leads to either increases or decreases in transcription of target genes Figure 1.3. Gene regulated
by PPREs may contain sequences that are not uniform, as they may differ by five nucleotides
at maximum. For example, Rat CYP4A1 has a PPRE sequence TCCCCT C TGACCT [72], Rat
acyl-CoA oxidase has PPRE sequence TGACCT T TGTCCT [73], and human fatty acyl-CoA
has PPRE sequence: AGGTCA G CTGTCA [74]. 
COOHAF-1 DBD Hinge LBD AF-2NH2
Figure 1.2 Functional domain of peroxisome proliferator activated receptor (PPARs). As any
nuclear receptor, PPAR protein has five domains, activation function domain (AF-1) in N-terminal. DNA-bind-
ing domain (DBD) consisting of two highly conserved zinc-finger motifs that bind the receptor to specific DNA
sequences. a hinge region that allows flexibility of the nuclear receptors to dimerise to other nuclear receptors
and binding to DNA. a large region containing the ligand-binding domain (LBD). Finally a second ligand depen-
dent activation function domain (AF-2) at the c-terminal.(Modified from Li and Palinski 2006 [212])
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Section 1.4.2 The Genetic variation in PPARD
Tugwood has reported that there are variants in the human PPARD gene. These included Thr71
to Met, Lys123 to Met, Ala268 to Val, Gly296 to Ala, and Val444 to Ala [75]. It has been proposed
that the amounts of PPARD mRNA expression in the liver were behind the difference between
responsive and non-responsive species since there was an estimation that human hepatocytes
express around 5-10% of the levels found in rodent hepatocytes [76]. However, despite the low
levels of mRNA, humans are still able to respond to PPs by decreasing serum lipid levels [77].
Section 1.4.3 PPARD knockout mice
PPARD KO mice are very informative to study relationship between the PPARD receptor and
livers response to peroxisome proliferators. Although mPPARD was shown to be activated by
peroxisome proliferators [78] [79] [80], it was not known if peroxisome proliferation can also
be stimulated by other receptor isoforms (mPPARGmPPARJand mPPARE). It was also un-
Modulator protein
LBD LBD
DBD DBD
RXR PPAR
PP9c-RA
Transcription alteration
Figure 1.3 Mechanism of gene transcription by a peroxisome proliferator-
activated receptor.  peroxisome proliferator (PP) binds to PPAR via LBD to activate the re-
ceptor, and then heterodimer with the retinoid X receptor (RXR), the receptor for 9-cis-retinoic
acid (9c-RA). The PPAR-RXR heterodimer, through their DNA-binding domains (DBD), binds
to the consensus sequence 5-AGGTCA-X-AGGTCA-3. Interactions between the PPAR-RXR
heterodimer, modulator proteins, and the transcription machinery initiate transcription process.
(Modified from Corton 2000 [64])
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clear whether the retinoid X receptor (RXR) is required for mPPARD activity in vivo. The gen-
eration of PPARD null mice has added much information in understanding the role of this
receptor in peroxisome proliferation and lipid metabolism. Gonzalez has developed a line of
mPPARD-deficient mice as a model to test the hypothesis that PPARD mediates the pleiotropic
response of peroxisome proliferators by disrupting the ligand-binding domain of the isoform of
mouse PPAR (mPPARD) by homologous recombination [81]. PPARD mutant mice are fertile
and healthy, but do not display the pleiotrophic effects of hepatomegaly, peroxisome prolifera-
tion or hepatocarcinogenesis that appear on the wild-type mice [81]. Evidence for the involve-
ment of PPARD in replicative DNA synthesis and hepatocarcinogenesis comes largely from
work with PPARD-null mice following dietary exposure to WY 14,643. In these studies, it was
shown that wild-type (129S4/SvJae) mice showed increased hepatic labeling by bromodeoxyu-
ridine (BrDU) compared to controls while no increase in hepatic labeling index was observed
in the Sv129 ter PPARD null mice. Also, chronic treatment with WY14,643 resulted in a 100%
incidence of hepatocellular neoplasia in wild type mice while the null mice were unaffected
[82]. Further analyses revealed that the basal expression of seven mitochondrial enzymes in the
liver, including very-long-chain acyl-CoA dehydrogenase, long chain acyl-CoA dehydroge-
nase, long chain acyl-CoA synthetase, and short chain-specific 3-ketoacyl-CoA thiolase, are
lower in Sv/129 PPARD-null mice as compared to wild-type animals [83]. This latter study em-
phases the importance of PPARD for the constitutive level of mitochondrial E-oxidation. In con-
trast, the constitutive expression of enzymes involved in peroxisomal E-oxidation of very long-
chain fatty acids, lignoceric acid, was unaffected in PPARD null mice (Sv/129), suggesting that
constitutive expression of enzymes involved in peroxisomal E-oxidation is independent in
PPAR-null mouse livers. Thus, it is clear that this receptor plays a necessary role in PPARD-
ligand-induced peroxisome proliferation and cell proliferation in the liver, and subsequent in-
creases in hepatocellular tumors.[83] [64].
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Section 1.5  Induction of hepatic DNA synthesis by peroxisome prolifera-
tors
Section 1.5.1 Acute effects of peroxisome proliferators 
Exposure to peroxisome proliferators in short term causes marked changes in liver characteris-
tics. These changes are associated with hepatocyte hypertrophy and hyperplasia and induction
of many peroxisomal, mitochondrial enzymes and cytochrome p450 which are involved in fatty
acid metabolism [84] [42]. Several reports have been published showing that liver enlargement
in male rats occurs within a few days of administering the peroxisome proliferators and reaches
a steady-state level within 10 to 14 days [85] [5]. The liver weight returns to normal usually
within 10 to 14 days after the cessation of administration of a peroxisome proliferator [5]. The
comparison of acute and chronic effects of peroxisome proliferators methylclofenapate (MCP)
rat liver was studied by Barrass et al.[86]. After acute (1 week) and chronic (26 week) treatment
with MCP, the relative liver weight was significantly increased to 170% of control and to 231%
of control respectively. Peroxisome proliferation as assessed by palmitoyl CoA oxidation was
also increased 17 and 12- fold over controls. Hepatic DNA replication and labelling indices
were also increased 5 and 5.7-fold over controls. The hepatomegaly is maintained for as long as
the PP is administered. This hyperplastic or mitogenic effect is maximum during the first week
of the treatment as assessed by Bromodeoxyuridine (BrdU) incorporation with immunohis-
tochemistry technique [87]. 
Sex differences studies on acute effect of peroxisome proliferators have been published. Naka-
jima et al. (2000) reported that the peroxisome proliferator trichloroethylene (0.75g/kg for 2
weeks by gavage) did not show any sex differences in peroxisome proliferation in SV/129 mice,
but the induction of PPARD protein and mRNA was greater in males than females [88]. In ad-
dition, other studies have reported that peroxisome proliferators perfluoro-octanoic acid [89],
and dehydroepiandrosterone [90] cause a greater induction of peroxisome proliferation and per-
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oxisomal E-oxidation in male rat than in female.
Section 1.5.2 Chronic effects of peroxisome proliferators
Chronic exposure of rodents to peroxisome proliferators not only induces cell proliferation, but
will lead to tumour growth [5]. Long-term administration of peroxisome proliferators to rodents
is associated with increased risk of hepatocarcinogenesis [43]. This incidence of tumorigenesis
depends on PP potency, species, and the dose [36]. Many peroxisome proliferators have been
reported to produce liver tumors, including hepatocellular carcinoma in life-long feeding of rats
or mice, although to a different extent. For example, potent compounds (e.g. Ciprofibrate, Wy-
14,643) may produce 100% incidence of tumors within a short period (40-60 weeks), whereas
weaker agents (e.g. Clofibrate, DEHP) may require two years of administration to produce he-
patocellular carcinomas [91] [36] [92]. Long term administration of the PPARD agonist, Wy
14,643, for 11 months caused a 100% incidence of liver tumors in Sv 129 wild type mice,
whereas PPARD-null mice were refractory to this effect [82]. In conclusion, marked compound
potency differences are known to exist. The mechanism by which peroxisome proliferators
cause liver cancer is not currently understood [93]. Several mechanisms have been proposed to
account for peroxisome proliferator-induced hepatocarcinogenesis. These hypotheses include
oxidative stress and promotion of liver preneoplastic lesions (see Section 1.9.3).
Section 1.6 Species differences in response to peroxisome proliferators
Many studies have investigated species differences in hepatic peroxisome proliferation [77]
[94] [45] [5] [95]. Clearly the rat and mouse are the most sensitive species to peroxisome pro-
liferators [96] [97] [94] [36] [98] [99], whereas the hamster shows an intermediate response
[100] and guinea pig, monkey, and human appear to be relatively insensitive comparing to the
mouse and rat [51] [101] [102] [77] [103] [98]. Several studies have examined the effect of the
PPARD agonist, diethylhexylphthalate (DEHP), on different species both in vivo and in vitro.
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In an in vivo study, after 4 days of exposure to DEHP, F-344 rats exhibited induction in perox-
isomal E-oxidation, DNA synthesis and suppression of apoptosis. In contrast, there was no re-
sponse of guinea pig liver to DEHP [104]. In rat hepatocytes in vitro, mono (2-
ethylhexyl)phthalate (MEHP), a principal metabolite of DEHP, induced peroxisomal E-oxida-
tion, DNA synthesis and suppressed apoptosis. In contrast to the pleiotropic response noted in
rat hepatocytes, there was no response of human hepatocytes to MEHP [105] [104]. More stud-
ies with a variety of compounds including ciprofibrate, methylclofenapate, DEHP, and
nafenopin have demonstrated that the Syrian hamster exhibit an intermediate response, whereas
in most studies the guinea pig is either nonresponsive or refractory [101] [94] [106] [98] [107]
[108]. Other studies have evaluated species differences in cell replication and hepatocarcino-
genesis. Although nafenopin and Wy-14,643 were potent mitogens in rat liver, they do not ap-
pear to stimulate replicative DNA synthesis in Syrian hamster hepatocytes after either acute or
chronic treatment [109] [110]. 
Lake et al. (2000) have evaluated species differences of rats (Male SpragueDawley), hamsters
(Syrian) and guinea pigs (DunkinHartley) in the hepatic effects of three potent rodent peroxi-
some proliferators, namely methylclofenapate (MCP), ciprofibrate (CIP) and Wy-14,643 (WY),
on hepatic peroxisomal and microsomal fatty acids enzyme activities, CYP4A mRNA level,
replicative DNA synthesis and transforming growth factor-E1 (TGF-E1) gene expression. He
showed that relative liver weights were significantly increased in treated rats and hamsters, but
not in guinea pigs. In addition, peroxisomal palmitoyl-CoA oxidation and microsomal lauric
acid 12-hydroxylase fatty acid oxidising enzyme activities and CYP4A isoform mRNA levels
were significantly increased in rats and Syrian hamsters, whereas only minor effects were ob-
served in the guinea pig. Labelling indices were increased by MCP in the rat, but neither MCP,
CIP nor WY produced any significant effect on replicative DNA synthesis in the Syrian hamster
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and guinea pig [111]. Similarly, no peroxisome proliferating was found in human liver of a
group males and female received fenofibrate for between 6 to 36 months [112]. However, hu-
mans are still able to respond to PPs by lowering serum lipid levels [77]. These results provide
further evidence for distinct species differences in response to peroxisome proliferators
Section 1.7 Strain differences in induction of DNA synthesis
It is well known that peroxisome proliferators exhibited species differences in PP-induced
pleiotropic effects (Section 1.6), with maximal effects in rats and mice e.g. [113]. However, lit-
tle information is available about strain differences in the effect of peroxisome proliferators ei-
ther in mice or rats. Some mouse strains show variation in susceptibility to liver-tumor
induction by genotoxins. For example, mouse strain C3H/HeJ are approximately 50-fold more
susceptible to liver-tumor induction by diethylnitrosamine (DEN) or ethylnitrosourea (ENU)
than C57BL/6J mice [114] [115]. However, bioassays have not been performed with peroxi-
some proliferators to determine if there is a strain difference in peroxisome proliferator-induced
tumorigenesis. A study by Dwivedi et al. (1989) [3] examined that the hepatic effect of cipro-
fibrate over 2 weeks in nine stains of mice, C3H/HeN, B6C3F1, CFW, CF-1, CB6F-1, CBA/
Ca, BALB/cAnN, DBA/2N, C3FeB6F1/J. The study revealed that C3H/HeN mice showed no
significant induction of hepatic DNA synthesis, but all other stains showed approximately the
same levels of DNA induction. However, the C3H/HeN mouse strain showed a trend for DNA
induction. Dwivedi et al. concluded there was no significant strain difference in ciprofibrate-
induced hepatic pleiotropic response across the mice strains [3].
In rats, Biegel et al.(1992) [116] demonstrated the strain differences in peroxisome proliferation
and hepatic cell replication in rat strain; F344 and CD BR (CD). He showed that basal E-oxida-
tion activity, a metabolic marker of peroxisome proliferation and hepatic cell replication were
about twofold higher in CD than F344. After treatment with WY-14,643 (1000ppm), peroxi-
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some proliferation and DNA synthesis in CD rats were significantly higher (~2-fold) than those
in F344 rats [116]. Ciprofibrate induced a ninefold increase in peroxisomal fatty acyl-CoA ox-
idase in Sprague-Dawley, Wister and F344 strains, whereas a marked 35-fold was noted in
Long-Evan strain [117]. 
Section 1.8 The biology of hepatocarcinogenesis
Cell proliferation plays a fundamental role in the initiation of liver carcinogenesis and DNA rep-
lication is required to sustain a permanent mutation. Columbano et al. (1981) showed that rats
treated with nonnecrogenic dose of a genotoxic carcinogen have shown very few or no foci.
However, when the genotoxic carcinogen was coupled with a cell-proliferative stimulus such as
partial hepatectomy, foci of preneoplastic hepatocytes were detected [118].
Cancer is a diverse class of diseases resulting from failure of mechanism that control the growth
and proliferation cells [13]. Cancer differs widely in their causes and biology. During normal
development, cells are in balance between cell division and death. However, in cancer cells, this
balance is interrupted and the cancer cells start to grow without respect to normal limits [13].
For this reason, the cancer cells could invade and destroy adjacent tissues, and may spread to
distant anatomic sites through a process called metastasis. So, cancer can be classified in to two
types: benign or malignant tumor. Benign tumors are characterised by an inability to spread to
other parts of the body or invade other tissues, and they are rarely a threat to life unless they
compress vital structures [119]. Moreover, benign tumor are encapsulated usually by a fibrous
capsule, which make it distinct from malignant tumor [13]. In contrast, cells composing a ma-
lignant cancer are differentiated from benign tumors in that they grow and divide rapidly, and
invade nearby tissue and other organs, spread to distant locations (metastasis) and become life
threatening [13]. Cancer may affect different organs in the body such as lung, breast, stomach
and liver [119]. Liver cancer is the sixth most common cancer worldwide in terms of numbers
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of cases (626,000 or 5.7% of new cancer cases). It is the third most common cause of death from
cancer [120]. Basically, liver tumors can be classified either as primary (which originate in the
liver itself) or secondary where the cancer started in another part of the body and has spread to
the liver by a process called metastasis. Liver is consider to be a common site for metastasis
from other organs. The most common types of benign liver tumors, include hemangiomas (a
swelling or cluster of blood vessel cells), focal nodular hyperplasia and adenomas (a cluster of
hepatocytes, often encapsulated). The most common type of diagnosed malignant liver tumors
is hepatocellular carcinoma, HCC [121] [122], these tumors arise from hepatocytes. The second
most common tumor in the liver is the cholangiocarcinoma (7-15%), these tumors arise form
bile duct cells [123]. Rare types of malignant liver tumors include, angiosarcomas (from blood
vessel endothelial cell tumor) and lymphomas (from Kupffer cells). Liver carcinogenesis is
characterized by the sequential stages defined as initiation, promotion and progression [124].
The initial stage is irreversible cellular alteration caused by a carcinogen resulting in the gener-
ation of mutation. Some initiators of liver tumour are able to interact directly with DNA such as
methylnitrosurea (MNU), while many chemical carcinogens need to be enzymatically activated
to electrophilic analogs mainly by microsomal cytochrome systems before they act as attack
DNA such as Benzo[a]pyrene [125]. It has been published that treatment of rats with single dose
of DEN (10 to 30 mg kg-1) produces irreversible liver foci and if the single dose DEN treatment
is preceded by 2/3 partial hepatectomy 20 to 24h earlier, the number of irreversible foci is in-
creased tenfold [126]. The second stage is promotion which causes pre-neoplastic cells to pro-
liferate. The promotion can be reversible or irreversible [124]. In the rat liver, tumor promotors
have been found to stimulate proliferation as well as to inhibit apoptosis both in normal hepa-
tocytes, foci, and nodules. In addition the response is much stronger in the preneoplastic islands
[211]. Some promoters exhibit specificity and differentiation on the stimulation of initiated
cells. For example, 2-acetylaminofluorene (2-AAF) can promote the outgrowth of foci and nod-
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ules without stimulating normal liver growth of rat [127]. It has also reported that phenobarbital
promotes the outgrowth of preneoplastic rat liver foci initiated by DEN, but has no effect on foci
initiated by aflatoxin B1 [128]. Cattley et al. (1994) also has examined the hypothesis that pro-
moting activity for peroxisome proliferators depends on selection of the initiating agent by
treating the rats with WY-14,643 or clofibrate after rats were initiated with either 2-acetylam-
inofluorene (2-AAF) or diethylnitrosamine (DEN). Homogeneous basophilic foci were ob-
served in PP-treated rats initiated with DEN, but not with PP-treated rats initiated with 2-AAF
[129]. Non-genotoxic carcinogens are believed in many cases to play a role in inducing hyper-
plasia resulting in tumour promotion [130]. Peroxisome proliferators as non-genotoxic carcin-
ogens promote the development of preneoplastic foci following initiation with DEN. Moreover,
administration of peroxisome proliferator without initiation can also lead to formation of focal
lesions after 5 to 6 months, neoplastic nodules after 6 to 12 months, and hepatocellular carcino-
ma after 1 to 2 years [131]. The final step in the hepatocellular process is progression which is
transformation of initiated cells to the fully malignant phenotype. In this stage preneoplastic foci
transform into neoplastic nodules after a few months after the start of the carcinogen treatment.
Like preneoplastic foci, nodules have been shown to be clonal in origin and have elevated pro-
liferative activity. Neoplastic nodules may be divided into at least two distinct subgroup, revers-
ible and persistent nodules [124].
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Section 1.9 Peroxisome proliferator-induced hepatocarcinogenesis in 
rodents
Several mechanisms have been proposed to describe the action of peroxisome proliferator in in-
duction of hepatocarcinogenesis in rodents. These hypotheses include: (a) The oxidative stress
model, (b) enhanced cell replication, and (c) the promotion of spontaneous preneoplastic le-
sions. 
Section 1.9.1 Oxidative stress hypothesis
The oxidative stress is hypothesized to be a common pathway for many non-genotoxic chemical
carcinogen [132]. However, the role of oxidative stress has been questioned. The oxidative
stress hypothesis is based on the hypothesis that long term administration of peroxisome prolif-
erators produces a sustained oxidative stress in rodent hepatocytes due to an imbalance in the
production and degradation of hydrogen peroxide [133] [134]. In rodent liver, peroxisome pro-
liferators markedly increase peroxisomal fatty acid E-oxidation and the H2O2-generating en-
zyme acyl-CoA oxidase but only yield a small increase in catalase activity [42]. Thus, the
hypothesis is that excess production of hydrogen peroxide from the E-oxidation pathway is not
destroyed by peroxisomal catalase will, and diffuse easily across the peroxisome membrane to
the cytoplasm where it will be degraded by other enzymes, such as glutathione peroxidase.
However, cytosolic selenium-dependent glutathione peroxidase activity and other enzymes
such as superoxide dismutase and glutathione S-transferase, cytoplasmic enzymes capable of
degrading H2O2, are often reduced by PPs [109] [134]. Thus, excess production of H2O2 could
result in H2O2 in the cytoplasm, where it can attack membranes and DNA either directly or via
other reactive oxygen species [43] [36] [109]. However, this hypothesis does not match with
other findings. Tamura et al.(1990) [135] has examined whether H2O2 has a role in PP-induced
hepatocarcinogenesis in vivo and in vitro using F-344 rat fed clofibrate, bezafibrate and DEHP
for up to 78 weeks. Hepatic hydrogen peroxide increased slightly by these chemicals. The rate
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of leakage of peroxisomal H2O2 into cytosol increased 2.5-4-fold. In contrast, the hepatocellular
contents of H2O2 were not affected by the induction. Moreover, the H2O2 leaked from peroxi-
some into cytosol would be quickly decomposed. Thus, peroxisomal H2O2 does not appear to
play an important role in liver tumour [135].
Weak evidence exists for the hypothesis that increasing H2O2 in PP-treated animals leads to
DNA adduct formation and hepatocarcinogenesis. Conway has reported no increase in exhala-
tion of ethane, a sensitive indicator of oxidative damage, on F-344 rats fed WY 14,643 for 23
to 345 days [136]. Formation of DNA adducts after exposure to peroxisome proliferators is also
very low. Oxygen radicals can attack DNA to form a variety of modified DNA bases including
8-hydroxydeoxyguanoside (8-OHdG). These adducts can lead to mutation during DNA replica-
tion. Treatment with a number of peroxisome proliferators has been reported to increase levels
of 8-OHdG in rat hepatic DNA [137] [138]. However, such increases are small and do not cor-
relate with chemical potency of peroxisome proliferators. For example, F-344 rats fed either
ciprofibrate (0.025%), DEHP (1.2%) or DEHP(2.5%) exhibited little difference in the level of
8-OHdG [137] [138] but substantial differences in carcinogenic potency. Another study report-
ed that 8-OHdG did not increase in rats treated with WY-14,643, (0.1% or 0.005%); di(2-eth-
ylhexyl)phthalate (1.2%); clofibric acid (0.5%) or phenobarbital (0.05%) for 3 or 11 weeks
[139]. Most studies of 8-OHdG have utilized whole liver homogenate which contain nuclear
and mitochondrial DNA, and normal levels of 8-OHdG in mitochondrial DNA are 16-fold
greater than in nuclear DNA due to the extensive oxygen metabolism in these organelles [140].
Isolated hepatic nuclei also exhibited no increase in adduct 8-OHdG in PP-treated rats [139].
Recently, a new approach was introduced to assess oxidative DNA damage by Rusyn et al.
(2000) [141]. The base excision repair (BER) system is a multiple enzyme system responsible
for repairing oxidative DNA damage [141]. BER enzymes are induced in vivo and in vitro by
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oxidative stress. The primary pathway for 8-OHdG removal is the enzymes OGG1, a glycosy-
lase/lyase, AP endonuclease (APE), polymerase (Pol) and ligase [142]. Rusyn et al. have report-
ed that PPs with varying carcinogenic potency induce the BER system in both rat and mouse
liver in a dose-, time-, and carcinogenic potency-dependent fashion. This work provide evi-
dence for the role of oxidative stress in PP-mediated carcinogenesis [141]
Although there is much speculation in the literature that oxidative stress may play a role in PP-
induced hepatocarcinogenesis through increasing in hydrogen peroxide after chronic adminis-
tration of PP, the evidence does not support the oxidative stress hypothesis as a model to explain
the mechanism of PP-induced hepatocarcinogenesis. For example, the evidence is poor that
there is mutation of DNA when animals are given peroxisome proliferators. Wy 14,643 at car-
cinogenic levels had no effect on unscheduled DNA synthesis [53].
Section 1.9.2 Enhanced cell replication
Cell division plays a critical role in the initiation stage of carcinogenesis. It has been proposed
that any agent that causes persistent cell replication can be indirectly mutagenic because cell
replication can increase the frequency of spontaneous mutations and the probability of convert-
ing DNA adducts into mutations before they can be repaired [143]. Cell replication is also an
important factor in the promotion and progression of initiated cells into tumors. Peroxisome
proliferators are known to increase cell replication in rodent hepatocytes during the first few
days of treatment [144] [145] [45]. Continuous infusion of DNA precursor rather than pulse-
labelling for detection of DNA replication in PP-treated animals is more sensitive and necessary
for detection of chronic replicative DNA synthesis [36]. For example, Popp et al. (1993) ob-
served a correlation between increases in chronic replicative DNA synthesis and hepatocarcino-
genesis in F-344 rats treated with DEHP and WY 14,643 for up to 365 days. All rats fed Wy-
14,643 for 365 days had numerous grossly visible nodules in comparison to none in the livers
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of DEHP-fed or control rats. Rats implanted with 7-day osmotic pumps containing tritiated thy-
midine produced 5- to 10-fold increase in replicative DNA synthesis after treatment with WY
14,643 for 18 to 365 days as compared to DEHP-fed rats or controls [145]. Apart from com-
pound potency, dose also plays an important role in sustained stimulation of cell proliferation.
Wada et al. [146] showed that hepatocellular replication in rats dosed with 5 and 10 ppm WY-
14,643 returned to control levels after three weeks. In contrast, rats dosed with 50, 100, and
1000 ppm WY-14,643s had sustained increases in cell replication for up to 13 weeks [146].
While there is a strong correlation between increases in cell replication and hepatocarcinogen-
esis, there was no relationship between the induction of peroxisome proliferation and hepato-
carcinogenesis [84]. Parzefall et al reported that in purified hepatocyte cultures, WY-14,643 and
nafenopin had no effect on DNA synthesis, whereas they did increase ACO activity [147]. In
addition, other study showed a poor correlation between peroxisome proliferation and hepato-
carcinogenesis after treating the rats with DEHP and WY-14,643 [145]. 
Section 1.9.3 Promotion of liver preneoplastic lesions.
The oxidative stress hypothesis does not explain well PP-induced hepatocarcinogenicity, which
suggests other potential mechanisms are important for how these PPs induce carcinogenicity.
One approach to characterization of the mechanism of PP-induced hepatocarcinogenicity is to
evaluate the stage of tumour development through the initiation-promotion system [148]. Lim-
ited evidence suggests that PP fail to initiate hepatocarcinogenesis in rats following in vivo treat-
ment [149]. But, it has been reported that PPs are efficient promoters of certain genotoxic
carcinogenic-induced lesions or other cells initiated spontaneously such as cells in the liver of
untreated mice and rats [36] [148]. In rats pretreated with diethylnitrosamine, nafenopin was
found to promote preneoplastic cells [211]. Age is another determinant of PP-induced tumour
progression in rodents. Several studies have demonstrated the presence of numerous foci in the
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livers of untreated old rats and mice [210]. These lesions act as spontaneous initiation to the
cells in the older animals, which increase the incidence of liver tumor after treating the animals
with peroxisome proliferators [150]. It has been posited that peroxisome proliferators have
greater ability to produce liver tumor in old rats than in young rats. This view is based on the
observation that in two studies with nafenopin [210] and WY -14,643 [151] using two groups
of rats with different ages, old rats (57 to 60 weeks) and young rats (8 to 13 weeks). These stud-
ies revealed that development of liver tumors was higher in old rats than in young rats. The in-
crease of liver tumor in old rats can be attributed to the promotion of a greater number of pre-
existing spontaneously developed lesions, whereas the development of tumour in young can be
attributed promotion of fewer pre-existing lesion [152] [209]. Figure 1.4 summarize the hypo-
thetical mechanism of peroxisome proliferators as promotion agents in the tumour develop-
ment. 
Figure 1.4 Hypothetical mechanism of peroxisome proliferator-induced hepatocarcinogenesis.  
Promotion Initiation 
Normal cells Pre-neoplastic focus Tumour 
Peroxisome proliferators 
  Progression 
Growth factor
Oncogenes 
Tumor suppressor genes 
Initiated cells 
 (Modified from Suga, 2004 [42])
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Section 1.10 Assessment of human hazard
Human are frequently exposed to peroxisome proliferators due to the number of PPs in the en-
vironment. This alerted many governments and regulatory agencies to assess whether these
agents were safe for humans or not [43]. Since it was first observed that hypolipidemic drugs
such as nafenopin induce carcinogenesis [153], many peroxisome proliferators that have been
adequately tested for carcinogenicity in chronic dose caused tumors in rodent [51]. In contrast
to the hepatocarcinogenesis in rodents, there is no published evidence that PPs are carcinogenic
in humans. Several studies have asserted that PPs do not pose a carcinogenic risk to human
[103]. An epidemiological study by the World Health Organization on clofibrate involving
208,000 men showed no excess cancer mortality [154] [155]. Furthermore, a volunteer study on
humans exposed to therapeutic doses of peroxisome proliferators (clofibrate, fenofibrate, cipro-
fibrate, and gemfibrozil) showed no convincing evidence for peroxisome proliferation [103].
Moreover, the hypolipidemic drugs, that lower abnormally high plasma concentrations of cho-
lesterol or triglycerides in human, are not accompanied by peroxisome proliferation nor by in-
duction of peroxisomal E-oxidation or other activities induced by PP in rodents [51]. Tugwood
reported that cloned human PPARD functions in a manner similar to its rodent counterpart but
the PPARD expression is lower in human cells [75]. Other findings support the same concept
that human hepatocytes express PPARD at 5-10% of the level found in rodent hepatocytes [79]
[76]. Interestingly, there is interindividual variation in human PPARD cDNA obtained from dif-
ferent individuals [75]. Thus, existence of variability in PPAR sequences among human suggest
that some individuals may be at risk to exposure to these potentially carcinogenic agents [208].
Finally, although the molecular mechanism of the carcinogenic action of PPs in the rodent liver
is not fully understood, the phenomena associated with the action of PPs on rodent hepatocytes
such as peroxisome proliferation and induction of cell proliferation are absent in human hepa-
tocytes. These data provide substantial weight of evidence to support that the PP class of
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nongenotoxic rodent hepatocarcinogens does not pose a cancer risk for human liver.
Section 1.11 Methodologies to measure DNA synthesis
Several techniques and methods are available to determine the rate of DNA synthesis whether
in vivo or in vitro. DNA synthesis is determined by administering isotopically-labelled precur-
sor ([3H]thymidine (TdR)) or non-isotopically labelled precursor 5-Bromo-2-deoxyuridine (Br-
dU), a synthetic analog of thymidine, and these are incorporated into DNA during S-phase in
hepatocytes [46]. These labelling agents can be administered via two different methods. First,
the pulse labeling method, where a single dose of BrdU or TdR is administered 1-2 hours before
an animals sacrifice. Pulse labelling is the method of choice for evaluating rapid induction of
DNA synthesis or in tissues with high division rates such as small intestine. Second, the contin-
uous labelling method is another method for introducing the labeling agent. With this technique,
labelling agent can be administered to the animal for several days by either using an osmotic
pump placed under the skin of the animal or by delivery of the labelling agent in the drinking
water of the test animals [46] [156]. The advantage of this method over pulse labelling method
is that all cells going into S-phase during the period of labelling will be labelled and this will
increase the sensitivity of the assay [46]. Once the labelling agent is incorporated into DNA,
BrdU-immunohistochemistry (BrdU-IHC) or Flow Cytometry (FC) techniques can be used to
determine the labelling index. In the immunohistochemistry method, incorporated BrdU in
newly synthesized DNA strands of actively proliferating cells is detected by using Anti-BrdU
antibodies and developed by e.g. the immunoperoxidase system, and visualised under the mi-
croscope. Flow cytometry provides a method for sorting different cell types based on size, shape
and granularity by using specific light-scatter characteristics and detection of fluorescent
probes. In FC, a laser beam is used as the source of scatter and fluorescence light. As a cell pass-
es through the laser beam, it will scatter the light in all directions. Consequently, forward scatter
can be used to determine the size of the cell, whereas side scatter can be used to measure gran-
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ularity and structural complexity inside the cell [13]. The total cellular DNA content can be
measured by staining a cell with DNA-binding dye such as Hoechst 33342, propidium iodide or
7-aminoactinomycin D. Incorporated BrdU can be determined either by using a monoclonal an-
tibody against BrdU or using DNA-binding dye, one that shows altered fluorescence with BrdU
substitution [157]. 
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Section 1.12 Aims of the thesis
This thesis aimed to characterise the induction of liver growth by peroxisome proliferators. The
specific objective were:
 -To determine the true time and dose-dependency of induction of PP-induced DNA synthesis
in liver of mouse
 - To determine whether mouse strains respond to peroxisome proliferators with different time-
and dose-dependency for induction of hepatic DNA synthesis
 - To determine whether these effects (induction of liver DNA synthesis and liver growth) are
mediated by the PPARD
 - To determine if rats and mice have a different time-course for induction of hepatic DNA syn-
thesis.
This information is an essential prerequisite for investigating the mechanisms of liver growth,
as it is essential to be able to relate the timing of changes in regulating genes to the timing of
DNA synthesis itself. 
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Chapter 2 Materials and Methods
Section 2.1 Materials
Section 2.1.1 Animals
Male and female 129S4/SvJae mice wild type or PPARD-null background (129S4/SvJae-
Pparatm1Gonz/tm1Gonz) were bred locally in the breeding colony, Biomedical Services Unit, Uni-
versity of Nottingham. Inbred Male C57BL/6J, DBA/2J and BALB/c mice were obtained from
Charles River Laboratories, UK. Outbred male Alderley Park (AP) mice were a gift from As-
traZeneca Pharmaceuticals. Male Fischer 344 (F344/NHsd) rats were purchased from Harlan
UK limited (Bicester, UK). Animal husbandry and handling were performed in accordance with
the animals (Scientific Procedures) Act 1986. All Animals were housed in groups in plastic cag-
es and were maintained on a 12-hr light/dark cycle. 
Section 2.1.2 Chemicals
Section 2.1.2.1 Immunohistochemistry materials
All chemical were obtained at highest grade possible. 5-bromo-2'-deoxyuridine (BrdU) and Tris
base ultrapure were obtained from Melford. 3,3' Diaminobenzidine tetrahydrochloride (DAB),
Polyoxyethylene sorbitane monolaureate (Tween-20), bovine serum albumin (BSA) and foma-
lin solution, 10% formalin (approx. 4% formaldehyde) were obtained from Sigma. Acetic acid
glacial, xylene, ethanol, methanol, sodium phosphate and haematoxylin stain were purchased
from BDH. DPX (Distyrene, plasticiser, and xylene), hydrochloric acid and 30% hydrogen per-
oxide were obtained from Fischer scientific, Ammonium hydroxide from Aldrich and cobaltous
chloride from AnalaR. Amersham cell proliferation kit were purchased from GE healthcare
(UK). Poly-L-lysine-coated slides (PolysineTM) were obtained from Fischer, pure paraffin wax
(MP 56 deg C) from RA lamb, Peel-A-Way® disposable histology molds from Polysciences Inc
and TAAB embedding stub (25mm) from TAAB. Pure water was produced in this laboratory at
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a quality of < 0.2 PS.
Section 2.1.2.2 Peroxisome proliferators 
2-4-(2,2-dichlorocyclopropyl)phenoxy)2-methylpropanoic acid (Ciprofibrate) was a kind gift
from Dr. T.J.B Gray, Sanofi-Aventis (Alnwick, UK), methylclofenapate (MCP) from Dr. C.R.
Elcombe, CXR Bioscience (Dundee, UK). 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio acetic
acid (Wy-14,643) was obtained from Chemsyn, Lenexa, a division of Aptuit. All these chemical
were dissolved in corn oil directly except Wy-14,643 which was dissolved in absolute ethanol
(70mg ml-1) and then dissolved in corn oil to bring up concentration 7mg ml-1 (dosing volume,
20ml kg-1 b.wt). 
Section 2.1.2.3 Other chemicals
Dimethyl sulphoxide (DMSO) 99.9% and 1,4-Bis[2-(3,5-Dichloropyridyloxy)] Benzene
(TCPOBOP) were purchased from Sigma. TCPOBOP was dissolved in DMSO (7.5mg ml-1)
and then dissolved in corn oil to bring up concentration 0.2mg ml-1 (dosing volume, 20ml kg-1
b.wt).
Section 2.2 Experimental design
Animal experiments were designed on the basis of using power analysis to estimate the least
number of animals required for meaningful statistical analysis of DNA synthesis. To exemplify
power analysis, we have typical control mean values for hepatic labelling index of ~0.26% with
a variance of 0.07%, and treated values of ~3% with a variance of 1.5%. To obtain a significance
test with P<0.05 for a treated mean of 1.8%, with a power of 90%, the number of animals per
group should be 6 [158]. Moreover, the least stressful procedure, suffering, distress of lasting
harm are employed, given that the experiment will be sufficient to produce satisfactory results.
In addition, all experiment were designed to study the liver growth and DNA synthesis in animal
as a result of peroxisome proliferators action without toxic or adverse effects where possible.
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The animals were matched for age within range of 9-10 weeks. The animals were matched for
sex, strain, and supplier. In addition, when animal arrived, they were randomised on the basis
of body weight into appropriate number of groups to minimise random variation. Positive and
negative controls were introduced and optimized to standardise the experiments and appropriate
method for administration of chemical and quantification of labelling index were optimized as
well so that scheduled DNA synthesis due to exposure to a PP can be measured. Pilot study was
introduced to the project to gather useful information prior to the start of larger scale studies. A
small feasibility experiment, can reveal deficiencies in the design of a experiment that can be
addressed before the start of larger experiments.
Section 2.2.1 Dosing of Animal
Section 2.2.1.1 BrdU-labelling protocol
In order to administer the DNA precursor, BrdU, without adverse effects, the BrdU-dosing re-
gime was optimised. The animals were kept in a temperature-controlled room with alternating
12hrs dark/light cycle. The animals were given free access to food and tap water until the be-
ginning of the experiments. At time zero (10a.m), the animals were randomly housed into
groups and then acclimatized to 10% orange juice as a sole source of drinking water for one
week. Then orange juice supplemented with 0.8mg ml-1BrdU was given continuously in drink-
ing water from one day prior to dosing with PP. All bottles-containing BrdU were protected
from light by aluminum foil and were changed every 3 days.
Section 2.2.1.2 Single dose protocol without acclimatisation 
Mice were dosed with 0.8mg ml-1 BrdU in drinking water for 3 days; after one day, the animals
were dosed by gavage with appropriate dose of peroxisome proliferators and the animals were
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killed after two days (Figure 2.1). 
Section 2.2.1.3 Single dose protocol after acclimatisation to 10% orange juice
After using the labelling protocol (Section 2.2.1.1), treated animals were gavaged with a single
dose of a peroxisome proliferator (PP) dissolved in corn oil (20ml kg-1). Control group was kept
under the same conditions, with the exception that gavage dose did not contain a peroxisome
proliferator. Animal were killed after three days or as stated (Figure 2.2). 
210
BrdU dosing
Day
PP or Vehicle Sacrifice
3
Figure 2.1 Schematic representation of single dose protocol 1. The schematic diagram represents the single
dose protocol without acclimatisation to 10% orange juice. The hash bar shows the number of days on the experi-
ment. The closed arrow indicates the time of dosing with peroxisome proliferator (PP) or vehicle, whereas the open arrow
indicates the sacrifice day of the animals. The solid horizontal line shows the period of time where the animals were given
BrdU continuously in drinking water (labelled BrdU dosing). 
9870
BrdU dosing
Day
PP or Vehicle Sacrifice
10
Figure 2.2 Schematic representation of single dose protocol 2. The schematic diagram describes the single
dose protocol of induction of DNA synthesis by peroxisome proliferator after acclimatisation with 10% orange
juice. The solid red bar shows the 7-day period where the animals were given 10% orange juice as sole source of drinking
water and the hash bar shows the number of days on the experiment. The closed arrow indicates the time of dosing with
peroxisome proliferator (PP) or vehicle, whereas the open arrow indicates the day of killing the animals. The solid hori-
zontal line shows the period of time where the animals were given BrdU continuously in 10% orange juice, their sole source
of drinking water (labelled BrdU dosing).
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Section 2.2.1.4  Time-course protocol
After using the labelling protocol (Section 2.2.1.1), groups of six animals were gavaged daily
with a peroxisome proliferator in corn oil (e.g. 100 mg kg-1 day-1ciprofibrate with 129S4/SvJae
mice) and killed on appropriate time points (e.g days 2, 3, 4, 5 and 6), and the control vehicle
groups were killed on first and last time points (e.g days 2 and 6) after dosing with vehicle con-
trol. No control animals were used (on days 3-5) because we assume that control hepatic DNA
synthesis rates are at steady state (which is tested by killing control animals at days 2 and 6) and
we have a legal obligation to reduce the number of animal used by home office legislation. An-
imal body weight was measured daily throughout the experiment as part of adverse effects as-
sessment (Figure 2.3).
 
1312100
BrdU dosing
Day:
7 1198 14
Dosing with peroxisome proliferator
Sacrifice
Figure 2.3 Schematic representation of multiple dose protocol 1. The schematic diagram shows a protocol for
studying the time course of induction of DNA synthesis, with multiple doses of peroxisome proliferator or vehicle. The solid
red bar shows the 7-day period where the animals were given 10% orange juice as sole source of drinking water and the hash
bar shows the number of days on the experiment The black arrows represent the day of dosing with peroxisome proliferator
or vehicle, whereas the red arrowheads represent the day of killing the animals. The control groups of animals were killed
in appropriate days (e.g on days 2 and 6 after dosing with vehicle control). The solid horizontal line shows the period of time
where the animals were given BrdU continuously in their sole source of drinking water (labelled BrdU dosing).
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Section 2.2.1.5 Dose dependency protocol 
After using the labelling protocol (Section 2.2.1.1), groups of six male 129S4/SvJae mice (9-10
wks old) were gavaged with 0,1,3,10,30,100 or 200 mg kg-1 day-1of ciprofibrate in corn oil for
3 days (Figure 2.4), and other set were gavaged with 0,10,30,100 mg kg-1 day-1of ciprofibrate
for 4 days (Figure 2.5). Control groups were dosed with corn oil vehicle. The animals were hu-
mane by killed at the end of experiment by an overdose of pentobarbital (Dolethal)
.
Figure 2.4 Schematic representation of multiple dose protocol 2 . The schematic diagram shows a proto-
col for studying the dose dependency of induction of hepatic DNA synthesis, with multiple doses of ciprofibrate for three
days. The solid red bar shows the 7-day period where the animals were given 10% orange juice as sole source of drinking
water and the hash blue bar shows the number of days on the experiment. The black arrows represent the day of dosing
with ciprofibrate or vehicle, whereas the red arrowhead represents the day of killing the animals. The solid horizontal
line shows the period of time where the animals were given BrdU continuously in their sole source of drinking water
(labelled BrdU dosing).
100
BrdU dosing
Day:
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Ciprofibrate: 0, 1, 3, 10, 30, 100 and 200 mg kg-1 day-1
Sacrifice
3 days
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Section 2.2.2 Tissue processing
Following treatment, the animals were exsanguinated under terminal anaesthesia with pentobar-
bital. Immediately after death, a blood sample was collected by using cardiac-puncture. The
whole liver was removed and weighed, and a section of left lobe of liver and small intestine (as
positive control) were fixed in 10% neutral buffered formalin overnight. The remaining liver
was snap-frozen in liquid nitrogen and kept at -80oC until use. Blood samples were centrifuged
and serum was frozen at -80oC until subsequent analysis.
Fixed tissues were dehydrated, cleared and infiltrated with paraffin by using Shandon Citadel
2000 Automated Tissue Processor with the following protocol:
Paraffin-infiltered tissues were manually embedded with paraffin and kept overnight at 4oC to
cool down before sectioning. Sections (4.5Pm) were mounted on adhesive coated slide, poly-
100
Day:
7 1198
Ciprofibrate: 0, 10, 30 and 100 mg kg-1 day-1
Sacrifice
4 days
12
BrdU dosing
Figure 2.5 Schematic representation of multiple dose protocol 3.  The schematic diagram shows
a protocol for studying the dose dependency of induction of hepatic DNA synthesis, with multiple doses of cip-
rofibrate for four days. The solid red bar shows the 7-day period where the animals were given 10% orange juice
as sole source of drinking water and the hash blue bar shows the number of days on the experiment. The black
arrows represent the days of dosing with ciprofibrate, whereas the red arrowhead represents the day of killing.
The solid horizontal line shows the period of time where the animals were given BrdU continuously in their sole
source of drinking water (labelled BrdU dosing).
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sineTM slide, and dried at 37oC overnight. 
Section 2.2.3 BrdU immunohistochemistry
Immunostaining was performed by dewaxing the sections in xylene for 30 minutes.The sections
were then rehydrated through a graded series of ethanol solutions (100%, 70%, 50%) and finally
washed in distilled water for 2 minutes. Endogenous peroxidase was quenched by treating the
slides with 3% hydrogen peroxide in methanol for 15 minutes. The sections were then rinsed
with phosphate buffer saline (PBS 100mM, pH 7.4/100 mM sodium chloride) twice for 5 min-
utes each. Antigen was retrieved by using heat induced epitope retrieval (HIER) technique using
700 watt-microwave. Sodium citrate buffer (10mM, pH 6) was microwaved at highest power
until boiling. The slides were then plunged into the boiling buffer, then heated again at same
power until boiling, followed by an additional 50 min at lowest power. The sections were
washed with PBS solution for 5 min, followed by a 15-min incubation with 0.5% BSA, 0.5%
Tween-20 in PBS for 5 minutes to reduce nonspecific binding. The slides were incubated with
Amersham mouse monoclonal anti-BrdU antibody (1:1000 dilution in TBS) for 1 hour and the
sections were then rinsed in distilled water for 5 minutes. Amersham HRP-conjugated goat anti-
mouse antibody (1:50 dilution in TBS) were added for 30 minutes and again the slides rinsed
with PBS twice for 5 minutes each. BrdU incorporation was detected by incubating the slide
with developing reagent (0.05% DAB, 0.025% Cobaltous chloride in 10mM Tris-HCl, pH 7.6)
for 10 minutes. The slides were then rinsed with distilled water for 3 minutes then counter-
stained, with Harris haematoxylin for 5 sec, dehydrated, and then mounted with DPX (Disty-
Table 2.1 Tissue processing protocol. 
 70% Ethanol 6.5 hrs
 80%, 90%, 95%, and 3X 100% Ethanol 1 hr each
 3X Xylene 1 hr each
2X Paraffin wax 1 hr each
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rene, plasticiser, and xylene). All incubations were done in a humidity chamber at room
temperature.
Section 2.2.4 Detection and quantification of DNA synthesis
Hepatocyte DNA synthesis was quantified under Leitz WetzlarTM light microscope by scoring
at least 2000 nuclei in random fields at 400X magnification per animal. The labelling index (LI)
in hepatocytes was generated by dividing the number of BrdU-labelled nuclei by the total num-
ber of nuclei counted and expressing the results as a percentage. Hepatocytes were identified
morphologically by using Leitz WetzlarTM light microscope at 400x.
Section 2.2.5 Alanine aminotransferase (ALT) measurement
Serum ALT activity was measured as a biomarker for liver injury since the ALT is highly spe-
cific to the liver [159]. The measurement was performed by using Vitros ALT slides (Ortho-
Clinical Diagnostics). Serum ALT test was performed in the clinical chemistry section, pathol-
ogy department in Queen Medical Centre (QMC), Nottingham.
Section 2.2.6 Statistics
Statistical evaluation of data was performed by using Excel, Prism, and Sigmaplot programs.
Students T-test was used for comparison of two groups; Paired t-test was used to test signifi-
cantly of relative body weight loss. The comparison was tested between the day of BrdU dosing
and the last day unless stated otherwise. Unpaired t-test was used to analyse significance be-
tween two groups on other occasions. One-way ANOVA followed by a post-hoc test (e.g. Dun-
netts, Newman-Keuls tests) was used for comparison of multiple treatment groups (e.g. during
a time course, or a dose-response). The assumption that liver DNA synthesis is parametric data
is described in [160]. Relative body weight was estimated by measuring the actual body weight
on the daily basis and calculated as relative to body weight on 0-day for each individual animal.
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Chapter 3 Results
Section 3.1 Method validation
Section 3.1.1 Fixation and detection
Section 3.1.1.1 Assessment of immunohistochemistry protocol with positive control 
It was necessary to ensure this protocol was able to localise incorporated BrdU in the cell nuclei
with a good signal-to-noise ratio. A positive control tissue which was known to have high levels
of BrdU labelling was used: this was xenograft tumour tissue (a kind gift from Dr. Phil Clarke,
from the cancer studies unit). Substantial efforts were made to test three different techniques to
restore antigenicity of incorporated BrdU, trypsin digestion, 0.5 M sodium hydroxide (denatur-
ing solution), and heat induced epitope retrieval (HIER) microwave method. Microwave treat-
ment was chosen as optimal (data not shown). A set of slides of liver section were stained by
immunohistochemical protocol as follow: (1) without primary antibodies to demonstrate non
specific binding; (2) stained without secondary antibodies to act as negative staining control; (3)
slide was stained in presence of both antibodies. As shown in Figure 3.1, there were no immu-
noreactivity observed in the slides A and B due to absence of primary and secondary antibodies
respectively. In contrast, the slide C which was stained in presence of both primary and second-
ary antibodies showed dark brown labelled nuclei. This demonstrates that the staining in (c) was
dependent upon the presence of both the primary and the secondary antibodies, and shows that
the staining was specific. These results confirm that the detection system works with good sig-
nal-to-noise ratio. 
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In order to assess the ability of detection system to detect the BrdU-labelled nuclei after in vivo
treatment of mice with BrdU, groups of two 129S4/SvJae mice were treated with 0 and 0.8mg
ml-1BrdU in tap water (over three days), which was the sole source of drinking water. In the
absence of BrdU administration, there was no immunostaining of nuclei in the liver or gut sec-
tions (Figure 3.2 A and B). The BrdU-labelled nuclei in the liver and gut sections of mice dosed
with 0.08% BrdU was stained with a high signal-to-noise ratio (Figure 3.2C). The crypts and
half of the villi section of the gut labelled with the BrdU, because cell division of epithelial cells
occurs in the crypts and gradually move toward the tips of the villi (Figure 3.2D). This results
confirm that labelling agent BrdU at this level was incorporated into the replicating DNA and
can be detected by the immunostaining protocol. 
Figure 3.1 Evaluation of immunodetection protocol on formalin-fixed, paraffin embedded tissue. 
BrdU-labelled Xenograft was stained with the immunohistochemical procedure and counterstained using Harris haematoxylin
as described in materials and methods Section 2.2.3. (A) Shows staining after the immunohistochemical procedure without
primary monoclonal anti-BrdU antibody. (B) Shows staining after the immunohistochemical procedure without secondary
goat anti-mouse antibody conjugated with HRP. (C) Stained in the presence of primary antibody for BrdU and secondary an-
tibodies. Arrows show BrdU-labelled nuclei. The scale bar = 50Pm.
A B C
50Pm 50Pm 50Pm
Abdullah Al Kholaifi   Section 3.1.1
Page 61
Figure 3.2 Assessment of anti-BrdU immunoreactivity in paraffin sections.   Groups of two 129S4/SvJae
mice were dosed with water and 0.8 mg ml-1 BrdU in drinking water for 3 days. Liver section (A) and gut section (B) from
water-treated mice and liver (C) and gut section (D) from BrdU-treated mice were harvested, fixed and processed for paraffin
sections as described in materials and methods, Section 2.2.2. The sections were stained with immunohistochemical protocol
using Amersham cell proliferation kit and counterstained with Harris haematoxylin as described in Figure 3.1. Gut section
was used throughout all project as positive control tissue to make sure BrdU was taken up by the animal. The scale bar =
50Pm.
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Section 3.1.1.2 Effects of fixation time and temperature on immunohistochemistry
The aim of this experiment was to evaluate the effects of fixation time and temperature on the
incorporated BrdU immunoreactivity in mouse gut and liver. Liver and gut tissues of groups of
two 129S4/svJae mice were fixed in 10% neutral buffered-formalin (cross-linking agent) over-
night, 3 or 7 days either at 4oC or room temperature (RT) and then evaluated for BrdU immu-
nohistochemistry. There was strong staining of nuclei with the immunohistochemical protocol
(not shown). Table 3.1 shows the length of fixation time has no significant effect on immuno-
reactivity of incorporated BrdU in liver sections but some effect on the gut sections. The liver
and gut sections fixed at room temperature had better BrdU-staining than those fixed at 4oC,
which was consistent with published data that the process of formalin fixation was temperature
dependent, i.e. higher temperatures produce more rapid fixation [161] [162]. Thus, this finding
confirms that fixing tissues at room temperature was better than at 4oC and immunohistochem-
ical staining of BrdU does not change after seven days fixation at room temperature.
Formalin fixation time Gut section Liver section
Days 4oC RT 4oC RT
Overnight + + + + + + + + + + +
3 + + + + + + + + +
7 + + + + + + + +
Table 3.1 Effects of length of formalin fixation and temperature on 
immunohistochemistry.  Liver and small intestine from groups of two
129S4/SvJae mice were fixed in 10 neutral buffered-formalin overnight, 3 or 7
days and stored either at 4OC or room temperature. The section from each tissues
were stained by immunoperoxidase staining as described in Figure 3.1. Intensity
of staining was graded from + to + + +.
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Section 3.1.1.3 Effects of fixation time on BrdU immunohistochemistry from mouse 
liver induced with TCPOBOP
Formalin a cross-linking agent seems to mask the reaction site of BrdU in DNA,. which may
make it difficult to identify BrdU-labelled nuclei [162]. It was necessary to evaluate the effects
of length of fixation duration on the BrdU-signal intensity in liver of mice with a high labelling
index. Liver and gut tissues from groups of five male or female 129S4/SvJae mice treated with
0 or 3 mg kg TCPOBOP (Section 3.3) were fixed into 10% neutral buffered formalin for 1, 3
and 7 days at room temperature. The formalin-fixed paraffin-embedded sections were examined
microscopically for the strength and signal-to-noise (S/N) ratio of BrdU-labelled nuclei. As
shown in Figure 3.3, BrdU-labeled nuclei in the different fixation time show a similar strength
of signal intensity of BrdU-labelled nuclei in both male and female mice. Moreover, the S/N
ratio was similar after different fixation times in both male and female mice. These findings ver-
ify that fixation length up to 7 days did not affect the strength of BrdU-labelled nuclei intensity
nor the signal-to-noise ratio.
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Control female Treated female
Overnight
7-day fixation
3-day fixation
Figure 3.3 Effects of fixation duration on the TCPOBOP-treated tissues.  Liver and
gut segments from control and treated of male and female 129S4/SvJae mice were fixed into
10%NBF for overnights, 3 and 7 days at room temperature. Gut was used as positive control to ensure
BrdU solution get into animal body as shown in Figure 3.2. The tissues were processed and stained
by routine protocol as described in Section 2.2.3. The sections were examined under light microscope
at 400x and positively labelled hepatocytes as dark brown in color against a light blue color counter-
stain. 
50Pm50Pm
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50Pm50Pm
50Pm
Abdullah Al Kholaifi   Section 3.1.2
Page 66
Section 3.1.2 Optimisation of in vivo BrdU dosing
Section 3.1.2.1 Induction of hepatic DNA synthesis by ciprofibrate: Pilot study
The aim of this experiment was to determine the dose of ciprofibrate that gives good DNA in-
duction without any adverse effects, and also to reveal a better idea of inter-animal variability.
129S4/SvJae mouse strain was chosen in this project for several reasons: a) capability of breed-
ing and supply the 129S4/SvJae strain in our location; b) this strain has a targeted knock-out of
the PPARD gene, which can be used to examine if the action of PPARD agonist, peroxisome
proliferators was mediated by PPARD receptor; c) since there was no published data in strain
differences of the induction hepatic DNA synthesis, we anticipated that this strain would be
valuable to study liver growth.
 Two male 129S4/SvJae mice per group (of different age) were treated with a single dose of 0,
12.5, 25, 75mg kg-1 ciprofibrate, and killed after two days. The liver:body weight ratio in cip-
rofibrate-treated groups did not differ obviously from the control group. (Figure 3.4A). Label-
ling index was not obviously increased in the treated group at all exposure levels of ciprofibrate
over the control (Figure 3.4B). In fact, inter-individual variation between the animals was large.
It was impossible to draw reliable conclusions from using two animals per group. Therefore, it
was essential in the future to use a larger group size to do statistical analysis. 
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Section 3.1.2.2 Induction of hepatic DNA synthesis in BALB/c mice
In order to demonstrate the induction of hepatic DNA synthesis in mice, the strain mice BALB/
c was used to induce hepatic DNA synthesis by ciprofibrate. Budroe et al. reported that BALB/
c mice demonstrated 24-fold increase in the labelling index after being exposed to 250ppm cip-
rofibrate for four days [11]. Groups of three Balb/c male mice (9-10 weeks old) were dosed with
BrdU (0.8mg ml-1) in drinking water, dosed once with ciprofibrate (0-300 mg kg-1), Wy 14,643
(100 mg kg-1) or methylclofenapate (25 mg kg-1) by gavage after one day of BrdU treatment,
and killed after two days. Body weight was measured daily. There was a dose dependent in-
crease in relative liver: body weight ratio in mice treated with ciprofibrate up to 157% of the
control value. In addition, the mice treated with a single dose of 25mg kg-1 methylclofenapate
showed a significant increases in liver: body weight ratio (37% increase) compared to the con-
Figure 3.4 Effect of dose of ciprofibrate on liver growth.   Groups of two male129S4/SvJae mice of varying age
(within the range 8-14 weeks) were dosed with 0.8mg ml-1 BrdU in drinking water for 3 days; after one day, the animals were
dosed by gavage with ciprofibrate (12.5, 25, or 75 mg kg-1) and corn oil for control group. The animals were killed after 2
days of ciprofibrate treatment as described in single dose protocol 1 (Section 2.2.1.2). (A) Liver-to-body weight ratios are ex-
pressed as liver/body weight ratio percent for each individual mouse; (B) Labelling index was determined by immunocy-
tochemical localization of BrdU and counterstaining with Harris haematoxylin as described in the Figure 3.1, and calculated
by counting at least 2000 hepatocyte nuclei per liver under microscope. The LI was expressed as number of (labelled nuclei /
total nuclei)x100 for each mouse as described in the materials and methods, Section 2.2.4. n=2. 
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trol, whereas the group of mice treated with 100 mg kg-1 Wy 14,643 did not display any signif-
icant difference as compared to the control (Figure 3.5A). Unexpectedly, the control group,
300mg kg-1ciprofibrate-treated group and Wy 14,643-treated group showed a significant de-
crease in body weight after three days of BrdU dosing, which was ~20% in the control group
(Figure 3.5B). This decrease in body weight was a confounding issue, since the effect on body
weight per se could have an effect on liver growth so the experiment provides no reliable infor-
mation about control of liver growth and it was difficult to interpret the results. It was therefore
necessary to alter the methodology to maintain the body weight of the mice before continuing.
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Figure 3.5 Effect of peroxisome proliferators on liver growth in Balb/c mice .  Group of three male BALB/c
mice were dosed with 0.8mg ml-1 BrdU in drinking water for 3 days; after one day, the animals were dosed by gavage with
increasing concentrations of ciprofibrate (75,130,200 and 300 mg kg-1), Wyeth-14,643 (100 mg kg-1) or methylclofenapate
(MCP; 25mg kg-1), and the animals were killed after 2 days as described in single dose protocol 1 (Section 2.2.1.2). (A) Liver-
to-body-weight (LBW) ratios were calculated as liver weight to the mouse body weight on the day of killing. (B) Body weight
was measured on daily basis for each individual mouse and relative body weight (RBW) was calculated relative to the body
weight for each individual mouse on day one. All data are expressed as mean±SD, n=3. One-way ANOVA and Dunnetts test
were used in statistical analysis of A (LBW), whereas paired t-test was used for statistical analysis of RBW between the day
of BrdU dosing and the day of killing as described in materials and methods, Section 2.2.6. = p<0.05 and = p<0.01.
B
A
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Section 3.1.2.3 Optimisation of BrdU uptake in drinking water
The hypothesis was the unpleasant taste of BrdU caused mice to reject BrdU-containing water.
One report showed that mice given BrdU in drinking water had slight body weight loss com-
pared to the control [163]. The labelling protocol was optimised whereby groups of three 129S4/
SvJae mice (-/-) were given various concentrations of BrdU (0.08, 0.05%) in 16% orange juice,
as taste enhancer, in tap water, which was the sole source of drinking water. The control group
was given tap water only and the other control group was given only diluted orange juice (16%).
The idea here was to enhance the amount of BrdU-containing water imbibed either by decreas-
ing level of BrdU (with the idea that the taste of BrdU will be reduced so the animal will drink
it) or hiding the BrdU tasting by using taste enhancer (orange juice). Figure 3.6 shows there was
no statistical difference in relative body weight of mice given orange juice, BrdU or BrdU sup-
plemented with orange juice as compared to the controls. However, while the mice in the control
group gained 4% of body weight after three days, the mice dosed with 0.08% BrdU + orange
juice or 0.05% BrdU lost 4% and 1% of body weight after three days of dosing respectively.
The mice dosed with 0.08% BrdU only was showed no change in relative body weight after
three days of dosing. The groups given 0.05% BrdU + orange juice or orange juice alone were
the only two groups which had gained 1% of body weight after three days of dosing. This study
shows 0.05% BrdU in 16% orange juice regime was the best regime to maintain the body weight
throughout the dosing period for this experiment only.
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Section 3.1.2.4 Induction of hepatocellular DNA synthesis by ciprofibrate 
The objective of this study was to induce DNA synthesis by ciprofibrate in mice treated with
0.05% BrdU supplemented with 16% orange juice regime. In this study, the labelling regime
optimised in  Section 3.1.2.3 was used to prevent body weight loss during the BrdU-dosing pro-
tocol. Groups of five male 129S4/SvJae mice (9-10 weeks old) were administered BrdU (0.5mg
ml-1) in 16% orange juice in drinking water, dosed once with ciprofibrate by gavage (0-300 mg
kg-1), and killed after two days. There was a dose-dependent increase in the liver: body weight
Figure 3.6 Effect of orange juice and BrdU on body weight.  Groups of three 129S4/SvJae
mice -/- were dosed with 0.5 or 0.8 mg ml-1 BrdU in drinking water with and without 16% orange juice for
3 days. Body weight was measured on daily basis for each individual mouse and relative body weight was
determined relative to the body weight for each individual mouse on day one. RBW was calculated as body
weight in day 3 to body weight in day 0 for each individual mouse. No significant difference was observed
between treated groups and control (water) group. Data are the mean±SD of the mice in each group, n=3.
Statistical analysis was calculated by one-way ANOVA with Dunnetts posttest.
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ratio, rising from 4.5± 0.3% in the control group (i.e. 16% orange juice plus BrdU) to 6.2±0.2%
in the 300 mg kg-1 ciprofibrate-treated group, which was significant at P<0.05 (Figure 3.7A).
Labelling index was not significantly increased in treated groups as compared to the control
(Figure 3.7B). However, the control and treated groups showed a ~ 4.5% loss in body weight,
which was statistically significant at day 3 (Figure 3.7C). ALT level, as a toxicity marker, in the
treated groups did not differ significantly from the control group (Figure 3.7D). This finding
shows that mice still lose some body weight after BrdU dosing, which necessitates further mea-
sures to reduce body weight loss. Figure 3.7C shows that the orange juice + BrdU regime results
in a significant decrease in body weight, whereas Figure 3.6 failed to detect any decrease: this
may be explained by the larger number of animals per group (5 vs. 3 respectively), thereby giv-
ing greater power for the detection of statistically significant difference.
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Section 3.1.2.5 Effect of acclimatisation and juice on body weight gain 
The mice exposed to 0.05% BrdU with 16% orange juice showed a significant decrease in body
weight (Section 3.1.2.4). We set out other protocols to maintain body weight during the BrdU-
dosing procedure by adapting the mice for one week to flavoured juice. This step was important
to acclimatise the mice to the juice taste before starting dosing. 10% juice was used instead of
16% dilution to reduce juice acidity. The adaptation protocol was used in different mice strains,
Figure 3.7 Effect of ciprofibrate on liver growth in 129S4/SvJae mice. Group of five male129S4/SvJae mice
were dosed 0.5mg ml-1 BrdU in 16% orange juice for three days; after one day of BrdU dosing, the animals were dosed once
by gavage with 0,100,200 and 300 mg kg-1 ciprofibrate, and the animals were killed after 2 days as described in single dose
protocol 1 (Section 2.2.1.2). (A) Liver-to-body-weight ratios are expressed as a percentage of mean±SD; (B) Labelling index
was calculated as described in Figure 3.4; (C) Relative body weight was calculated and statistically tested using paired stu-
dent t-test as described in Figure 3.5; (D) Serum alanine aminotransferase (ALT) activity was determined using Vitros ALT
slides (Ortho-Clinical Diagnostics). The procedure was performed in the clinical chemistry department, Queen medical cen-
ter (QMC) at Nottingham. One-way ANOVA and Dunnetts test were used for statistical analysis of A, B and D, while paired
t-test was used for figure C as described in Figure 3.5. = p<0.05. N.D.: data not analysed. n=5.
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129S4/SvJae, DBA/2J, C57BL/6J and Alderley park (AP), and rats (F-344/NHsd) to assess the
effect on body weight.
Section 3.1.2.5.1 129S4/SvJae mice
Groups of three 129S4/SvJae PPARD -/- mice were acclimatised with different diluted juices
(orange, apple and blackcurrant) without BrdU for one week, then the animals were given
0.8mg ml-1 BrdU + diluted juices (10% v/v) as a sole source for drinking water for 3 days. The
relative body weight in mice given juice were similar to the mice in control group. After BrdU
dosing, the mice treated with BrdU + juice did not show any reduction in body weight and there
were no significant differences in RBW increases between the treated group. These finding
show that BrdU solution has no negative effect on body weight, if mice were previously accli-
matised to drinking diluted juices. Thus, this acclimatisation regime will be used in labelling
protocol prior treating the animal with peroxisome proliferator (Figure 3.8).
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Figure 3.8 Effect of acclimatisation and juice on 0.08% BrdU on relative body weight.  Four
groups of three 129S4/SvJae PPARD -/- mice were acclimatised to different flavour juices (10% v/v in tap water)
for a week as their sole water source, then to 0.08% BrdU in 10% juice for 3 days. Mice body weights were mea-
sured on daily basis for each individual mouse and relative body weight was calculated relative to the body weight
for each individual mouse on day 0. The arrow shows the start of administration of BrdU. Data are the mean±SD. 
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Section 3.1.2.5.2 DBA/2J mice
Groups of two DBA/2J mice were acclimatised in 10% orange juice for a week, then were dosed
0.8mg ml-1 BrdU supplemented with 10% orange juice as a sole source of drinking water for
six days. Control group was dosed with tap water. No body weight reduction was observed in
the mice after administration of BrdU (Figure 3.9). This finding shows that the labelling proto-
col can be used to administer BrdU in this strain (DBA/2J) of mice without causing any reduc-
tion in the body weight. 
Figure 3.9 Effect of acclimatisation and orange juice on body weight of DBA/2J 
mice. Group of two DBA/2J mice were acclimatised in 10% orange juice for a week, then were
dosed with 0.08% BrdU+orange juice for six days. Control group was given a tap water. Relative
body weight was measured as described in Figure 3.8. Data was expressed for each individual mouse
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Section 3.1.2.5.3 C57BL/6J mice
In order to assess the adaptation of C57BL/6J strain onto the labelling protocol, groups of two
male C57BL/6J mice were acclimatised to 10% orange juice for a week, then were dosed 0.8mg
ml-1 BrdU supplemented with 10% orange juice as a sole source of drinking water. Control
group was dosed with tap water. No body weight reduction was noticed in the BrdU-treated
mice after BrdU treatment. Thus, the labelling protocol with BrdU does not have an adverse ef-
fect on body weight.
 
Figure 3.10 Effect of acclimatisation and orange juice on body weight of C57BL/6J 
mice. Group of two C57BL/6J mice were acclimatised in 10% orange juice for a week, then were
dosed with 0.08% BrdU+orange juice for six days. Control group was given a tap water. The relative
body weight was measured as described in Figure 3.8. Data was expressed for each individual mouse.
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Section 3.1.2.5.4 Alderley park (AP) mice
Group of four mice were dosed with 10% orange juice for a week, then dosed with 0.8mg ml-1
BrdU + orange juice for four days. The orange juice period was used as a control due to the lim-
ited availability of this strain. No body weight loss was observed after dosing the mice with
0.08% BrdU (Figure 3.11). The labelling protocol was good for administration of BrdU in
drinking water.
Figure 3.11 Effect of acclimatisation and orange juice on body weight gain of Alderley 
park (AP) mice. Group of four mice were dosed with 10% orange juice for a week then 0.8mg ml-1
BrdU + orange juice for four days. Relative body weight was measured as described in Figure 3.8. The
time of orange juice dosing was used as control for BrdU+orange juice dosing. Student paired t-test was
used in the analysis. Data was expressed as mean±SD.
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Section 3.1.2.5.5 F344/NHsd rats
The BrdU-labelling protocol (Section 2.2.1.1) was assessed in male F-344/NHsd rats before de-
signing the experiment of species differences. Groups of two male F-344/NHsd rats were accli-
matised to 10% orange juice for a week, then were dosed with 0.8mg ml-1 BrdU supplemented
with 10% orange juice as a sole source of drinking water. Control group was dosed with tap wa-
ter. No body weight reduction was noticed in the BrdU-treated rat after BrdU treatment. Thus,
the labelling protocol with BrdU does not show an adverse effect on rat body weight.
Figure 3.12 Effect of acclimatisation and orange juice on body weight gain of F-344/NHsd Rat. 
Group of two F-344/NHsd rats were acclimatised in 10% orange juice for a week, then were dosed with 0.08% Br-
dU+orange juice for six days. Control group was given a tap water. The body weight was measured daily and relative
body weight is relative to body weight on day one. Data was expressed as mean±SD.
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Section 3.2 Induction of DNA synthesis by ciprofibrate in 129S4/SvJae 
mice; dose-dependency 
Maintaining body weight during BrdU exposure prompted a repeat of dosing the mice with cip-
rofibrate to characterize the induction of hepatic DNA synthesis. In this study, the acclimatising
regime (Section 2.2.1.1) was introduced in the experiment to maintain body weight. Five groups
of five male129S4/SvJae mice were dosed with 100-400 mg kg-1ciprofibrate once, and killed
after two days. This range was chosen to find out the optimal dose of ciprofibrate that produce
a significant induction of liver growth without toxicity since up to 75mg kg-1 ciprofibrate does
not show any induction in the liver growth. Under these conditions, the relative body weights
do not decrease over the 10 days of the study period (Figure 3.13A). Liver to body weight ratios
increase substantially and significantly at the 100 mg kg-1dose level, and hit a plateau at 200 mg
kg-1 ciprofibrate, with a 44% increase over control (Figure 3.13B), validating that the protocol
can be used successfully for chronic administration of doses of BrdU sufficient to measure DNA
synthesis.
Figure 3.13 Effect of single dose of ciprofibrate over two days on liver growth. Group of five 129S4/SvJae
mice were acclimatised on labelling protocol as described on material and method, Section 2.2.1.1. All groups were admin-
istered once with ciprofibrate by gavage (0-400 mg kg-1), and vehicle for control group as described in single dose protocol
2 (Section 2.2.1.3). The mice were killed after two days. (A) Relative body weight was calculated as described in Figure
3.5. Paired student t-test was used for statistical analysis. (B) Liver-to-body weight ratio (as a percentage) was calculated as
shown in Figure 3.5. One-way ANOVA with Dunnetts test as post hoc was used in statistical analysis. All data expressed
as mean ± SD. Solid horizontal line represents a time when animal were exposed to BrdU in 10% orange juice.
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However, although there was a non significant increase in labelling index (LI) at 300 mg kg-1
over the control, the mice exposed to a single dose of ciprofibrate (up to 400 mg kg-1) did not
show a significant induction of hepatic DNA synthesis within two days (Figure 3.14A). Alanine
aminotransferase (ALT) was measured in serum as a test for any hepatic damage. ALT level in
treated mice did not differ significantly from the control mice (Figure 3.14B). Thus, my results
reveal: (1) the labelling protocol was good; (2) the ciprofibrate causes substantial induction of
liver weight by two days; (3) even in the presence of a ~50% increase in liver weight, there was
no increase in DNA synthesis; (4) the lack of induction was not due to gross liver toxicity, as
there was no increase in ALT activity. Therefore, ciprofibrate does not induce LI within two
days. This result was in contrast to the work of Styles, who showed that peroxisome prolifera-
tors strongly induce DNA synthesis in mouse liver by 24 hours [113] [164]. This finding re-
quires further investigation to characterise the early proliferative response of hepatic DNA
synthesis by ciprofibrate.
Figure 3.14 Effect of single dose of ciprofibrate on liver growth in 129S4/SvJae mice.  Group of five male
129S4/SvJae mice were acclimatised to labelling protocol as described in Figure 3.13, then dosed once with ciprofibrate by
gavage (0-400 mg kg-1), and vehicle for control group. The mice were killed after two days. (A) Labelling index was deter-
mined as described in Figure 3.4. (B) Serum ALT activity was determined as described in Figure 3.7. One-way ANOVA with
Dunnetts test as post hoc was used in statistical analysis. All data expressed as mean ± SD.
A B
Abdullah Al Kholaifi   Section 3.3
Page 82
Section 3.3 Effect of TCPOBOP on DNA synthesis in 129S4/SvJae mouse 
Section 3.2 had shown that there was no proliferative response to ciprofibrate within two days.
In order to confirm whether failure of ciprofibrate to increase the LI was due to defective meth-
odology used for measuring DNA synthesis in the liver, replicative DNA synthesis was exam-
ined with a positive control compound which acts via activation of the CAR receptor [207].
TCPOBOP was used to induce liver growth in male and female mice within 48 hours, as it was
reported to cause induction of DNA synthesis within 48 hours [207]. Groups of five male or fe-
male 129S4/SvJae mice were acclimatised to the labelling protocol as described in Section
2.2.1.1 before treatment with a single dose of 3mg kg-1 TCPOBOP by gavage over two days.
The control groups were treated with vehicle (dimethyl sulphoxide-corn oil solution). No body
weight reduction was observed following BrdU administration among the mice in all groups
(Figure 3.15A). 
 
Figure 3.15 Effect of TCPOBOP on mice liver.  Groups of five male and female 129S4/svJae mice treated with la-
belling protocol as described in Figure 3.13 were given a single dose of 3 mg kg-1 TCPOBOP dissolved in dimethyl sulphoxide
as described in single dose protocol 2 (Section 2.2.1.3). Control groups received vehicle only. All animal were humanely killed
after 48 hours of treatment. Blood was drawn by cardiopuncture technique to determine serum ALT. (A) Relative body weight
was determined and calculated as described in Figure 3.5. (B) Serum alanine aminotransferase (ALT) activity was measured
as described in Figure 3.7. Unpaired student t-test was used for statistical analysis of two groups (ALT data), whereas paired
student t-test was used to analyse relative body weight as described in Figure 3.5. All data expressed as mean ± SD, = p<0.01.
Solid line represents a time when animal were exposed to BrdU in 10% orange juice.
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However, treatment with TCPOBOP results in a statistically significant increase in serum ALT,
an index of hepatocyte injury, in male treated mice, but not in the female-treated mice compared
to corresponding control (Figure 3.15B). Administration of TCPOBOP significantly increased
liver-to-body ratio by to 65 and 96% of control in male and female treated groups respectively
(Figure 3.16A). TCPOBOP caused a significant increase in hepatic labelling index compared to
corresponding control, rising from 0.2±0.1% and 1.4±1.0% in the control groups to 27.5±6.1%
(~ 145-fold increase) and 48± 9.8% (35-fold increase) in the treated male and female groups re-
spectively (Figure 3.16B). Histologically, Figure 3.16C showed liver sections from treated male
and female mice with high magnitude of BrdU-labelled nuclei compared to the corresponding
control. This amount of increase was greater in female than male mice. These findings confirm
that the method used in this study detected hepatocyte labelling within 48 hours. This shows that
the failure of ciprofibrate to increase the LI was not a consequence of defective methodology. 
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Figure 3.16 Effects of TCPOBOP on hepatic DNA synthesis in 129S4/SvJae mice.   Groups of male and fe-
male mice were dosed with TCPOBOP as described in Figure 3.15. (A) Liver:body weight ratio (as a percentage) was calcu-
lated as shown in Figure 3.5. (B) Labelling index percent was determined as described in Figure 3.4. (C) Representative liver
sections labelled with anti-BrdU antibody (Black nuclei) and counterstained with haematoxylin of TCPOBOP-treated (Treat-
ed) male (ƃ) and female (Ƃ) mouse and untreated (Control) mouse. Liver sections from control and treated male and female
mice were fixed overnight and stained with immunohistochemical protocol as described in Figure 3.1. Gut section was used
as positive control as described in Figure 3.2. Results are expressed as means± SD of five mice per group. Significant differ-
ence was determined by Student's t-test;  =p<0.00001.
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Section 3.4 Induction of hepatic DNA synthesis by Methylclofenapate 
(MCP)
An alternative hypothesis to explain the failure to detect early induction of DNA synthesis by
ciprofibrate, was that this was an idiosyncratic response to ciprofibrate, which was not typical
of PPARD agonists in general. Methylclofenapate (MCP) was a potent peroxisome proliferator
and it has been reported to increase DNA synthesis (>10%) in mice at 24 hours after dosing with
25mg kg-1 [164]. To examine this hypothesis, a group of seven 129S4/SvJae mice were treated
with a single dose of 25mg kg-1 MCP and killed after two days (as described in Section 2.2.1.3);
a control group was dosed with corn oil vehicle. No body weight reduction occurred in the mice
following administration of BrdU in drinking water (Figure 3.17A). Serum ALT in the treated
group did not significantly differ from the control group (Figure 3.17B). 
Liver-to-body weight ratio was significantly increased in the MCP-treated group compared to
the control group (Figure 3.18A), whereas the labelling index in the MCP-treated group did not
Figure 3.17 Effect of a single dose of methylclofenapate on relative body weight and ALT in mice. 
Groups of seven male129S4/SvJae mice were acclimatised to the labelling protocol as described in Figure 3.13, and were
dosed with 25mg kg-1 MCP-corn oil solution as described in single dose protocol 2 (Section 2.2.1.3). Control group was dosed
with corn oil. (A) Relative body weight was determined as described in Figure 3.5. (B) Serum alanine aminotransferase (ALT)
as liver toxicity marker was measured as described in Figure 3.7. Data was expressed as mean ± SD for groups of seven mice
(n = 7). Paired and unpaired student t-test were used for statistical analysis of A and B respectively. The arrow represents the
day of dosing with MCP or vehicle, whereas solid line represents a time when animal were exposed to BrdU in 10% orange
juice.
A BMCP
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differ significantly from the control group (Figure 3.18B). This result shows that the failure of
induction of DNA synthesis within two days was not unique to ciprofibrate, and suggests it was
common to PPARD agonists in general. 
Section 3.5 Effect of ciprofibrate on liver growth over five days
Administration of a single dose of ciprofibrate over two days does not cause induction of DNA
synthesis (Section 3.2). In this study, induction of DNA synthesis after a single dose of ciprofi-
brate over five days was tested to determine if ciprofibrate (300mg kg -1) was capable of induc-
ing DNA synthesis over five days. Groups of five 129S4/SvJae mice were treated with a single
dose of 300 mg kg-1 ciprofibrate or vehicle and killed after five days. No body weight loss was
observed in either group, but the treated group showed a significant body weight gain on the day
of killing as compared to the day of BrdU dosing (Figure 3.19A). Relative liver weight was sig-
nificantly increased from 4.2±0.39% in the control group to 5.3±0.22% in the group treated with
300 mg kg-1 ciprofibrate (Figure 3.19B). The labelling index in the treated group was signifi-
cantly increased from 0.2±0.1% in the control to 3±1.3% (15-fold increase) in the treated group
Figure 3.18 Induction of hepatic DNA synthesis after a single dose of methylclofenapate. Group of seven
mice treated with labelling protocol as described in Figure 3.13 were given a single dose of 25mg kg-1 MCP or corn oil vehicle
and killed after two days. (A) liver:body weight ratio was calculated as described in Figure 3.5. (B) hepatocyte labelling index
was calculated as described in Figure 3.4. Significantly difference was determined by unpaired Student's t-test,  p<0.01.
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(Figure 3.19C). ALT activity in treated mice did not significantly differ from the control group
(Figure 3.19D). This result shows that induction of DNA synthesis occurs within 5 days of a
single dose of ciprofibrate without liver toxicity. Together with Figure 3.14, it shows that cip-
rofibrate induces DNA synthesis more than two days after treatment with ciprofibrate. 
Figure 3.19 Induction of DNA synthesis in hepatocytes by ciprofibrate over five days.   Single dose of 300
mg kg-1 ciprofibrate was administered to five 129S4/SvJae male mice by gavage for five days as described in single protocol
2 (Section 2.2.1.3). Control group was dosed corn oil as vehicle. All mice were acclimatised in labelling protocol as described
in Figure 3.13. A: relative body weight and B: Liver-to-body weight percent were calculated as described in Figure 3.5; C:
Labelling index as percentage was calculated as described in Figure 3.4; D: serum ALT level as marker for hepatic damage
was determined as described in Figure 3.7. The bars show the mean ± SD and significant difference was determined by un-
paired Student's t-test for B, C and D and paired student t-test for A as described in Figure 3.5,  p<0.05. The arrow represents
the day of dosing with ciprofibrate or vehicle, whereas solid line represents a time when animal were exposed to BrdU in 10%
orange juice.
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Section 3.6 Kinetic studies on induction of liver growth in 129S4/SvJae 
mice
Previous sections had shown that peroxisome proliferators (ciprofibrate and methylclofenapate)
do not induce hepatic DNA synthesis within 48 hours (Section 3.2 and Section 3.4). We set out
experiments to characterise the time- and dose dependency of hepatic DNA synthesis, and
whether these effects were mediated by the PPARDreceptor. 
Section 3.6.1 Time-course effect of ciprofibrate in wild type 129S4/SvJae mice
The aim of the time-course experiment was to find out the earliest time point at which the in-
crease in hepatic DNA synthesis was significantly greater than control levels. Groups of five
male129S4/SvJae mice were acclimatised as described in Section 2.2.1.1, and were treated with
100mg kg-1day-1 ciprofibrate and killed on days 2, 3, 4, 5 and 6. Control groups were killed on
days 2 and 6 after dosing with the vehicle control. No significant body weight loss was observed
in the mice over 14 days (Figure 3.20A). Serum alanine aminotransferase (ALT) levels in treat-
ed groups at all time points did not differ significantly from the control groups (Figure 3.20B)
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Liver-to-body weight (LBW) ratio was significantly increased in treated groups by 48% at 2
days up to 113% at 6 days, as compared to the control (Figure 3.21A). Ciprofibrate failed to in-
duce DNA synthesis in the liver in the first two days, but days 3, 4 and 6 days showed significant
induction (11, 20 and 14-fold, respectively) compared to the control group (Figure 3.21B). Ad-
ditionally, even though the inter-animal variation in the treated groups at days 3 and 4 was high,
each individual animal has a labelling index that was higher than any of the animals treated with
corn oil vehicle. These results revealed that day 3 was the earliest time point when DNA syn-
thesis was significantly greater than control level. Treatment with 100mg kg-1day-1 for 6 days
ciprofibrate does not cause liver damage in 129S4/SvJae mice. 
Figure 3.20 Time course of effect of ciprofibrate on relative body weight and ALT level on wild-type 
129S4/SvJae mice.  Groups of five mice were dosed with ciprofibrate (100mg kg-1day-1) for 2, 3, 4, 5 and 6 days as de-
scribed in multiple dose protocol 1 (Section 2.2.1.4). Control groups were dosed with corn oil on days 2 and 6. (A) Relative
body weight (RBW) of the control and the treated groups pooled into two groups were determined as described in the Figure
3.5. Statistical analysis was performed between the day of BrdU dosing and the last day by using paired student t-test. Although
the result shows no significant body weight loss in the groups, 4-days and 6-days (wild type) treated groups showed a signifi-
cant increased in RBW (B) Serum ALT level was measured as stated in Figure 3.7. Statistical analysis was performed using
ANOVA described in Figure 3.5. Results are expressed as mean± SD of five mice per group. 5- and 6-day groups were given
BrdU on day 7. The remaining groups were given BrdU in day 8. Closed circles are control and open triangles are treated. Solid
line labelled BrdU represents the time when animals were exposed to BrdU in the 10% orange juice, whereas the solid line
labelled ciprofibrate represents the period of ciprofibrate dosing at daily intervals.
A BCiprofibrate
BrdU
Abdullah Al Kholaifi   Section 3.6.1
Page 90
 
Figure 3.21 Time course of effects of ciprofibrate on liver-to-body weight ratio and label-
ling index in male 129S4/SvJae mice.  Groups of five mice were treated as described in Figure 3.20.
(A) Liver:body weight (LBW) ratio as a percentage was determined as described in Figure 3.5. (B) Labelling
index was calculated as described in Figure 3.4. Data shown are mean ± SD. Significantly different from the
control was determined by one-way ANOVA and Dunnetts test.  = p<0.01;  = p<0.001. Closed circles
are control groups and triangle downs are ciprofibrate-treated groups.
A
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Section 3.6.2 Effect of ciprofibrate in PPARD knockout mice
The aim of this study was to test whether the effects of ciprofibrate seen in the Section 3.6.1
were mediated by the PPARD. The experiment was performed by using PPARD -/- mice
(129S4/SvJae background) [81]. Group of five null mice were treated with 0 and 100mg kg-1
day-1 ciprofibrate then killed on days 2 and 6. No significant body weight reduction was ob-
served in treated and control groups (Figure 3.22A). Liver enzyme alanine aminotransferase
level in treated groups did not differ from vehicle control after two or 6 days of treatment with
ciprofibrate.
Administration of ciprofibrate (100mg kg-1 day-1) did not affect the liver weight of PPARD KO
mice. The LBW ratio in ciprofibrate-treated mice was not significantly different compared to
control (Figure 3.23A). Moreover, labelling index in treated groups also did not differ from the
Figure 3.22 Assessment of body weight and liver status on 129S4/SvJae null mice treated with ciprofi-
brate.  Groups of five null mice were dosed with ciprofibrate (100mg kg-1day-1) for 2 and 6 days. Control groups were dosed
with corn oil.(A) Relative body weight (RBW) of the control and the treated groups pooled into two groups were determined
as described in the Figure 3.5. Statistical analysis was performed between the day of BrdU dosing and the last day by using
paired student t-test. Relative body weight; (B) ALT level on null mice were measured as described in Figure 3.7. Statistical
analysis was performed using ANOVA described in Figure 3.5. Results are expressed as means± SD of five mice per group.
Closed circles are control groups and open triangle are ciprofibrate-treated groups. Solid line labelled BrdU represents the time
when animals were exposed to BrdU in the 10% orange juice, whereas the solid line labelled ciprofibrate represents the period
of ciprofibrate dosing at daily intervals.
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control group on both days (Figure 3.23B). This finding demonstrate that the induction of DNA
synthesis by ciprofibrate was dependent on the PPARD receptor
 
Section 3.6.3 Dose-related effects of ciprofibrate on hepatic DNA synthesis in 129S4/
SvJae mice
To demonstrate whether there was a dose dependency in the response of mouse liver to induc-
tion of DNA synthesis by the peroxisome proliferator ciprofibrate, groups of six mice were gav-
aged with 0, 1, 3, 10, 30, 100 or 200 mg kg-1 day-1 ciprofibrate in corn oil for 3 days, or were
gavaged with 0,10,30,100 mg kg-1 day-1 ciprofibrate for 4 days. Control animals were given ve-
hicle (corn oil). 3 and 4 days of treatment were chosen in this study because they showed a max-
imal induction of DNA synthesis in the time-course study (Section 3.6.1). Dosing the animals
with ciprofibrate and BrdU did not cause any body weight reduction during the study (Figure
3.24A). However, RBW at the day of killing in 3-day control showed a statistical decrease,
Figure 3.23 Effect of ciprofibrate on induction of DNA synthesis in 129S4/SvJae null mice. Group of five
null mice acclimatized as described in Section 2.2.1.1 were dosed with 100mg kg-1day-1ciprofibrate for 2 and 6 days. (A) Liv-
er/body weight ratio was calculated as described in Figure 3.5; (B) Labelling index percent was calculated as described in
Figure 3.4. Unpaired t-test was used for statistical analysis. Data was expressed as mean±SD. 
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whereas in the 4-day treated group there was a statistical increase in RBW as compared to the
corresponding group in the day of BrdU dosing. Both these effects were small, and it was not
clear if they were of biological significance. Moreover, serum ALT levels in treated groups of
mice treated with ciprofibrate for 3 and 4 days did not display any significant difference from
the corresponding control group (Figure 3.24B). 
Figure 3.25A showed that dosing of ciprofibrate for 3-day period at concentration up to 3mg kg-
1day-1 produced no change in the liver-to-body weight (LBW) ratio. However, the dose-depen-
dency study revealed that liver to body weight ratios were statistically increased in mice treated
with 10mg kg-1day-1 and greater ciprofibrate at 3- and 4-days. The LBW ratio was 5.2% (1.2-
fold over control) at 10mg kg-1 day-1 for both exposure times. The LBW ratio increased in a
dose-dependent manner with maximum increase to 6.7% (1.5-fold over control) at 200mg kg-
1day-1 for 3-day dosing, and 7% (1.7-fold over control) at 100mg kg-1day-1 for 4-day dosing.
Induction of hepatic DNA synthesis was measured in these animals. Figure 3.25B showed that
Figure 3.24 Assessment of body weight and liver status in dose-related effects of ciprofibrate.  Groups of
six male 129S4/SvJae mice were dosed with 0, 1, 3, 10, 30, 100 or 200 mg kg-1 day-1 ciprofibrate in corn oil for 3 days (Figure
2.4), or were gavaged with 0,10,30,100 mg kg-1 day-1 ciprofibrate for 4 days (Figure 2.5). Control animals were given vehicle
(corn oil). (A) Relative body weight (RBW) was calculated and statistical tested as described in Figure 3.5; (B) Serum ALT
level were measured and statistically tested as described in Figure 3.7. Results are expressed as means±SD of six mice per
group. Closed circles are 3-day control, open circles are 3-days treatment, closed triangle downs are 4-days control and open
triangle up are 4-day treatment. Solid line labelled BrdU represents the time when animals were exposed to BrdU in the 10%
orange juice, whereas the solid line labelled ciprofibrate represents the period of ciprofibrate dosing at daily intervals.
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after 4 days of ciprofibrate treatment, the animals demonstrated progressively increased BrdU-
labelled DNA of 2.7±0.97% (8-fold over control) and 3.7±1.49% (11-fold over control) at dose
levels of 30 and 100mg kg-1day-1 ciprofibrate respectively as compared to control, while ani-
mals treated with ciprofibrate over 3 days showed a significant increase in labelling index by 7-
fold increase (1.0±0.59%) over the control only at an exposure level of 100mg kg-1day-1 cipro-
fibrate. The magnitude of induction of DNA synthesis at dose levels 30 and 100mg kg-1day-1 in
4 days treatment were 7- and 4-fold higher than those in 3 days treatment. These results confirm
that ciprofibrate at dose 30 mg kg-1day-1 for four days or 100mg kg-1day-1for three days were
doses that induce hepatic DNA synthesis significantly over the control male 129S4/SVJae mice
without any liver toxicity.
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Figure 3.25 Dose-related effects of ciprofibrate on liver growth in 129S4/SvJae mice.  Group of six mice
were acclimatized as described in Section 2.2.1.1. The groups were gavaged with 0, 1, 3, 10, 30, 100 or 200 mg kg-1 day-1
ciprofibrate, or with 0,10,30,100 mg kg-1 day-1 ciprofibrate and killed after three or four days respectively. Control groups
were dosed with corn oil as vehicle. (A) liver-to-body weight ratio was calculated as described in Figure 3.5; (B) hepatic la-
belling index was determined as described in Figure 3.4. Statistical analysis was performed as described in Figure 3.21. Data
shown are mean ±SD. Circles are 3 days treatment and triangles down are 4 days treatment.
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Section 3.7  Induction of liver growth by ciprofibrate in female 129S4/
SvJae mice
In order to characterise the induction of DNA synthesis in both sexes of 129S4/SvJae mice,
groups of female mice were dosed with 100mg kg-1day-1 ciprofibrate by gavage then killed after
3 or 4 days of treatment. 
Section 3.7.1 Three days dosing
Group of seven female 129S4/SvJae mice (9-10 weeks old) were dosed with 100mg kg-1day-1
ciprofibrate by gavage for three days. control group was dosed with corn oil as vehicle. All mice
were acclimatised as described in Section 2.2.1.1 before treatment with ciprofibrate. Relative
body weight and serum ALT level were measured. As shown in Figure 3.26A, no body weight
reduction was seen in the mice in either group. However, the treated group showed a significant
increase in body weight at the day of killing when compared to the day of BrdU dosing. Serum
ALT level of the ciprofibrate-treated group was not statistically different from the control group
(Figure 3.26B). 
Figure 3.26 Body weight and ALT of female 129S4/SvJae mice treated with ciprofibrate for three days. 
Groups of seven female mice were dosed with 100mg kg-1 day-1 ciprofibrate then killed after three days as described in mul-
tiple protocol 2 (Figure 2.4). Control group was dosed with corn oil. All mice were acclimatised as described in Figure 3.13.
(A) Relative body weight was calculated and statistically tested as described in Figure 3.5; (B) Serum ALT level was measured
and statistically tested as described in Figure 3.7. Data was expressed as mean±SD, n=7. Solid line labelled BrdU represents
the time when animals were exposed to BrdU in the 10% orange juice, whereas the solid line labelled ciprofibrate represents
the period of ciprofibrate dosing at daily intervals.
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Figure 3.27A shows liver:body weight ratio was significantly increased from 4±0.4% in the
control group to 6±0.3% in the 100mg kg-1day-1 treated group. However, although labelling in-
dex was higher in the treated group as compared to the control, labelling index in the treated
group did not differ significantly from the control (Figure 3.27B). These results shows that al-
though three days of ciprofibrate (100mg kg-1day-1) dosing induced hypertrophy in liver, it did
not significantly induce DNA synthesis over the control. 
Figure 3.27 Induction of DNA synthesis in female 129S4/SvJae mice by ciprofibrate for three days. 
Group of seven female 129S4/SvJae mice were dosed with 100mg kg-1day-1ciprofibrate and killed after three days. The mice
were treated as described in Figure 3.26. (A) Liver: body weight ratio (%) was calculated as in Figure 3.5 (B) Labelling index
was calculated as described in Figure 3.4. Significantly difference was determined by Student's t-test,  p<0.01. Data was
expressed as mean±SD.
A
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Section 3.7.2 Four days dosing
Groups of six female 129S4/SvJae mice was gavaged with 100mg kg-1day-1 ciprofibrate for
four days. The control group was treated with corn oil vehicle. All animals were acclimatised
using the protocol described in Section 2.2.1.1. before dosing. No body weight loss was ob-
served in the mice after dosing with BrdU. In the treated group, there was a significant increase
in RBW at day 12 as compared to the day of BrdU dosing (Figure 3.28A). There was no signif-
icant difference in ALT between treated and control mice after four days of ciprofibrate dosing
(Figure 3.28B). 
Mice treated with ciprofibrate showed a significant increase in liver:body weight ratios, rising
from 4±0.7% in the control group to 6.8±0.5% in the treated group (Figure 3.29A). In contrast
to 3 days dosing, the labelling index was significantly increased from 0.7±0.5% in the control
group to 4.4±3.9% in the treated group (6-fold increase) after 4 days dosing with ciprofibrate
(Figure 3.29B). Thus, four days dosing with ciprofibrate (100mg kg-1day-1) can induce DNA
synthesis (hyperplasia) as well as liver growth (hypertrophy) in female mice.
Figure 3.28 Body weight and ALT level of female 129S4/SvJae mice treated with ciprofibrate for four 
days. Groups of female mice were dosed with 100mg kg-1 day-1 ciprofibrate and killed after four days as described in mul-
tiple protocol 2 (Figure 2.5). Control group was dosed with corn oil. All mice were acclimatised as described in Figure 3.13.
(A) Relative body weight was calculated and statistically tested as described in Figure 3.5; (B) Serum ALT level was mea-
sured and statistically tested as described in Figure 3.7. Data was expressed as mean±SD, n=6. Solid line labelled BrdU rep-
resents the time when animals were exposed to BrdU in 10% orange juice, whereas the solid line labelled ciprofibrate
represents the period of ciprofibrate dosing at daily intervals. 
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Figure 3.29 Induction of DNA synthesis in female 129S4/SvJae mice by ciprofibrate for four days. 
Group of six female 129S4/SvJae mice were treated as mentioned in Figure 3.28 (A) Liver: body weight ratio (%) was cal-
culated as in Figure 3.5 (B) Labelling index was calculated as described in Figure 3.4. All data was expressed as
mean±SD.Significant difference was determined by Student's unpaired t-test,  p<0.05 and  p<0.0001. 
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Section 3.8 Sex differences of liver growth induction by ciprofibrate in 
129S4/SvJae mice
The aim of this study was to examine sex differences in the induction of liver growth by cipro-
fibrate. The effect of ciprofibrate (100mg kg-1day-1) treatment on hepatic DNA synthesis was
compared in male and female mice by comparing the results of female mice in the Section 3.7
with the results of male mice in the Section 3.6.1 and Section 3.6.3. As shown in Figure 3.30,
liver:body weight (LBW) ratio in treated-males was significantly greater than in treated-females
receiving ciprofibrate for three days. Moreover, LBW of treated male mice (experiment 1) was
significantly higher than those in treated female mice over four days. 
No sex differences in the labelling index induction of DNA synthesis by ciprofibrate was ob-
served as the labelling index in treated males did not significantly differ from those in the treated
Figure 3.30 Sex differences in relative liver growth on 129S4/SvJae mice induced by ciprofibrate. 
Liver:body weight (LBW) ratios of treated female group dosed with 100mg kg-1day-1ciprofibrate were compared with
those of treated-male groups over three and four days. Liver:body weight (LBW) ratio from two experiments, time-
course (1) and dose dependency studies (2) of male mice were used for comparison with LBW of female mice. All data
was expressed as mean±SD. Significant difference was determined by one-way ANOVA and posthoc by Newman-
Keuls.  significant difference was compared between treated female and treated male of same day.
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females (Figure 3.31). 
Figure 3.31 Sex differences in labelling index on 129S4/SvJae mice following treatment with ciprofi-
brate. Labelling index of treated female group dosed with 100mg kg-1day-1ciprofibrate were compared with those of
treated-male group over three and four days. The male mice had the same dose of ciprofibrate. Labelling index from two
experiments, time-course (1) and dose dependency studies (2) of male mice were used for comparison with LI% of female
mice. All data was expressed as mean±SD. Significant analysis was determined by one-way ANOVA and Newman-Keuls.
 significant difference as compared to treated female in the same day.
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Section 3.9 Time-course effect of methylclofenapate on 129S4/SvJae mice
Section 3.6.1 had shown that the induction of DNA synthesis occur after three-to-four days of
ciprofibrate dosing (Section 3.6.1). To investigate if this time-course of DNA induction was an
idiosyncratic response to ciprofibrate, methylclofenapate was used to study the time-course of
induction of DNA synthesis. Groups of six male 129S4/SvJae mice (9-10 weeks old) were
dosed with 25mg kg-1day-1 methylclofenapate and killed 2,3 and 4 days later. The control
groups were killed on days 2 and 4 after dosing with corn oil as vehicle. Administration of BrdU
or MCP did not cause any statistically significant body weight loss in the mice, as determined
using a paired t-test on the pooled control or MCP-treated relative body weights, comparing be-
tween the initial day of dosing and subsequent days. However, there was a statistically signifi-
cant increase in relative body weight in the animals killed after 2 or 3 days treatment with MCP
(but not vehicle), as compared with day 0 (paired t-test, p<0.05) (Figure 3.32A). No liver tox-
icity was noticed among the mice treated with MCP as ALT activities in treated mice were not
significantly different from those in the control groups (Figure 3.32B). 
Figure 3.32 Time course effect of methylclofenapate on relative body weight and ALT activity. Groups
of six 129S4/SvJae mice were dosed with 25mg kg-1 day-1 MCP and killed on days 2, 3 and 4 as described in multiple pro-
tocol 1 (Figure 2.3). Control groups were dosed with corn oil as vehicle and killed on days 2 and 4 after dosing. All mice
were acclimatised as described Figure 3.13. (A) Relative body weight was calculated and statistically tested as described in
Figure 3.5; (B) Serum ALT level a liver toxicity marker was measured and statistically tested as described in Figure 3.7. All
data was expressed as mean±SD, n=6. Solid line labelled BrdU represents the time when animals were exposed to BrdU in
10% orange juice, whereas the solid line labelled MCP represents the period of MCP dosing at daily intervals.
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 As shown in Figure 3.33A, treatment of the mice with 25mg kg-1day-1 MCP for four days
caused enlargement of the liver by up to ~66% of control. Liver-to-body weight (LBW) ratio
was significantly increased from 4.0±0.27% in control group up to 7.3±0.19% in treated groups
at day 4. The LBW increased in a time dependent manner (Figure 3.33B). Similar to ciprofibrate
action, methylclofenapate (25mg kg-1day-1) failed to induce hepatic DNA synthesis within 2
days, but a significant increase in labelling index was observed by day 3 and maintained on day
4 (Figure 4.32C). Thus, the delayed time course of induction of hepatic LI was not a conse-
quence of the particular PP (ciprofibrate), since another peroxisome proliferator methylclofena-
pate (MCP) gives similar results. 
Figure 3.33 Time course of effects of methylclofenapate on DNA synthesis in 129S4/SvJae mice. Groups of
six male mice were acclimatized as described Figure 3.13 before gavage with 25 mg.kg-1.day-1 methylclofenapate (MCP) in
corn oil. The mice were killed after 2, 3 and 4 days of treatment with MCP. The control groups were killed on first and last
time points. (A) Enlargement the liver after treated with MCP for 4 days. (B) Liver:body weight ratio (%) was determined and
statistically tested as described in Figure 3.5. (C) Labelling index (%) was calculated and statistically tested as described in
Figure 3.4. Data shown are mean ± SD.  = p<0.01.
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Section 3.10 Strain differences in induction of DNA synthesis by methyl-
clofenapate in mice
A time course was performed in a different mouse strain, Alderley Park mice, to find out if there
was a strain-dependent difference in DNA synthesis using the peroxisome proliferator MCP.
Styles had reported that treatment of AP mice with 25mg kg-1day-1 methylclofenapate (MCP)
induced hepatic DNA synthesis by ~ 24 hours [113]. Groups of six AP mice were treated with
25mg kg-1day-1 methylclofenapate and killed on days 1, 2, 3 and 4. Control groups were killed
on days 1 and 4 after dosing with a vehicle control. Body weight was not significantly decreased
by treatment with MCP or corn oil (Figure 3.34A). However, 3 days-treated group shows sig-
nificant body weight gain at the day of killing compared to the day of BrdU dosing. No liver
injury occurred since the ALT activities in the treated groups did not significantly differ from
those in the control group (Figure 3.34B). 
The liver:body weight ratio was significantly increased from 5±0.55% in the control group to
5.7±0.34% (14% increase), 6.8±0.49% (36% increase), 7.9±0.5% (58% increase) and 8.3±0.7%
Day
1 2 3 4
A
L
T
 (
U
/L
)
0
100
200
300
Corn oil
Methylclofenapate (25mg kg
-1
day
-1
)
Figure 3.34 Time course of effects of methylclofenapate (MCP) on relative body weight and ALT activi-
ties in Alderley park (AP) mice. :Groups of six Alderley Park mice were dosed with 25mg kg-1 day-1 MCP and killed
on days 1,2, 3 and 4 as described in multiple protocol 1 (Figure 2.3). Control groups were dosed with corn oil as vehicle and
killed on days1 and 4 after dosing. All mice were acclimatised as described Figure 3.13 (A) Relative body weight was calcu-
lated and statistically tested as described in Figure 3.5; (B) Serum ALT level a liver toxicity marker was measured and sta-
tistically tested as described in Figure 3.7. All data was expressed as mean±SD, n=6. Solid line labelled BrdU represents the
time when animals were exposed to BrdU in 10% orange juice, whereas the solid line labelled MCP represents the period of
MCP dosing at daily intervals.
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(66% increase) in treated groups at 1, 2, 3,and 4 days respectively (Figure 3.35A). However,
MCP induced DNA synthesis in AP mice after 4 days of dosing. This increase was statistically
significant (584% increase) at day 4, but not significant (183% increase) at day 3 compared to
the control group (Figure 3.35B). These results show that treatment of AP mice with 25mg kg-
1day-1 methylclofenapate (MCP) failed to induce DNA synthesis within 48 hours as Styles re-
ported, and confirm my data with a different peroxisome proliferator (ciprofibrate) and different
strain (129S4/svJae), and show that the difference between our results and those of Styles were
not due to mouse strain or peroxisome proliferator. 
For comparison purposes, liver:growth ratio and labelling index data from 129S4 and AP mice
treated with 25mg kg-1day-1 methylclofenapate were plotted together to examine strain differ-
ences. As shown in Figure 3.36, data for the 129S4 mice day one was not available as this group
had shown previously no induction on DNA synthesis within 48 hours (Section 3.4). The basal
levels of Liver:body weight ratio in AP mice were greater than those in 129S4 mice. Also, the
liver:body weight (LBW) ratio in MCP-treated AP mice was significantly greater than at in
Figure 3.35  Time course of effects of methylclofenapate (MCP) on DNA synthesis in Alderley park (AP) 
mice.  Groups of six male AP mice were treated as described in Figure 3.34. (A) Liver:body weight ratio (%) was determined
and statistically tested as described in Figure 3.5; (B) Labelling index ratio (%) was calculated and statistically tested as de-
scribed in Figure 3.4. Data shown are expressed as mean±SD, n=6.
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MCP-treated 129S4 mice at all time points. However, the magnitude of induction of LBW in
129S4 (84% increase) was greater than that in AP mice (65% increase) at day 4 (Figure 3.36A).
On the other hand, the basal levels of labelling index in AP mice (0.8±0.9) were greater than
those in the 129S4 mice (0.15±0.1). Labelling index was significantly increased in 129S4 mice
on days 3 and 4, but it increased significantly at day 4 in AP mice compared to the correspond-
ing control., 
Section 3.11 Time course of ciprofibrate on liver growth in F-344/NHsd 
Rat
The hypothesis that ciprofibrate induces hepatic DNA synthesis during the process of augmen-
tative growth in rats with a different time-course to mice was examined. The species differences
was examined by dosing groups of male F344/NHsd rats with 50mg kg-1day-1 ciprofibrate for
1, 2, 4 days. Control groups were dosed with corn oil as vehicle and killed on the first and last
days of dosing. 
Unexpectedly, in this experiment, dosing the rats with 0.08% BrdU resulted in a confounding
issue. There was a significant (p<0.01) loss in the body weight which was 5% in the control
Figure 3.36 Strain differences in induction of liver growth by methylclofenapate (MCP). Groups of six
male 129S4/SvJae and AP mice were dosed with 25mg kg-1day-1MCP for 2, 3, 4 or 1, 2, 3 and 4 days respectively. Control
groups were dosed corn oil on the first and last days of dosing. (A) Liver: body weight ratio (%) was determined and statis-
tically tested as described in Figure 3.5; (B) Labelling index ratio (%) was calculated and statistically tested as described in
Figure 3.4. Data was expressed as mean±SD, n=7.
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groups and 7% in the treated groups after BrdU-dosing. This confounding result limits the in-
terpretation of information from this study of the liver growth in the rat (Figure 3.37A). How-
ever, treatment with MCP (50mg kg-1day-1) did not cause liver toxicity to the rat since the ALT
level in the treated rat did not significantly differ from the control rats (Figure 3.37B). 
A
B
Figure 3.37 Time course of effects of ciprofibrate on relative body weight and ALT activities in F-344/
NHsd rat. Groups of six rats acclimatised as described in Figure 3.13 were dosed with 50mg kg-1 day-1 ciprofibrate and
killed on days 1,2, and 4 as described in multiple protocol 1 (Figure 2.3). Control groups were dosed with corn oil as vehicle
and killed on days1 and 4 after dosing. All mice were acclimatised as described Figure 3.13 (A) Relative body weight was
calculated and statistically tested as described in Figure 3.5; (B) Serum ALT level a liver toxicity marker was measured and
statistically tested as described in Figure 3.7. All data was expressed as mean±SD, n=5,  p<0.001. Solid line labelled BrdU
represents the time when animals were exposed to BrdU in 10% orange juice, whereas the solid line labelled ciprofibrate
represents the period of ciprofibrate dosing at daily intervals.
ciprofibrate
BrdU
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Liver: body weight ratio was significantly increased in treated groups at all times in a time-de-
pendent manner, rising from 3.7±0.23% in the control group to the 4.2±0.29% (14% increase),
4.65±0.25% (26% increase), and 5.66±0.3% (54% increase) in the treated groups at 1, 2, 4 days
respectively (Figure 3.38A). Labelling index was significantly increased rising from 1.3±0.37
in the control to 24.3±10%, and 38.4±16% in the treated groups at 2 and 4 days respectively
(Figure 3.38B). Although there was a significant body weight loss during the dosing, labelling
index was significantly increased at day 2 of ciprofibrate dosing, which shows that rat has an
earlier induction of DNA synthesis than mouse. 
Figure 3.38 Time course effect of ciprofibrate on liver growth on F-344/NHsd rat. Groups of six rats were
treated as described in Figure 3.37. (A): Liver-to-body weight percent was measured and statistically tested as described in
Figure 3.5; (B): Labelling index (%) was calculated and statistically tested as described in Figure 3.4. The bars show the mean
± SD.  p<0.01.
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B
Abdullah Al Kholaifi   Section 4.1
Page 109
Chapter 4 Discussion
Section 4.1 Method validation
Section 4.1.1 Assessment of immunohistochemical detection 
Immunohistochemistry is a common technique for detection of incorporated BrdU during rep-
lication of DNA in hepatocytes [165] [166] [207]. The procedure requires successful denatur-
ation of DNA to facilitate the binding of Anti-BrdU antibodies to incorporated BrdU in DNA.
Moreover, an optimized concentration of primary and secondary antibodies is also required to
yield a good signal-to-noise ratio for BrdU-labelling. For these reasons, histologic estimation of
S-phase labelling indices was employed to ensure the ability of the detection protocol to detect
BrdU-labelled nuclei with a good signal-to-noise (S/N) ratio and to exclude any false positive
or false negative. The detection system was examined by using different levels of positive con-
trol tissues: xenograft tumour tissue, which was known to have a high level of BrdU incorpora-
tion, to evaluate the immunohistochemical detection; liver and gut tissues from mice treated
with BrdU (0.8mg ml-1) to assess the labelling and detection of BrdU-labelled nuclei in vivo.
The results showed that the detection system is specific and reliable for determination of BrdU
in tissue (Figure 3.1 and Figure 3.2).
Section 4.1.2 Assessment of fixation time and temperature on immunohistochemistry
Fixation time and temperature play a role in successful immunohistochemistry. Formalin is the
most commonly used fixative [167], and forms a cross-linking methylene bridge between ba-
sic amino acids. This cross-link can mask the antigenic sites of BrdU in DNA and longer fixa-
tion in formalin is associated with less intense staining [162]. For this reason, liver and gut
tissues from 0.08% BrdU-treated mice were used to optimise the fixation time and tempera-
tures. Furthermore, liver tissues from animals treated with TCPOBOP were also used to evalu-
ate the affect of fixation time since the BrdU-labelled nuclei were higher in the TCPOBOP-
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treated liver, which yielded easier microscopic characterisation to evaluate signal intensities of
labeled nuclei (Figure 3.3). The data was consistent with the work of Hayashi et al. (1988) who
showed that fixation length of up to 7 days does not affect the intensity of staining of BrdU-
labelled rat gut tissues [162]. On the other hand, temperature effects on the fixation process were
significant, with room temperature fixation yielding better staining than fixation at 4ºC. This
may be due to higher temperature producing rapid fixation as proposed by [168].
Section 4.1.3 Optimisation of in vivo BrdU dosing
BrdU is rapidly degraded by dehalogenation in the liver [169] [170] [171], so the level of sys-
temic BrdU will reduce rapidly after an acute bolus dose, e.g. by gavage or intra-peritoneal in-
jection, leading to a limitation in availability of BrdU for incorporation into DNA [170]. Given
the short half-life of BrdU, it was essential to validate that dosing with 0.8mg ml-1BrdU in
drinking water continuously for three days lead to effective labelling of DNA. In this in vivo
model, gut sections were used as a positive control to evaluate BrdU delivery and immunohis-
tochemical staining since this tissue has fast cell turnover (Figure 3.2B and D). After three days
of treatment with BrdU, labelled nuclei in the gut covered all the intestinal crypts and most of
the villi compartment; the proliferation and differentiation of epithelial cells occurs in the
crypts, and the cells gradually move toward the tips of the villi [172] (Figure 3.2D).
Section 4.1.4 BrdU-labelling protocol
BrdU has been routinely used in study of induction of DNA synthesis for long time [156], fre-
quently used as an alternative labelling agent in place of [3H]-thymidine. [3H]-thymidine and
BrdU have been shown to give equivalent results under some circumstances [173], and BrdU
allows faster studies without radioactive containment problems. The relationship between
BrdU-labelling, as a function of time, and incorporation of BrdU during DNA synthesis in he-
patocytes is not fully understood. In small intestine, as the duration of BrdU exposure increased,
Abdullah Al Kholaifi   Section 4.1.4
Page 111
the numbers of BrdU-labelled nuclei were increased [156]. This finding is consistent with my
work; as the number of days of BrdU exposure increased, the percentage of labelled nuclei on
the villi of gut section increase linearly. Moreover, Kiel et al. (2007) examined haematopoietic
stem cells (HSCs) in C57BL/ka mice treated with BrdU, and found that BrdU incorporation
over time was linear [174]. However, in liver, the linearity of BrdU labelling over time is con-
troversial. Ton et al. (1997) have shown that the number of BrdU-labelled hepatocyte nuclei in
mice increased over time when using a mini-pump, but not with drinking water, over three days
of BrdU dosing [156]. However, this relationship between exposure time to BrdU, and labelling
index, was not seen in rats in the same study. In present study, the labelling index (LI) after three
days of BrdU in control group was similar to the LI of control group after 6 days of dosing, al-
though the failure to discriminate between these two time-points might be due to a lack statisti-
cal power arising from the low labelling index in control animals. In general, potential
explanations of non linearity include that the cells that undergo DNA synthesis subsequently
die, or alternatively that the same individual cell undergoes DNA synthesis many times.
In this project, the continuous labelling method was chosen over single pulse injection based on
published literature showing that continuous labelling increase the sensitivity of the assay, by
measuring the cumulative number of BrdU-labelled cells in S-phase rather than labelling cells
at a particular point in time [175] [46]. Additionally, continuous labelling avoids pitfalls asso-
ciated with any diurnal variation in DNA synthesis [176]. Thus, continuous labelling is consid-
ered as a method of choice for studying cells characterised by low cell turnover i.e. hepatocytes
[175]. The advantage of continuous labelling over a single dose was demonstrated by Marsman
et al. (1988). Animals were treated with the peroxisome proliferators, Wy14,643 or DEHP, and
the LI response evaluated with a single acute dose, or 7-day osmotic pumps, containing tritiated
thymidine. The LI response detected with 7-day osmotic pumps increased 5- to 10-fold in the
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rats receiving Wy14,643 as compared to control or DEHP-fed rat, whereas using a single acute
dose of thymidine did not show any difference in labelling index between the three groups
[145]. This is evidence that the chronic labelling protocol has greater sensitivity for detecting
low levels of DNA synthesis.
BrdU can be continuously administered either by osmotic pump or in the drinking water. In this
study, drinking water was used to administer BrdU since it involves easier application and
avoidance of surgical stress to the animal [46] [156], by comparison to implanting mini-pumps.
The dosing of BrdU at a concentration of 0.8mg ml-1 in drinking water was chosen based on
previous literature [177] [46] [163] [156], and it has been reported that continuous administra-
tion of BrdU at up to 1mg ml-1 had no adverse effect on the animal [156]. 
In this study, dosing mice with BrdU in drinking water decreased body weight (Figure 3.5B).
This issue might affect the induction of DNA synthesis and confound the interpretation. This
phenomenon has been described previously in the literature. For example, Jecker et al. (1997)
reported that water consumption was reduced when LEW rats were given 1mg ml-1 BrdU with-
out 16% orange juice, and LEW rats refused to drink at a BrdU concentration of 1.5mg ml-1
[169]. Reome et al. (2000) also reported that C57BL/6 mice given 1 mg ml-1 BrdU in drinking
water exhibited a body weight loss as compared to control [163]. However, the elementary con-
trol of measuring body weight is rarely described in the contemporary literature; thus many
studies may have a confounding effect of body weight loss. It was therefore necessary to alter
the experimental design to maintain the body weight of the mice before continuing; in all sub-
sequent experiments, mouse body weight was measured. 
An unpleasant taste of BrdU in water was postulated to be the factor causing the mice to stop
drinking BrdU-containing water and then lose body weight. Several attempts were made to
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overcome this problem. The unpleasant taste of BrdU was masked by adding orange juice (1:6)
to 0.08% BrdU water as proposed by Jacker et al. (1997), decreasing the level of BrdU (up to
0.05%) or both. Although the 0.05% BrdU supplemented with 16% orange juice regime in-
creased body weight about 2% in 3 days in the optimising experiment (Figure 3.6), this labelling
regime (0.05%BrdU+16% orange juice) did not help to maintain body weight in control and
treated mice as shown in Figure 3.7C. This might be because: a) the number of mice in the op-
timising experiment was insufficient to reveal the effect of 0.05%BrdU+16% orange juice re-
gime; b) acidity of orange juice; or c) a lack of mouse acclimatisation.
The BrdU dosing protocol was varied in two parameters in an attempt to control body weight
during experimental work. Firstly, review of experimental data revealed that mice undergoing
experimental work lost approximately one gram in body weight in the first day of treatment.
One possible explanation is that the mice were not used to handling, consequently urinated
when handled, and so weight loss could arise partly from urination. Therefore, the animals were
acclimatised to handling on a daily basis for seven days, prior to beginning dosing with xeno-
biotics. Secondly, the palatability of the BrdU remained as a possibility. So, animals were ac-
climatized to 10% juice, with the intention that this would mask the taste of the BrdU, whilst
not making the orange juice too concentrated for consumption by the animals. This protocol was
implemented in 129S4/Jae mice, and it successfully maintained body weight during dosing with
0.08% BrdU, and dosing with ciprofibrate (Figure 3.13A), whilst maintaining effective label-
ling of cells undergoing DNA synthesis (Figure 3.14A). The maintenance of mouse body
weight during the experimental protocol removes a potentially confounding variable from the
experiments.
Although Figure 3.13A validates the protocol for 129S4/SvJae mice, it did not immediately fol-
low that the protocol could be simply applied to other mice strains. For example, there were
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large strain differences in body weight, food intake, and water intake in 28 inbred mouse strains
[178], and the variation in water intake between the mice strains would cause the mice to be ex-
posed to different levels of BrdU on a mg/kg body weight basis. There were also the possibilities
that different mouse strains could have different taste responses to BrdU, or differentially suffer
from BrdU toxicity. For these reasons, it was necessary to test the BrdU dosing protocol on each
strain of mouse (and F-344 rat) tested. DBA/2J (Figure 3.9), C57BL/6J (Figure 3.10) and AP
(Figure 3.11) mice were acclimatized successfully to the protocol and administration of BrdU
in 10% orange juice and did not show any body weight loss.
Section 4.2 Serum ALT as a marker for liver injury
PPARD ligands can cause focal necrosis [133], thereby leading to regenerative growth and cell
proliferation. For example, Woods et al. (2007) have shown there was body weight loss in
C57BL/6J and congenic p47phox-/- mice after treatment with WY-14,643 (0.1%), ALT levels
increased significantly after one week of dosing, and there was marked hepatic necrosis and in-
flammation [179]. Therefore, serum ALT (a marker of liver cell damage) was measured to en-
sure the doses used for the induction of liver growth were not cytotoxic, and consequently
inducing regenerative regrowth, but were rather a PP-induced augmentative liver growth. ALT
has been used extensively to assess liver injury in animals [180] [179]. ALT was preferred over
AST because ALT is more specific for liver than AST; specifically, the ALT assay is not affect-
ed by hemolysis, whereas the AST assay is so affected [181] (Al Kholaifi et al., unpublished
data). In this study, ALT activity in the serum was unaffected by the doses of PPARD ligands
used either in rats or in mice. This finding was consistent with published data by Bondy et al.,
showing that dosing F-344 rat with 0.025% ciprofibrate up to 40 weeks did not elevate ALT
level over the control [180]. Although administration of TCPOBOP, a CAR ligand, increased
ALT levels three-fold in male mice, but not in females, the increased level of cell death associ-
ated with this increase in ALT would not be sufficient to induce large scale regenerative growth
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in the liver, and consequently, the increase in ALT and cell death does not account for the potent
mitogenicity of TCPOBOP (Figure 3.16). For example, an agent like carbon tetrachloride pro-
duces >10000-fold increase in serum ALT level in mice [182]; and so, TCPOBOP is only in-
creasing hepatocyte death marginally.
Section 4.3 Induction of hepatic DNA synthesis in vivo by peroxisome 
proliferators
Section 4.3.1 Induction of DNA synthesis by single dose of peroxisome proliferators
It was reported that the induction of DNA synthesis in the mouse occurred as early as 24 hours
after dosing with the potent PPARD ligand, MCP [113] [164]. Mouse was used as a model in
the current study because the availability of mouse genetic models, such as knock-out mice, en-
ables investigations that would not otherwise be possible. The 129S4/SvJae strain was charac-
terized initially, as the PPARD null strain [81] is available on this genetic background, and the
comparison of the effects of a chemical between PPARD wild-type and nullizygous mice en-
ables an experimental determination of the role of PPARD in the response to the chemical. 
Marked differences in potencies of PPARD ligands are known to exist [36] [92]. Reddy reported
that treatment of rats with ciprofibrate (0.01%), DEHP (1%) or DEHA (1%) for 30 days in-
creased the liver weight 100%, 75% or 12% respectively [92]. Treatment of rat hepatocytes with
various PPs at 100-500µM for 72 hours induced peroxisome proliferation in the following se-
quence: ciprofibrate = nafenopin > benzafibrate > clofibric acid > di-(2-ethylhexyl)phthalate
[183]. The available evidence supports the fact that ciprofibrate is a potent PPARD ligand; how-
ever, it is necessary to examine the possibility that the dose of ciprofibrate was insufficient to
induce hepatic DNA synthesis. The range of doses of ciprofibrate (0-75mg kg-1) used in the pi-
lot study (Figure 3.4) did not provide any sign that induction of DNA synthesis occured over
two days. This might be because the dose range used was not capable of inducing DNA synthe-
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sis, and so a dose ranging study using 100-400 mg kg-1 ciprofibrate was tested in 129S4/SvJae
mice acclimatised to 10% orange juice. This dose range of ciprofibrate caused a significant in-
duction in the liver: body weight ratio in treated animals without any hepatic toxicity (i.e. no
significant increase in ALT of treated mice, or grossly altered liver histology), but no significant
induction in hepatic DNA synthesis was observed, and the incidence of mitotic figures was not
measured. The fact that ciprofibrate caused an induction in the liver: body weight ratio is strong
evidence that the ciprofibrate is being given at a dose that causes an effect; hence it was neces-
sary to determine if other factors were responsible for the failure to detect or induce S-phase in
the liver of ciprofibrate treated mice. 
The first issue to be considered was whether the methodology was sensitive enough to measure
an early induction of DNA synthesis in the liver within 48 hours. This issue was addressed by
using a positive control compound, TCPOBOP; TCPOBOP does not activate PPARD, but in-
stead activates a different nuclear receptor, CAR, to mediate its effects on liver [47]. TCPOBOP
triggered a fast DNA synthesis response in mouse liver two days after dosing [207]. Figure 3.2
shows clear labelling of replicating cells in liver and intestine, and in mice treated with 3mg kg-
1 TCPOBOP, there was a large and statistically significant induction of the hepatocyte labelling
index compared to vehicle treated animals. In addition, because sex differences in induction of
DNA synthesis by TCPOBOP exist, the current protocol was capable of measuring the differ-
ence in LI between male and female mice, which reflects the reliability of the protocol. This
finding shows that the methodology was capable of detecting an induction of hepatocyte DNA
synthesis within 48 hours after dosing with test compound, and hence, a defect in the ability of
the methodology to measure hepatic DNA synthesis within this time frame is not the reason be-
hind the failure to detect of induction of DNA synthesis by ciprofibrate within 48 hours. The
consistency between the results in Figure 3.16B, and those of Columbano [207] provides addi-
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tional support to the notion that the labelling protocol yields a reliable measure of hepatocyte
labelling.
The possibility of an off-target effect is an aspect that needed to be considered in clarifying the
failure of ciprofibrate to induce DNA synthesis over two days. It is known that one compound
can have multiple modes of actions and be able to activate completely different signal pathways.
For example, indomethacin is an antagonist of cyclooxygenase activity (COX-1 and COX-2),
and it also binds and activates PPARs D and J [184]. For this reason, the possibility that cipro-
fibrate had an off-target (i.e. non-PPARD mediated) effect that prevented induction of liver
DNA synthesis (whilst leaving intact the liver growth function) was also considered. One way
to address this issue is to use a different PPARD ligand that has previously been shown to induce
hepatic DNA synthesis. MCP was chosen because Styles had shown an early induction in he-
patic DNA synthesis after administration of methylclofenapate (MCP) [113] [164], and it is ad-
ditionally known to be a potent PPARD ligand. In the current study methylclofenapate caused
a hypertrophic response in treated mice, but that no induction in hepatic DNA synthesis follow-
ing treatment for two days (Figure 3.18B). This result confirmed that the potent peroxisome pro-
liferator MCP [96] [97] had similar effects to ciprofibrate, showing that the effects of
ciprofibrate were not unique, and suggests that the absence of induction of hepatic DNA syn-
thesis within two days of dosing is characteristic for PPARD ligands in mice.
The result from these control experiments, confirms that ciprofibrate fails to induce hepatocyte
DNA synthesis within two days after dosing (Figure 3.14A), which was in contrast to our ex-
pectations from the work of Styles [113]. It was therefore essential to define the time frame
wherein DNA synthesis is induced after treatment with ciprofibrate. Five days rather than two
days exposure to a single dose of 300mg kg-1 ciprofibrate was investigated to characterise the
early induction point of DNA synthesis in 129S4/SvJae mice. This dose was chosen because it
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was the dose showing the highest LI (Figure 3.14A). Although there was a 15-fold increase in
labelling index in treated mice five days after administration of 300mg kg-1 ciprofibrate, no he-
patotoxicity was observed (Figure 3.19D). In conclusion, this result confirms that induction of
hepatic DNA synthesis occurred later than 48 hours after dosing.
Section 4.3.2 Characterisation of induction of DNA synthesis by peroxisome prolifer-
ators
Analysis of the time-course of induction of liver DNA synthesis by ciprofibrate in 129S4/SvJae
mice was evaluated in detail. 100mg kg-1day-1ciprofibrate was dosed to male129S4/SvJae mice
for 6 days. This dose was chosen to avoid any hepatotoxicity that could result from the high dose
of ciprofibrate. Although the previous experiment (Figure 3.14) had shown no obvious toxicity
of a single dose of ciprofibrate up to 400 mg kg-1,  ciprofibrate has a hydrophobic (dichlorocy-
clopropyl) side chain, which gives the drug a longer half life (80 hour) [185] [186] and the LD50
for ciprofibrate is ~700mg kg-1. If the mice were given 400mg kg-1 daily, there might be accu-
mulation to frankly toxic concentrations as a result of the repeated dosing; the dose used did not
show any toxicity to the mice. The present study revealed that treatment of mice with ciprofi-
brate caused enlargement of liver in time-dependent manner (Figure 3.21A). This indicate that
there were significant changes occurring in the liver starting after two days of dosing, which saw
the liver:body weight ratio increase 50% after 2 days of dosing with ciprofibrate. However, in-
duction of hepatic replicative DNA synthesis does not synchronize with the liver growth (hy-
pertrophy). This study shows the induction of DNA synthesis (hyperplasia) started at three days
after treatment with ciprofibrate (Figure 3.21). The delayed response of the induction of DNA
synthesis shows that there were different kinetics of liver growth and liver DNA synthesis in
response to PPARD ligands, and begs the question of how these two responses are co-regulated.
Additionally, the delay in response in DNA synthesis does not mean the mouse is not capable
of having a rapid response because administration of TCPOBOP showed a fast response in
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DNA synthesis in mouse. The delay in response by at least 48 hours after the start of dosing 100
mg kg-1 day-1 ciprofibrate is consistent with Ledda-Columbano's work, who reported that in-
duction of labelling index was observed at 3 days of ciprofibrate feeding and was maximal at 4
days [207]. Notably, there was considerable animal to animal variability in LIs exhibited in
treated mice on day 3 and 4 with a coefficient of variation (%CV) of 93% and 71% respectively.
In control mice, hepatic DNA synthesis during the study period is at steady state.
The time course of induction of DNA synthesis was characterised using another peroxisome
proliferator, methylclofenapate to find out if there was a discrepancy in the early time point of
induction of DNA synthesis arising from an idiosyncrasy of ciprofibrate. The compound and the
doses were selected because they were reported to show a high induction of hepatic DNA syn-
thesis in treated mice [113] [164]. Studies reported by Styles, using 25 mg kg-1 MCP in AP
mice, showed marked induction of DNA synthesis in the liver by 24 hours after dosing, using
flow cytometry analysis to quantify replicative DNA synthesis [113]. In the current study, al-
though the liver growth was increased by two days, significant induction of DNA synthesis was
shown to occur no earlier than day 3 (Figure 3.33C). This finding with MCP treatment confirms
that the early induction of DNA synthesis in 129S4/SvJae mice occurred after three days of PPs
dosing, which is consistent with the work of Ledda-Columbano who showed induction began
at 72 hours after feeding CD-1 mice with 0.025% ciprofibrate-supplemented diet [207]. 
In conclusion, the conflict between this work and Styles's work [164] might be attributed to: a)
methodology; b) dose effect or c) strain differences. A possible explanation for the different re-
sults that we have obtained is that they were due to a dose effect and/or a strain difference in
responsiveness to induction of hepatic replicative DNA synthesis induced by peroxisome pro-
liferators rather than methodology. However, the method that is being used in this study was
validated to measure DNA synthesis in 129S4/SvJae mouse liver within 0-48 hours after admin-
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istration of compound (Section 3.3).
Section 4.3.3 Dose response of induction of DNA synthesis by ciprofibrate
Dose is another important factor in determining whether a particular peroxisome proliferator
can affect the stimulation of cell replication in rodent hepatocytes. A dose-response study was
undertaken in order to establish whether there was a dose dependency in the response of mouse
liver to induction of DNA synthesis by the peroxisome proliferator, ciprofibrate. In this study,
we established a lowest observable effect level (LOEL) for the induction of DNA synthesis by
ciprofibrate. The same mouse strain (129S4/SvJae) used in the time course study was gavaged
with 0,1,3,10,30,100 or 200 mg kg-1 day-1 ciprofibrate in corn oil for 3 days, or was gavaged
with 0,10,30,100 mg kg-1 day-1 ciprofibrate for 4 days. We chose the 3 and 4 day time- points
to test dose dependency on the basis these two days showed the earliest time point for induction
of hepatic DNA synthesis. The choice of dose was based upon the dose which we have charac-
terised the DNA synthesis response, which is 100 mg kg-1 day-1 of ciprofibrate, a relatively high
dose. However, it is also known that 10 mg kg-1 day-1 of ciprofibrate was used in a mouse bio-
assay and which causes liver growth (Tim Gray, Sanofi-Aventis, personal communication). It
is not possible to increase the dose of ciprofibrate greatly, as the LD50 is ~700 mg kg-1 (Tim
Gray, Sanofi-Aventis, personal communication), and higher doses would risk non-specific tox-
icity. However, doses as low as 10 mg kg-1 day-1 of ciprofibrate also give rise to liver growth. 
Within the two time frames, ciprofibrate induced hepatomegaly at 10 mg kg-1day-1 and greater
(Figure 3.25A). However, there is a discrimination in induction of DNA synthesis between day
3 and 4. In the four day study, an 8-fold induction with 30 mg kg-1 day-1 was observed in treated
animals indicating the start of a proliferative response to ciprofibrate, whereas 100 mg kg-1 day-
1 ciprofibrate (the lowest observable effect level (LOEL)) showed a proliferative response after
three days dosing (Figure 3.25B). Ciprofibrate was highly carcinogenic in liver at 10 mg kg-
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1day-1 in Swiss mice (Sanofi, personal communication), and so it is of interest to compare this
dose level with our findings. There is the possibility of strain differences in metabolism, but also
the long half-life of ciprofibrate means that the serum level of ciprofibrate would continue to
increase after the four days of dosing in our experiments. Therefore, it is possible that the 10 mg
kg-1day-1 dose level may lead to a mitogenic response in the liver if tested over a longer time
period, but the data confirmed that this dose level definitely leads to a hepatic growth response.
Ciprofibrate was shown to be mitogenic in a dose-related manner in mice treated for four days.
Also, it was shown that 100 mg kg-1day-1 is the optimal dose (of those tested) for inducing DNA
synthesis. Therefore, the failure to detect ciprofibrate-induced hepatic DNA synthesis within
two days (Figure 3.14, 3.21) of dosing is not due to the use of a sub-optimal dose of ciprofibrate.
Section 4.3.4 Strain differences in the induction of DNA synthesis
Mouse strain differences are known to cause significant phenotypic effects (e.g. variation in
susceptibility to liver-tumor induction by genotoxins [114] [115]), but there is little direct evi-
dence of strain differences significantly affecting peroxisome proliferation [11] [3]. Styles
found rapid induction of hepatocyte DNA synthesis by PPARD ligands in Alderley Park (AP)
[113] and heterozygous Snell dwarf mice, which originated on the C57Bl/6J mouse background
[164]. In this study, the induction of liver growth was demonstrated in 129S4/SvJae mice, sug-
gesting that a strain difference might be responsible for the discrepancy from Styles's work. AP
mice are an outbred stock of Swiss origin [187] [188], and so we directly tested in AP mice us-
ing the same dose of the same PPARD ligand described by Styles et al. [113]. Figure 3.36B
shows that the induction of hepatocyte DNA synthesis response is delayed until three/ four days
after administration of MCP in 129S4/SvJae and in AP mice, thus showing no effect of strain
in the response of the mouse to PPARD ligands. Control and treated AP mice demonstrated a
higher liver: body weight ratio and a greater maximal response than 129S4/SvJae mice (Figure
Abdullah Al Kholaifi   Section 4.3.5
Page 122
3.36A). AP mice had a hepatocyte labelling index higher than that of 129S4/ SvJae mice at all
time points (Figure 3.36B). However, because the basal levels of LIs in control mice were high-
er than in 129S4/SvJae mice, AP mice demonstrated a significantly increased LI at day four on-
ly, whereas 129S4/SvJae mice showed a significant increased in LIs at day three and four. The
LI for AP mice was 4-fold higher than the value for the 129S4/SvJae mice at day 4. In addition,
no toxic effect was observed during the dosing of AP mice as demonstrated by the liver marker
enzyme ALT (Figure 3.34B) and body weight (Figure 3.34A). Moreover, unpublished results
from our laboratory showed the kinetics of induction of liver growth and DNA synthesis in
C57BL/6J mice (which the same strain used by Styles [164]) after treatment with ciprofibrate
(Amer, personal communication) were similar to that seen in 129S4/SvJae mice. The findings
in 129S4/SvJae, AP and C57BL/6J mice confirm that strain differences do not affect the kinetics
of induction of liver growth or hepatic DNA synthesis, and are consistent with previous exam-
inations of strain differences in peroxisome proliferation in mice [11] [3], which show minimal
effect due to the strain. Thus, we have been unable to replicate the results of Styles in the AP
mouse strain; while it is possible that the AP mice, being outbred, may have undergone strain
drift, the C57BL/6J mice are inbred, and were unlikely to show significant strain drift. More-
over, the concordance between the results obtained in 129S4/SvJae and AP and mice in our
hands excludes the possibility that the discordance between our data, and those of Styles [113]
[164], arises from mouse strain differences.
Section 4.3.5 PPARD receptor is required for the action of peroxisome proliferators
129S4/SvJae mice were chosen as a model in this study due to the availability of a congenic
strain of 129S4/SvJae-PPAR tm1Gonz/tm1Gonz mice, a null allele of the PPARD gene[81], which
is required to test whether the action of peroxisome proliferators is mediated by the PPARD. The
hypothesis that the effects of a specific peroxisome proliferator were mediated by the PPARD
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was tested with 100 mg kg-1 day-1 ciprofibrate for 2 and 6 days. This experiment showed no
induction in liver growth or hepatic DNA synthesis occurred in ciprofibrate-treated PPARD null
mice, which proves that PPARD is required for mediating the pleiotropic response resulting
from the action of the peroxisome proliferator ciprofibrate (Figure 3.23). This finding extends
published reports [81] [82] by showing that PPARD is required for the early induction of DNA
synthesis in liver and also excludes off-target effects of ciprofibrate as a cause of the DNA syn-
thesis in liver.
Section 4.3.6 Sex differences in the induction of liver growth by ciprofibrate
To complete the characterisation of hepatic DNA synthesis in both sexes of 129S4/SvJae mice,
the study was extended to female mice to find out if there were sex differences in the augmen-
tative liver growth induced by peroxisome proliferators. Several studies have reported that male
rats were more responsive to various effects of fibrates than female rats, including increased liv-
er weight, peroxisome proliferation, and peroxisomal E-oxidation, as well as changes in various
enzyme activities [189] [190] [191] [89] [192] [193]. Furthermore, studies in Sv/129 mice given
the peroxisome proliferator trichloroethylene show that liver growth and peroxisome prolifera-
tion in males is more responsive than in females [88]. However, no information was available
about sex-related differences in the induction of hepatic DNA synthesis by peroxisome prolif-
erators. For this reason, female 129S4 mice were tested with ciprofibrate (100 mg kg-1 day-1) at
the same dose as given to male mice for three and four days. Figure 3.30 showed that liver/body
weight ratio was significantly higher in treated male over treated female mice, which confirm
the published report on Sv/129 mice [88]. In contrast, induction of DNA synthesis by ciprofi-
brate does not show any sex-related differences after three or four days dosing (Figure 3.31). 
Section 4.3.7 Differences between the current protocol and Styles' protocol
Styles [113] [164] reported substantively different kinetics of induction of hepatic DNA synthe-
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sis by PPARD ligand, compared to this study. There were numerous possible variables that
could explain the differences between the experiments of Styles, and this study. However, sys-
tematic investigation of these variables has excluded:
(1) The validity of the DNA labelling methodology (Figure 3.16B). 
(2) Dose of PPARD ligand (ciprofibrate) being either too high, or too low (Figures 3.14A and
3.25B).
(3) Off-target effects of ciprofibrate, as judged by the similar effect of methylclofenapate to cip-
rofibrate, and the absence of effect of ciprofibrate in PPARD null mice.
(4) Strain differences in response, as the same mouse strains used by Styles fails to show an ear-
ly induction of DNA synthesis.
Thus, it is difficult to explain the difference in kinetics of induction of DNA synthesis reported
by Styles [113] [164], and in this study. The principal remaining variable is that this study uses
immunohistochemical detection of incorporated BrdU, whereas Styles detected incorporated
BrdU by isolation of hepatocytes, and flow cytometry of the isolated hepatocytes [194]. The ex-
perimental methodology in this thesis has an internal control (labelling of gut nuclei) to control
for correct dosing of BrdU, and the methodology has been shown to detect high level induction
of hepatic DNA synthesis as reported by other authors (Section 3.3). Immunohistochemical de-
tection of BrdU to detect hepatic DNA synthesis has been independently validated [166], and
the method is specific for hepatocytes as a result of morphologically identifying the cell. More-
over, the method involves few steps that could affect the representation of liver cells (i.e. the
liver is directly fixed, and then embedded), and the method is.in widespread use [195] [196] [46]
[197]. 
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By contrast, flow cytometry requires significant sample processing (Figure 4.1 steps 1-8) prior
to analysis of the BrdU labelling index. Figure 4.1 outlines the flow cytometry protocol used by
Styles for determination of DNA content and S-phase in hepatocytes [194] [113] [164] There
were numerous stages during this protocol which show limited or inadequate controls. For ex-
ample, during liver isolation (step 2), collagenase (747Pg ml-1) is used to isolate liver cells. Col-
lagenase is known to destroy membrane structures [198], and there is no control to determine
whether collagenase treatment differentially recovered the liver cells during the hepatocyte iso-
lation procedure, either between different hepatocyte preparations, or systematically between
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control and treated animals.
For measuring DNA content by flow cytometry, propidium iodide (PI) was used for this purpose
(step 9). Propidium iodide is known to bind to RNA as well as DNA [199]. This fact can over-
estimate the actual level of DNA on the cell. Styles used RNase treatment to get rid of RNA.
Figure 4.1 The flow cytometry protocol.  This protocol outlined the method that has been
used by Styles et al to determine DNA content and S-phase in hepatocyte and analysis by two-param-
eter flow cytometry using an Ortho 2150 Cytofluorograf
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However, it is unclear whether the altered hepatocyte size after treatment with PPARD ligands
would affect the propidium iodide staining used in this methodology, and also there were no
controls to ensure that RNase has degraded the intact RNA, or to determine if there is any
DNAase contamination of the RNAase, which would degrade nuclear DNA. Both such artefacts
could significantly affect the determination of propidium iodide fluorescence, and hence the de-
rived DNA content in the cells. 
Signal-to-noise (S/N) ratio also is another factor that needs to be considered in term of sensitiv-
ity of the method. In Styles's procedure, partial hepatectomy was used as a positive control to
validate the method [194]. However, the data was gated, and the authors did not show the non-
gated signal. Thus it was not possible to determine the signal/noise ratio of Stylesmethod for
detecting the content of DNA in cells, the proportion of the 2n and 4n cells in all cells, or wheth-
er these change between preparations or treatment groups. This is a serious limitation in inter-
preting the results of their positive control experiment that validates the methods ability to
measure DNA synthesis. Moreover, the S/N ratio for detection of BrdU was poor, with a max-
imal 5-fold difference in BrdU signal between labeled and unlabelled cells, and overlapping
BrdU signal between labeled and unlabelled cells. Moreover, the data presentation allows
no analysis of the density of data within different fluorescence, calling into question the reliabil-
ity of the determination of immunofluorescent detection of BrdU in this methodology. This con-
trasts markedly with the high signal-to-noise ratio obtained using immunohistochemistry.
In modern flow cytometry, forward scatter and side scatter profiles are used to differentiate the
cells within heterogeneous population based on size and complexity of the cells. This would
help to eliminate any background noise resulting from non hepatocytes. In Styles' method, flu-
orescence technique was used only to determine the DNA content and S-phase without differ-
entiating the cells based on size. Therefore, non-parenchymal cells were another source of
Abdullah Al Kholaifi   Section 4.3.7
Page 128
interference in hepatocyte estimation, particularly if these show differential recovery between
control and treated animals. 
All of these issues could introduce artefactual error into the determination of the proportion of
labelled hepatocytes by flow cytometry. There are therefore severe difficulties in interpreting
the flow cytometric data, in the absence of adequate control experiments and data to validate the
methodology. Notably, other investigators using the same methodology have reported different
effects on hepatocyte ploidy in rat to those reported by Styles [200] [194], which shows diffi-
culty in reproducing results obtained by this methodology. The concordance between inade-
quate control experimentation and lack of reproducibility provide compelling reasons to believe
that these experiments cannot be relied upon.
The reason for the difference in results remains obscure, but we have excluded the choice of
PPARD ligand, dose, sex and strain differences as possible variables. Further, our results are
consistent with other reports [207], and so we conclude that the induction of hepatocyte DNA
synthesis is delayed until three days after administration of PPARD ligand, and we propose that
the results obtained by Styles are an artefact arising from the cell isolation and flow cytometric
analysis of liver cells.
Polyploidy was investigated to determine whether induction of liver growth by peroxisome pro-
liferators might affect the ploidy status in the liver, and cause divergent results between Styles's
work and this work. Styles et al. [113] hypothesised that induction of liver growth by MCP
caused conversion of some 2x2N cell to 4N in rat and mice by amitotic cytokinesis, and the
DNA synthesis occurred mainly in the 2x2N cell [113]. In contrast, Miller et al (1996) reported
that there was no significant alteration in these cell populations, and DNA synthesis occurred
mainly in 4N cells not in 2x2N [200]. In principle, increasing nuclear ploidy during augmenta-
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tive liver growth either in 4N (amitotic cytokinesis) or in 2x2N (no cytokinesis) would be asso-
ciated with increasing of BrdU-containing hepatocytes. Both techniques, flow cytometry and
immunohistochemistry, are still able to detect the incorporated BrdU during DNA synthesis in
the same sensitivity. Therefore, polyploidy is unlikely to be a reason for the divergence of the
results between Styles' work and this work.
Section 4.3.8 Species differences in the induction of liver growth by ciprofibrate
It would be impossible in the mouse model to define a narrow time period when the immediate
early genes are switched on to signal DNA synthesis, because the DNA synthesis response was
delayed by 72 hours. To identify the switch on/off gene(s), the DNA synthesis response must
be a strong response, and arise rapidly (by ~24 hours) after treatment with peroxisome prolifer-
ator; given that it takes mammalian cells ~20 hours to prepare for DNA synthesis, it follows that
the signalling which gives rise to this process must occur in a synchronous manner in the first
four hours after treatment with compound. Under those circumstances, it would be possible to
identify immediate early genes in the first four hours after treatment which are linked to the
induction of hepatic DNA synthesis. This approach was used to investigate the signalling mech-
anisms during liver regeneration after partial hepatectomy [6] [19]. 
A species differences was also considered as a factor that might control early induction in liver
growth. It is not known whether rats have a different time-course of induction of hepatic DNA
synthesis to mice, but it had been assumed that induction of hepatocyte DNA synthesis by PPA-
RD ligands was similar between mouse and rat [113]. The only paper to undertake a detailed
and contemporaneous comparison of mouse and rat responses is by Styles [113], and we have
been unable to repeat their mouse data. There are some reports that show that induction of he-
patic DNA synthesis by peroxisome proliferators is rapid (~24 hours) in rat, e.g. [201] [200]
[202] [113]. In the current study, F-344/ NHsd rats were used to characterise the time-course of
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induction of hepatocyte DNA synthesis by ciprofibrate. The Fischer F-344 strain was selected
since this strain is an inbred rat characterised by homozygosity in most genetic loci [203]. F-344
rats were dosed with 50mg kg-1day-1 ciprofibrate for 1, 2 and 4 days. No liver injury was ob-
served in the treated rats, as assessed by serum ALT, after dosing with ciprofibrate, demonstrat-
ing that the DNA synthesis is not regenerative (Figure 3.37B). Liver-to-body weight showed an
early induction at day one (Figure 3.38A), and induction of DNA synthesis significantly in-
creased by day 2, demonstrating that induction of DNA synthesis in rat was earlier than mouse
(Figure 3.38B). However, there was a statistically significant body weight loss in the rats (~ 2-
4%). Therefore, it is difficult to draw an unambiguous conclusion from this experiment, since
the early induction of DNA synthesis may have been affected by the decrease in body weight.
Nonetheless, there was a large and significant induction of hepatocyte DNA synthesis at 48
hours after dosing, and it is unlikely that this induction of hepatic DNA synthesis is caused by
the loss in body weight. This result has since been confirmed by further work in our lab (A. Am-
er, personal communication), who showed that the induction of DNA synthesis is significantly
increased at 24 hours after dosing. Moreover, the results in the rat study are consistent with pub-
lished work that PPARD ligands cause rapid (ca. 24 hours) induction of DNA synthesis in rat
hepatocytes in vitro [204], and the finding that the PPARD ligands, nafenopin and Wyeth-
14,643, causes induction of hepatic DNA synthesis at 24 hours after dosing in Wistar and Fisher
344 rats, respectively [201] [200]. 
These data therefore show that the Fischer 344 rat shows a much more rapid induction of hepatic
DNA synthesis in response to PPARD ligands in comparison to the mouse. Although there are
reports in the literature of different time courses of induction of hepatic DNA synthesis by PPA-
RD ligands in different species, it is essential to use the same methodology in the same labora-
tory to obtain a reliable comparison of mouse and rat. Our results therefore show a species
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difference between mouse and rat in the kinetics of hepatic response to PPARD ligands.
The delayed response of the mouse to induction of hepatocyte DNA synthesis is reminiscent of
the response to partial hepatectomy, where mouse hepatocyte DNA synthesis commences 12-
16 hours later than in the rat; after partial hepatectomy, it has been shown that the faster re-
sponse of the rat hepatocyte is maintained by an intrinsic program inside the hepatocytes (cell
autonomy) [205]. Weglarz et al. showed that timing and magnitude of DNA synthesis is in-
structed by intrinsic factors within hepatocytes. These factors maintain the species-specific re-
sponse of hepatocytes after partial hepatectomy. Other growth factors such as HGF and TGFD
drive the cell cycle progression and increase hepatocyte turnover, but do not show any signifi-
cant alteration in the timing of cell cycle progression after partial hepatectomy ([15] [205]).
The species difference in response is unlikely to be due to a species difference in the amount of
the PPARD, since the receptor is present at high levels in mouse, compared to other rodents
[101]. Although PPARD is present in both responsive and non-responsive species, the response
of species to Peroxisome proliferators may vary due to the relative level of PPARD present in
the liver [94]. Choudhury et al. examined the level of PPARD in both mouse and guinea pig liv-
er, showing that PPARD in mouse was 10 times higher in mouse, compared to guinea pig. A
study by Palmer et al. (1998) showed that PPARD mRNA was found to be 1 order of magnitude
higher in mouse than that observed in humans [76]. Thus, these studies confirm that the species
differences in the induction DNA synthesis between mouse and rat is not a consequence of low
level of PPARD in mouse liver. 
Section 4.4 Future work in the induction of liver growth by peroxisome 
proliferator
Data presented here characterises the kinetics of induction of DNA synthesis by peroxisome
proliferators, which is important to investigate the mechanism of augmentative liver growth.
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Future work requires the identification of liver cell populations undergoing DNA synthesis
(polyploidisation) by using flow cytometry analysis, or lobular localisation of cells that have un-
dergone DNA synthesis. In addition, the genes and proteins induced by specific peroxisome
proliferators have not been identified. It is essential to set up an experiment to identify the genes
that are induced by peroxisome proliferators that cause hepatic replicative DNA synthesis (i.e.
the regulatory mechanisms involved in liver growth). The DNA synthesis response must be a
strong response, and arise rapidly (by ~24 hours) after treatment with peroxisome proliferator,
then it would be possible to identify immediate early genes in the first four hours after treat-
ment which are linked to the DNA synthesis response by using microarray analysis. I have now
established a model system which has great promise for meeting these criteria.
Abdullah Al Kholaifi   Section 4.4
Page 133
Chapter 5 References
1. Moore, K.L. and A.F. Dalley, Clinically oriented anatomy. 2002, Baltimore, MD: 
Lippincott Williams& Wilins.
2. Dekant, W., Tissue-specific Toxicity: Biochemical mechanisms. 1992: Academic press 
limited.
3. Dwivedi, R.S., et al., Comparison of the peroxisome proliferator-induced pleiotropic 
response in the liver of nine strains of mice. Toxicol Pathol, 1989. 17(1 Pt 1): p. 16-26.
4. Junqueira, L.C., Basic histology. 11th edition ed. 2003.
5. Reddy, J.K. and N.D. Lalwai, Carcinogenesis by hepatic peroxisome proliferators: 
evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit 
Rev Toxicol, 1983. 12(1): p. 1-58.
6. Fausto, N. and E.M. Webber, Control of liver growth. Crit Rev Eukaryot Gene Expr, 
1993. 3(2): p. 117-35.
7. Fausto, N., Liver regeneration. J Hepatol, 2000. 32(1 Suppl): p. 19-31.
8. Timbrell, J., Principles of biochemical toxicology. Third edition ed. 2000: Taylor and 
Francis.
9. Hayes, A.W., Principles and Methods of Toxicology. Fourth edition ed. 2001: Taylor 
and Francis.
10. Michael, H.R., Histology. Fourth ed. 2003.
11. Budroe, J.D., et al., Dose-response relationships of hepatic acyl-CoA oxidase and 
catalase activity and liver mitogenesis induced by the peroxisome proliferator 
ciprofibrate in C57BL/6N and BALB/c mice. Toxicol Appl Pharmacol, 1992. 113(2): p. 
192-8.
12. Health, J.K., Principles of cell proliferation. 2001, Blackwell Science.
13. Lodish, H., et al., Molecular cell biology. 2007, New York: W. H. Freeman and 
company. .
14. Tamura, J., et al., Cell kinetics of regenerating liver after 70% hepatectomy in rats--2-
color flow cytometric analysis. HPB Surg, 1992. 5(2): p. 103-14; discussion 114-5.
15. Fausto, N., J.S. Campbell, and K.J. Riehle, Liver regeneration. Hepatology, 2006. 
43(2): p. S45-S53.
16. Gandillet, A., et al., Hepatocyte ploidy in normal young rat. Comparative Biochemistry 
and Physiology a-Molecular & Integrative Physiology, 2003. 134(3): p. 665-673.
17. Columbano, A. and H. Shinozuka, Liver regeneration .8. Liver regeneration versus 
direct hyperplasia. Faseb Journal, 1996. 10(10): p. 1118-1128.
18. Kountouras, J., P. Boura, and N.J. Lygidakis, Liver regeneration after hepatectomy. 
Hepatogastroenterology, 2001. 48(38): p. 556-62.
19. Taub, R., Liver regeneration: From myth to mechanism. Nature Reviews Molecular 
Cell Biology, 2004. 5(10): p. 836-847.
20. Leddacolumbano, G.M., et al., Compensatory Regeneration, Mitogen-Induced Liver 
Growth, and Multistage Chemical Carcinogenesis. Environmental Health 
Perspectives, 1993. 101: p. 163-168.
21. Michalopoulos, G.K. and M. DeFrances, Liver regeneration. Adv Biochem Eng 
Biotechnol, 2005. 93: p. 101-34.
Abdullah Al Kholaifi   Section 4.4
Page 134
22. Sigal, S.H., et al., Partial hepatectomy-induced polyploidy attenuates hepatocyte 
replication and activates cell aging events. American Journal of Physiology-
Gastrointestinal and Liver Physiology, 1999. 276(5): p. G1260-G1272.
23. Locker, J., et al., A common set of immediate-early response genes in liver 
regeneration and hyperplasia. Hepatology, 2003. 38(2): p. 314-25.
24. Michalopoulos, G.K. and M.C. DeFrances, Liver regeneration. Science, 1997. 
276(5309): p. 60-6.
25. Cornell, R.P., B.L. Liljequist, and K.F. Bartizal, Depressed Liver-Regeneration after 
Partial-Hepatectomy of Germ-Free, Athymic and Lipopolysaccharide-Resistant Mice. 
Hepatology, 1990. 11(6): p. 916-922.
26. Mastellos, D., et al., A novel role of complement: Mice deficient in the fifth component 
of complement (C5) exhibit impaired liver regeneration. Journal of Immunology, 2001. 
166(4): p. 2479-2486.
27. Strey, C.W., et al., The proinflammatory mediators C3a and C5a are essential for liver 
regeneration. Journal of Experimental Medicine, 2003. 198(6): p. 913-923.
28. Maione, D., et al., Coexpression of IL-6 and soluble IL-6R causes nodular regenerative 
hyperplasia and adenomas of the liver. Embo J, 1998. 17(19): p. 5588-97.
29. Nakamura, T., K. Nawa, and A. Ichihara, Partial purification and characterization of 
hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res 
Commun, 1984. 122(3): p. 1450-9.
30. Mead, J.E. and N. Fausto, Transforming growth factor alpha may be a physiological 
regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad 
Sci U S A, 1989. 86(5): p. 1558-62.
31. Su, A.I., et al., Gene expression during the priming phase of liver regeneration after 
partial hepatectomy in mice. Proceedings of the National Academy of Sciences of the 
United States of America, 2002. 99(17): p. 11181-11186.
32. Haber, B.A., et al., The Induction-Patterns of 70 Genes during 9 Days 
Posthepatectomy Define the Temporal Cours of Liver-Regeneration. Gastroenterology, 
1993. 104(4): p. A911-a911.
33. Derynck, R. and Y.E. Zhang, Smad-dependent and Smad-independent pathways in 
TGF-beta family signalling. Nature, 2003. 425(6958): p. 577-584.
34. Deduve, C. and P. Baudhuin, Peroxisomes (Microbodies and Related Particles). 
Physiological Reviews, 1966. 46(2): p. 323-&.
35. Reddy, J.K., Peroxisome proliferators and peroxisome proliferator-activated receptor 
alpha: biotic and xenobiotic sensing. Am J Pathol, 2004. 164(6): p. 2305-21.
36. Lake, B.G., Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs 
and chemicals. Annu Rev Pharmacol Toxicol, 1995. 35: p. 483-507.
37. Singh, I., Biochemistry of peroxisomes in health and disease. Molecular and Cellular 
Biochemistry, 1997. 167(1-2): p. 1-29.
38. Latruffe, N.M., et al., Molecular basis of gene regulation by peroxisome proliferators, 
in Peroxisomes: Biology and Importance in Toxicology and Medicine, G. Gibson and 
B. Lake, Editors. 1993, Taylor and Francis: London. p. 173-203.
39. Reddy, J.K. and T.P. Krishnakantha, Hepatic peroxisome proliferation: induction by 
two novel compounds structurally unrelated to clofibrate. Science, 1975. 190(4216): p. 
787-9.
Abdullah Al Kholaifi   Section 4.4
Page 135
40. Sher, T., et al., cDNA cloning, chromosomal mapping, and functional characterization 
of the human peroxisome proliferator activated receptor. Biochemistry, 1993. 32(21): 
p. 5598-604.
41. Rakitsky, V.N., V.A. Koblyakov, and V.S. Turusov, Nongenotoxic (epigenetic) 
carcinogens: pesticides as an example. A critical review. Teratog Carcinog Mutagen, 
2000. 20(4): p. 229-40.
42. Suga, T., Hepatocarcinogenesis by peroxisome proliferators. J Toxicol Sci, 2004. 
29(1): p. 1-12.
43. Gonzalez, F.J., J.M. Peters, and R.C. Cattley, Mechanism of action of the nongenotoxic 
peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. 
J Natl Cancer Inst, 1998. 90(22): p. 1702-9.
44. Columbano, A., et al., Cell-Proliferation and Promotion of Rat-Liver Carcinogenesis - 
Different Effect of Hepatic Regeneration and Mitogen Induced Hyperplasia on the 
Development of Enzyme-Altered Foci. Carcinogenesis, 1990. 11(5): p. 771-776.
45. Moody, D.E., et al., Peroxisome Proliferation and Nongenotoxic Carcinogenesis - 
Commentary on a Symposium. Fundamental and Applied Toxicology, 1991. 16(2): p. 
233-248.
46. Goldsworthy, T.L., et al., Guidelines for measuring chemically induced cell 
proliferation in specific rodent target organs. Prog Clin Biol Res, 1991. 369: p. 253-
84.
47. Tzameli, I., et al., The xenobiotic compound 1,4-bis[2-(3,5-
dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol 
Cell Biol, 2000. 20(9): p. 2951-8.
48. Honkakoski, P., et al., The nuclear orphan receptor CAR-retinoid X receptor 
heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B 
gene. Mol Cell Biol, 1998. 18(10): p. 5652-8.
49. James, N.H. and R.A. Roberts, Species differences in response to peroxisome 
proliferators correlate in vitro with induction of DNA synthesis rather than 
suppression of apoptosis. Carcinogenesis, 1996. 17(8): p. 1623-32.
50. Ledwith, B.J., et al., Growth regulation by peroxisome proliferators: opposing 
activities in early and late G1. Cancer Res, 1996. 56(14): p. 3257-64.
51. Ashby, J., et al., Mechanistically-based human hazard assessment of peroxisome 
proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol, 1994. 13 Suppl 2: p. 
S1-117.
52. Pitot, H.C., et al., Quantitation of multistage carcinogenesis in rat liver. Toxicol 
Pathol, 1996. 24(1): p. 119-28.
53. Cattley, R.C., et al., Failure of the peroxisome proliferator WY-14,643 to induce 
unscheduled DNA synthesis in rat hepatocytes following in vivo treatment. 
Carcinogenesis, 1988. 9(7): p. 1179-83.
54. Reisenbichler, H. and P.M. Eckl, Genotoxic effects of selected peroxisome 
proliferators. Mutat Res, 1993. 286(2): p. 135-44.
55. Glauert, H.P., et al., Effect of hypolipidemic peroxisome proliferators on unscheduled 
DNA synthesis in cultured hepatocytes and on mutagenesis in Salmonella. Cancer Lett, 
1984. 24(2): p. 147-56.
Abdullah Al Kholaifi   Section 4.4
Page 136
56. Nilsson, R., et al., On the mechanism of the hepatocarcinogenicity of peroxisome 
proliferators. Chem Biol Interact, 1991. 78(2): p. 235-50.
57. Gupta, R.C., et al., 32P-postlabeling analysis of peroxisome proliferator-DNA adduct 
formation in rat liver in vivo and hepatocytes in vitro. Carcinogenesis, 1985. 6(6): p. 
933-6.
58. Olefsky, J.M., Nuclear receptor minireview series. J Biol Chem, 2001. 276(40): p. 
36863-4.
59. Mangelsdorf, D.J., et al., The nuclear receptor superfamily: the second decade. Cell, 
1995. 83(6): p. 835-9.
60. Aranda, A. and A. Pascual, Nuclear hormone receptors and gene expression. Physiol 
Rev, 2001. 81(3): p. 1269-304.
61. Issemann, I. and S. Green, Activation of a member of the steroid hormone receptor 
superfamily by peroxisome proliferators. Nature, 1990. 347(6294): p. 645-50.
62. Sertznig, P., et al., Present concepts and future outlook: function of peroxisome 
proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of 
cancer. J Cell Physiol, 2007. 212(1): p. 1-12.
63. Zhu, Y., et al., Structural organization of mouse peroxisome proliferator-activated 
receptor gamma (mPPAR gamma) gene: alternative promoter use and different 
splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci U S A, 1995. 92(17): 
p. 7921-5.
64. Corton, J.C., P.J. Lapinskas, and F.J. Gonzalez, Central role of PPARalpha in the 
mechanism of action of hepatocarcinogenic peroxisome proliferators. Mutat Res, 
2000. 448(2): p. 139-51.
65. Berger, J. and D.E. Moller, The mechanisms of action of PPARs. Annual Review of 
Medicine, 2002. 53: p. 409-435.
66. Michalik, L., et al., Nuclear hormone receptors and mouse skin homeostasis: 
implication of PPARbeta. Horm Res, 2000. 54(5-6): p. 263-8.
67. Bastie, C., et al., Alterations of peroxisome proliferator-activated receptor delta 
activity affect fatty acid-controlled adipose differentiation. J Biol Chem, 2000. 
275(49): p. 38768-73.
68. Dreyer, C., et al., Control of the peroxisomal beta-oxidation pathway by a novel family 
of nuclear hormone receptors. Cell, 1992. 68(5): p. 879-87.
69. Gottlicher, M., et al., Fatty acids activate a chimera of the clofibric acid-activated 
receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A, 1992. 89(10): p. 
4653-7.
70. Guan, Y., et al., Expression of peroxisome proliferator-activated receptors in urinary 
tract of rabbits and humans. Am J Physiol, 1997. 273(6 Pt 2): p. F1013-22.
71. Rosenfeld, M.G. and C.K. Glass, Coregulator codes of transcriptional regulation by 
nuclear receptors. J Biol Chem, 2001. 276(40): p. 36865-8.
72. Aldridge, T.C., J.D. Tugwood, and S. Green, Identification and Characterization of 
DNA Elements Implicated in the Regulation of Cyp4a1 Transcription. Biochemical 
Journal, 1995. 306: p. 473-479.
73. Tugwood, J.D., et al., The mouse peroxisome proliferator activated receptor 
recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase 
gene. Embo J, 1992. 11(2): p. 433-9.
Abdullah Al Kholaifi   Section 4.4
Page 137
74. Varanasi, U., et al., Identification of a peroxisome proliferator-responsive element 
upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem, 
1996. 271(4): p. 2147-55.
75. Tugwood, J.D., et al., Peroxisome proliferator-activated receptors: structures and 
function. Ann N Y Acad Sci, 1996. 804: p. 252-65.
76. Palmer, C.N., et al., Peroxisome proliferator activated receptor-alpha expression in 
human liver. Mol Pharmacol, 1998. 53(1): p. 14-22.
77. Bentley, P., et al., Hepatic peroxisome proliferation in rodents and its significance for 
humans. Food Chem Toxicol, 1993. 31(11): p. 857-907.
78. Gonzalez, F.J., Recent update on the PPAR alpha-null mouse. Biochimie, 1997. 79(2-
3): p. 139-44.
79. Holden, P.R. and J.D. Tugwood, Peroxisome proliferator-activated receptor alpha: 
role in rodent liver cancer and species differences. J Mol Endocrinol, 1999. 22(1): p. 1-
8.
80. Takeuchi, S., et al., In vitro screening of 200 pesticides for agonistic activity via mouse 
peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma and 
quantitative analysis of in vivo induction pathway. Toxicol Appl Pharmacol, 2006. 
217(3): p. 235-44.
81. Lee, S.S., et al., Targeted disruption of the alpha isoform of the peroxisome 
proliferator-activated receptor gene in mice results in abolishment of the pleiotropic 
effects of peroxisome proliferators. Mol Cell Biol, 1995. 15(6): p. 3012-22.
82. Peters, J.M., R.C. Cattley, and F.J. Gonzalez, Role of PPAR alpha in the mechanism of 
action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. 
Carcinogenesis, 1997. 18(11): p. 2029-33.
83. Aoyama, T., et al., Altered constitutive expression of fatty acid-metabolizing enzymes 
in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J 
Biol Chem, 1998. 273(10): p. 5678-84.
84. Bosgra, S., W. Mennes, and W. Seinen, Proceedings in uncovering the mechanism 
behind peroxisome proliferator-induced hepatocarcinogenesis. Toxicology, 2005. 
206(3): p. 309-323.
85. Lake, B.G., et al., Dose-related effects of the peroxisome proliferator 
methylclofenapate in rat liver. Environmental Toxicology and Pharmacology, 2002. 
11(3-4): p. 233-242.
86. Barrass, N.C., et al., Comparison of the acute and chronic mitogenic effects of the 
peroxisome proliferators methylclofenapate and clofibric acid in rat liver. 
Carcinogenesis, 1993. 14(7): p. 1451-6.
87. Bieri, F. and J.C. Lhuguenot, Toxicity of peroxisome proliferators. Biochimie, 1993. 
75(3-4): p. 263-8.
88. Nakajima, T., et al., Sex-dependent regulation of hepatic peroxisome proliferation in 
mice by trichloroethylene via peroxisome proliferator-activated receptor alpha 
(PPARalpha). Carcinogenesis, 2000. 21(4): p. 677-82.
89. Kawashima, Y., N. Uy-Yu, and H. Kozuka, Sex-related difference in the inductions by 
perfluoro-octanoic acid of peroxisomal beta-oxidation, microsomal 1-
acylglycerophosphocholine acyltransferase and cytosolic long-chain acyl-CoA 
hydrolase in rat liver. Biochem J, 1989. 261(2): p. 595-600.
Abdullah Al Kholaifi   Section 4.4
Page 138
90. Yamada, J., et al., Characteristics of dehydroepiandrosterone as a peroxisome 
proliferator. Biochim Biophys Acta, 1991. 1092(2): p. 233-43.
91. Conway, J.G., et al., Relationship of oxidative damage to the hepatocarcinogenicity of 
the peroxisome proliferators di(2-ethylhexyl)phthalate and Wy-14,643. 
Carcinogenesis, 1989. 10(3): p. 513-9.
92. Reddy, J.K., et al., Comparison of hepatic peroxisome proliferative effect and its 
implication for hepatocarcinogenicity of phthalate esters, di(2-ethylhexyl) phthalate, 
and di(2-ethylhexyl) adipate with a hypolipidemic drug. Environ Health Perspect, 
1986. 65: p. 317-27.
93. Peters, J.M., C. Cheung, and F.J. Gonzalez, Peroxisome proliferator-activated 
receptor-alpha and liver cancer: where do we stand? J Mol Med, 2005. 83(10): p. 774-
85.
94. Choudhury, A.I., et al., Species differences in peroxisome proliferation; mechanisms 
and relevance. Mutat Res, 2000. 448(2): p. 201-12.
95. Stott, W.T., Chemically-Induced Proliferation of Peroxisomes - Implications for Risk 
Assessment. Regulatory Toxicology and Pharmacology, 1988. 8(2): p. 125-159.
96. Bell, D.R., et al., Localization and differential induction of cytochrome P450IVA and 
acyl-CoA oxidase in rat liver. Biochem J, 1991. 275 ( Pt 1): p. 247-52.
97. Bell, D.R. and C.R. Elcombe, Induction of acyl-CoA oxidase and cytochrome 
P450IVA1 RNA in rat primary hepatocyte culture by peroxisome proliferators. 
Biochem J, 1991. 280 ( Pt 1): p. 249-53.
98. Lake, B.G., et al., Comparative studies on nafenopin-induced hepatic peroxisome 
proliferation in the rat, Syrian hamster, guinea pig, and marmoset. Toxicol Appl 
Pharmacol, 1989. 99(1): p. 148-60.
99. Lake, B.G. and T.J. Gray, Species differences in hepatic peroxisome proliferation. 
Biochem Soc Trans, 1985. 13(5): p. 859-61.
100. Choudhury, A.I., et al., Molecular analysis of peroxisome proliferation in the hamster. 
Toxicol Appl Pharmacol, 2004. 197(1): p. 9-18.
101. Bell, A.R., et al., Molecular basis of non-responsiveness to peroxisome proliferators: 
the guinea-pig PPARalpha is functional and mediates peroxisome proliferator-induced 
hypolipidaemia. Biochem J, 1998. 332 ( Pt 3): p. 689-93.
102. Bell, D.R., et al., Species-specific induction of cytochrome P-450 4A RNAs: PCR 
cloning of partial guinea-pig, human and mouse CYP4A cDNAs. Biochem J, 1993. 294 
( Pt 1): p. 173-80.
103. Cattley, R.C., et al., Do peroxisome proliferating compounds pose a 
hepatocarcinogenic hazard to humans? Regulatory Toxicology and Pharmacology, 
1998. 27(1): p. 47-60.
104. Hasmall, S.C., et al., Species differences in response to diethylhexylphthalate: 
suppression of apoptosis, induction of DNA synthesis and peroxisome proliferator 
activated receptor alpha-mediated gene expression. Arch Toxicol, 2000. 74(2): p. 85-
91.
105. Elcombe, C.R. and A.M. Mitchell, Peroxisome proliferation due to di(2-ethylhexyl) 
phthalate (DEHP): species differences and possible mechanisms. Environ Health 
Perspect, 1986. 70: p. 211-9.
Abdullah Al Kholaifi   Section 4.4
Page 139
106. Elcombe, C.R., et al., Peroxisome proliferators: species differences in response of 
primary hepatocyte cultures. Ann N Y Acad Sci, 1996. 804: p. 628-35.
107. Lake, B.G., et al., Comparative studies on di-(2-ethylhexyl) phthalate-induced hepatic 
peroxisome proliferation in the rat and hamster. Toxicol Appl Pharmacol, 1984. 72(1): 
p. 46-60.
108. Makowska, J.M., G.G. Gibson, and F.W. Bonner, Species differences in ciprofibrate 
induction of hepatic cytochrome P450 4A1 and peroxisome proliferation. J Biochem 
Toxicol, 1992. 7(3): p. 183-91.
109. Lake, B.G., Role of oxidative stress and enhanced cell replication in the 
hepatocarcinogenicity of peroxisome proliferators, in Peroxisome: Biology and 
Importance in Toxicology and Medicine, G.G.a.B. Lake, Editor. 1993, Taylor & 
Francis.
110. Price, R.J., J.G. Evans, and B.G. Lake, Comparison of the effects of nafenopin on 
hepatic peroxisome proliferation and replicative DNA synthesis in the rat and Syrian 
hamster. Food Chem Toxicol, 1992. 30(11): p. 937-44.
111. Lake, B.G., et al., Species differences in hepatic peroxisome proliferation, cell 
replication and transforming growth factor-beta1 gene expression in the rat, Syrian 
hamster and guinea pig. Mutat Res, 2000. 448(2): p. 213-25.
112. Blumcke, S., et al., Influence of fenofibrate on cellular and subcellular liver structure 
in hyperlipidemic patients. Atherosclerosis, 1983. 46(1): p. 105-16.
113. Styles, J.A., et al., A species comparison of acute hyperplasia induced by the 
peroxisome proliferator methylclofenapate: involvement of the binucleated hepatocyte. 
Carcinogenesis, 1988. 9(9): p. 1647-55.
114. Bennett, L.M., P.J. Farnham, and N.R. Drinkwater, Strain-dependent differences in 
DNA synthesis and gene expression in the regenerating livers of CB57BL/6J and C3H/
HeJ mice. Mol Carcinog, 1995. 14(1): p. 46-52.
115. Drinkwater, N.R. and J.J. Ginsler, Genetic control of hepatocarcinogenesis in C57BL/
6J and C3H/HeJ inbred mice. Carcinogenesis, 1986. 7(10): p. 1701-7.
116. Biegel, L.B., et al., Comparison of the effects of Wyeth-14,643 in Crl:CD BR and 
Fisher-344 rats. Fundam Appl Toxicol, 1992. 19(4): p. 590-7.
117. Makowska, J.M., et al., Characterization of the hepatic responses to the short-term 
administration of ciprofibrate in several rat strain. Co-induction of microsomal 
cytochrome P-450 IVA1 and peroxisome proliferation. Biochem Pharmacol, 1990. 
40(5): p. 1083-93.
118. Columbano, A., S. Rajalakshmi, and D.S. Sarma, Requirement of cell proliferation for 
the initiation of liver carcinogenesis as assayed by three different procedures. Cancer 
Res, 1981. 41(6): p. 2079-83.
119. Murry, R.K., Cancer, cancer genes, and growth factors, in Harper's Biochemistry, 
R.K. Murry, Editor. 1996, Appleton and Lange. p. 757-778.
120. Parkin, D.M., et al., Global cancer statistics, 2002. CA Cancer J Clin, 2005. 55(2): p. 
74-108.
121. Chen, X., et al., Gene expression patterns in human liver cancers. Mol Biol Cell, 2002. 
13(6): p. 1929-39.
Abdullah Al Kholaifi   Section 4.4
Page 140
122. Tiribelli, C., et al., Prevalence of hepatocellular carcinoma and relation to cirrhosis: 
comparison of two different cities of the world--Trieste, Italy, and Chiba, Japan. 
Hepatology, 1989. 10(6): p. 998-1002.
123. Clark, K.a., Clinical medicine. Fourth ed. 2001.
124. Saeter, G. and P.O. Seglen, Cell biology of hepatocarcinogenesis. Crit Rev Oncog, 
1990. 1(4): p. 437-66.
125. Lai, C.C., et al., Initiation of hepatocarcinogenesis in infant male B6C3F1 mice by N-
hydroxy-2-aminofluorene or N-hydroxy-2-acetylaminofluorene depends primarily on 
metabolism to N-sulfooxy-2-aminofluorene and formation of DNA-(deoxyguanosin-8-
yl)-2-aminofluorene adducts. Carcinogenesis, 1987. 8(3): p. 471-8.
126. Scherer, E., et al., Quantitative study on foci of altered liver cells induced in the rat by 
a single dose of diethylnitrosamine and partial hepatectomy. J Natl Cancer Inst, 1972. 
49(1): p. 93-106.
127. Saeter, G., et al., 2-Acetylaminofluorene promotion of liver carcinogenesis by a non-
cytotoxic mechanism. Carcinogenesis, 1988. 9(4): p. 581-7.
128. Shirai, T., et al., Different responses to phenobarbital promotion in the development of 
gamma-glutamyltranspeptidase-positive foci in the liver of rats initiated with 
diethylnitrosamine, N-hydroxy-2-acetyl-aminofluorene and aflatoxin B1. Jpn J Cancer 
Res, 1985. 76(1): p. 16-9.
129. Cattley, R.C., et al., Initiator-specific promotion of hepatocarcinogenesis by WY-
14,643 and clofibrate. Carcinogenesis, 1994. 15(8): p. 1763-6.
130. Green, S., The search for molecular mechanisms of non-genotoxic carcinogens. Mutat 
Res, 1991. 248(2): p. 371-4.
131. Rao, M.S., N.D. Lalwani, and J.K. Reddy, Sequential histologic study of rat liver 
during peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]-acetic 
acid (Wy-14,643)-induced carcinogenesis. J Natl Cancer Inst, 1984. 73(4): p. 983-90.
132. Klaunig, J.E., et al., The role of oxidative stress in chemical carcinogenesis. Environ 
Health Perspect, 1998. 106 Suppl 1: p. 289-95.
133. Rao, M.S. and J.K. Reddy, An overview of peroxisome proliferator-induced 
hepatocarcinogenesis. Environ Health Perspect, 1991. 93: p. 205-9.
134. Reddy, J.K. and M.S. Rao, Oxidative DNA damage caused by persistent peroxisome 
proliferation: its role in hepatocarcinogenesis. Mutat Res, 1989. 214(1): p. 63-8.
135. Tamura, H., et al., Long-term effects of peroxisome proliferators on the balance 
between hydrogen peroxide-generating and scavenging capacities in the liver of 
Fischer-344 rats. Toxicology, 1990. 63(2): p. 199-213.
136. Conway, J.G. and J.A. Popp, Effect of the hepatocarcinogenic peroxisome proliferator 
Wy-14,643 in vivo: no increase in ethane exhalation or hepatic conjugated dienes. 
Toxicol Appl Pharmacol, 1995. 135(2): p. 229-36.
137. Kasai, H., et al., Formation of 8-hydroxydeoxyguanosine in liver DNA of rats following 
long-term exposure to a peroxisome proliferator. Cancer Res, 1989. 49(10): p. 2603-5.
138. Takagi, A., Production of 8-hydroxydeoxyguanosine in rodent liver by the 
administration of peroxisome proliferators, in Peroxisome: Biology and Importance in 
Toxicology and Medicine, G. G., Editor. 1993: London. p. 569-594.
Abdullah Al Kholaifi   Section 4.4
Page 141
139. Cattley, R.C. and S.E. Glover, Elevated 8-Hydroxydeoxyguanosine in Hepatic DNA of 
Rats Following Exposure to Peroxisome Proliferators - Relationship to Carcinogenesis 
and Nuclear-Localization. Carcinogenesis, 1993. 14(12): p. 2495-2499.
140. Richter, C., J.W. Park, and B.N. Ames, Normal oxidative damage to mitochondrial and 
nuclear DNA is extensive. Proc Natl Acad Sci U S A, 1988. 85(17): p. 6465-7.
141. Rusyn, I., et al., Expression of base excision repair enzymes in rat and mouse liver is 
induced by peroxisome proliferators and is dependent upon carcinogenic potency. 
Carcinogenesis, 2000. 21(12): p. 2141-5.
142. Tomkinson, A.E. and Z.B. Mackey, Structure and function of mammalian DNA 
ligases. Mutat Res, 1998. 407(1): p. 1-9.
143. Ames, B.N. and L.S. Gold, Too many rodent carcinogens: mitogenesis increases 
mutagenesis. Science, 1990. 249(4972): p. 970-1.
144. Lake, B.G., et al., Comparison of the hepatic effects of nafenopin and WY-14,643 on 
peroxisome proliferation and cell replication in the rat and Syrian hamster. Environ 
Health Perspect, 1993. 101 Suppl 5: p. 241-7.
145. Marsman, D.S., et al., Relationship of hepatic peroxisome proliferation and replicative 
DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-
ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-
14,643) in rats. Cancer Res, 1988. 48(23): p. 6739-44.
146. Wada, N., D.S. Marsman, and J.A. Popp, Dose-related effects of the hepatocarcinogen, 
Wy-14,643, on peroxisomes and cell replication. Fundam Appl Toxicol, 1992. 18(1): p. 
149-54.
147. Parzefall, W., et al., Peroxisome proliferators do not increase DNA synthesis in 
purified rat hepatocytes. Carcinogenesis, 2001. 22(3): p. 519-23.
148. Popp, J.A. and R.C. Cattley, Peroxisome proliferators as initiators and promoters of 
rodent hepatocarcinogenicity, in Peroxisomes: Biology and Importance in Toxicology 
and Medicine, G. Gibson, Editor. 1993, Taylor & Fracis. p. 653-665.
149. Cattley, R.C. and J.A. Popp, Differences between the promoting activities of the 
peroxisome proliferator WY-14,643 and phenobarbital in rat liver. Cancer Res, 1989. 
49(12): p. 3246-51.
150. Rao, M.S., Biological aspects of peroxisome proliferator-induced liver tumours in the 
rat, in Peroxisome: Biology and Importance in Toxicology and Medicine, G. Gibson, 
Editor. 1993, Taylor and Francis: London. p. 513-524.
151. Cattley, R.C., D.S. Marsman, and J.A. Popp, Age-related susceptibility to the 
carcinogenic effect of the peroxisome proliferator WY-14,643 in rat liver. 
Carcinogenesis, 1991. 12(3): p. 469-73.
152. Barnett, Y.A. and C.M. King, An investigation of antioxidant status, DNA repair 
capacity and mutation as a function of age in humans. Mutat Res, 1995. 338(1-6): p. 
115-28.
153. Reddy, J.K. and M.S. Rao, Malignant tumors in rats fed nafenopin, a hepatic 
peroxisome proliferator. J Natl Cancer Inst, 1977. 59(6): p. 1645-50.
154. IARC, Clofibrate. IARC Monogr Eval Carcinog Risks Hum, 1996. 66: p. 391-426.
155. Roberts, R., G. Moffat, and J. Ashby, Exposure to peroxisome proliferators: 
reassessment of the potential carcinogenic hazard. Environ Health Perspect, 2001. 
109(10): p. A462-4.
Abdullah Al Kholaifi   Section 4.4
Page 142
156. Ton, T., Feasibility of administering 5-bromo-2'-deoxyuridine (BrdU) in drinking 
water for labeling S-phase hepatocytes in mice and rats. Toxicology Methods, 1997. 
7(2): p. 123-136.
157. Noguchi, P.D., J.B. Johnson, and W. Browne, Measurement of DNA synthesis by flow 
cytometry. Cytometry, 1981. 1(6): p. 390-3.
158. Kirkwood, F.L. and J.A.C., Essentials of Medical Statistics. 2 ed ed. 2003, Oxford: 
Blackwell Publishing Ltd.
159. Sturgill, M.G. and G.H. Lambert, Xenobiotic-induced hepatotoxicity: mechanisms of 
liver injury and methods of monitoring hepatic function. Clinical Chemistry, 1997. 
43(8): p. 1512-1526.
160. Morris, R.W., Analysis of cell proliferation data. Environ Health Perspect, 1993. 101 
Suppl 5: p. 73-7.
161. Fox, C.H., et al., Formaldehyde fixation. J Histochem Cytochem, 1985. 33(8): p. 845-
53.
162. Hayashi, Y., et al., Effects of Fixation Time and Enzymatic Digestion on 
Immunohistochemical Demonstration of Bromodeoxyuridine in Formalin-Fixed, 
Paraffin-Embedded Tissue. Journal of Histochemistry & Cytochemistry, 1988. 36(5): 
p. 511-514.
163. Reome, J.B., et al., The effects of prolonged administration of 5-bromodeoxyuridine on 
cells of the immune system. Journal of Immunology, 2000. 165(8): p. 4226-4230.
164. Styles, J.A., et al., Effects produced by the non-genotoxic hepatocarcinogen 
methylclofenapate in dwarf mice: peroxisome induction uncoupled from DNA synthesis 
and nuclearity changes. Carcinogenesis, 1990. 11(3): p. 387-91.
165. deFazio, A., et al., Immunohistochemical detection of proliferating cells in vivo. J 
Histochem Cytochem, 1987. 35(5): p. 571-7.
166. Eldridge, S.R., et al., Measurement of chemically induced cell proliferation in rodent 
liver and kidney: a comparison of 5-bromo-2'-deoxyuridine and [3H]thymidine 
administered by injection or osmotic pump. Carcinogenesis, 1990. 11(12): p. 2245-51.
167. Farmilo, A.J. and R.H. Stead, HANDBOOK: Immunochemical Staining Methods. 2001, 
Carpinteria, California: DAKO Corp.
168. Shi, S.R., M.E. Key, and K.L. Kalra, Antigen retrieval in formalin-fixed, paraffin-
embedded tissues: an enhancement method for immunohistochemical staining based on 
microwave oven heating of tissue sections. J Histochem Cytochem, 1991. 39(6): p. 
741-8.
169. Jecker, P., et al., Long-term oral application of 5-bromo-2-deoxyuridine does not 
reliably label proliferating immune cells in the LEW rat. J Histochem Cytochem, 1997. 
45(3): p. 393-401.
170. Kriss, J.P. and L. Revesz, The distribution and fate of bromodeoxyuridine and 
bromodeoxycytidine in the mouse and rat. Cancer Res, 1962. 22: p. 254-65.
171. Taupin, P., BrdU immunohistochemistry for studying adult neurogenesis: Paradigms, 
pitfalls, limitations, and validation. Brain Research Reviews, 2007. 53(1): p. 198-214.
172. Wille, A.C., et al., Cell cycle time and rate of entry of cells into mitosis in the small 
intestine of young rats. Cell Prolif, 2004. 37(2): p. 189-94.
Abdullah Al Kholaifi   Section 4.4
Page 143
173. Miyagawa, M., et al., Measurement of replicative DNA synthesis (RDS) by a 5-bromo-
2'-deoxyuridine (BrdU) labeling technique for detection of hepatocyte proliferation. J 
Vet Med Sci, 1997. 59(1): p. 45-9.
174. Kiel, M.J., et al., Haematopoietic stem cells do not asymmetrically segregate 
chromosomes or retain BrdU. Nature, 2007. 449(7159): p. 238-42.
175. Goldsworthy, T.L., B.E. Butterworth, and R.R. Maronpot, Concepts, Labeling 
Procedures, and Design of Cell-Proliferation Studies Relating to Carcinogenesis. 
Environmental Health Perspectives, 1993. 101: p. 59-65.
176. Hume, W.J. and J. Thompson, Double labeling of cells with tritiated-thymidine and 
bromodeoxyuridine reveals a circadian rhythm-dependent variation in duration of 
dna-synthesis and s-phase flux rates in rodent oral epithelium. Cell and Tissue 
Kinetics, 1990. 23(4): p. 313-323.
177. Feng, C., et al., A potential role for CD69 in thymocyte emigration. Int Immunol, 2002. 
14(6): p. 535-44.
178. Bachmanov, A.A., et al., Food intake, water intake, and drinking spout side preference 
of 28 mouse strains. Behav Genet, 2002. 32(6): p. 435-43.
179. Woods, C.G., et al., WY-14,643-induced cell proliferation and oxidative stress in 
mouse liver are independent of NADPH oxidase. Toxicological Sciences, 2007. 98(2): 
p. 366-374.
180. Bondy, G.S., et al., Retrospective evaluation of serum ornithine carbamyltransferase 
activity as an index of hepatotoxicity in toxicological studies with rats. Toxicol Lett, 
2000. 114(1-3): p. 163-71.
181. Dufour, D.R., et al., Diagnosis and monitoring of hepatic injury. I. Performance 
characteristics of laboratory tests. Clin Chem, 2000. 46(12): p. 2027-49.
182. Otsuka, T., et al., CCl4-induced acute liver injury in mice is inhibited by hepatocyte 
growth factor overexpression but stimulated by NK2 overexpression. FEBS Lett, 2002. 
532(3): p. 391-5.
183. Goll, V., et al., Comparison of the effects of various peroxisome proliferators on 
peroxisomal enzyme activities, DNA synthesis, and apoptosis in rat and human 
hepatocyte cultures. Toxicol Appl Pharmacol, 1999. 160(1): p. 21-32.
184. Lehmann, J.M., et al., Peroxisome proliferator-activated receptors alpha and gamma 
are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol 
Chem, 1997. 272(6): p. 3406-10.
185. Bardot, O., et al., Delayed effects of ciprofibrate on rat liver peroxisomal properties 
and proto-oncogene expression. Biochem Pharmacol, 1995. 50(7): p. 1001-6.
186. Turpin, G. and E. Bruckert, Efficacy and safety of ciprofibrate in 
hyperlipoproteinaemias. Atherosclerosis, 1996. 124 Suppl: p. S83-7.
187. Beck, J.A., et al., Genealogies of mouse inbred strains. Nat Genet, 2000. 24(1): p. 23-5.
188. Chia, R., et al., The origins and uses of mouse outbred stocks. Nat Genet, 2005. 37(11): 
p. 1181-6.
189. Gray, R.H. and F.A. de la Iglesia, Quantitative microscopy comparison of peroxisome 
proliferation by the lipid-regulating agent gemfibrozil in several species. Hepatology, 
1984. 4(3): p. 520-30.
Abdullah Al Kholaifi   Section 4.4
Page 144
190. Hawkins, J.M., et al., The effect of peroxisome proliferators on microsomal, 
peroxisomal, and mitochondrial enzyme activities in the liver and kidney. Drug Metab 
Rev, 1987. 18(4): p. 441-515.
191. Jalouli, M., et al., Sex difference in hepatic peroxisome proliferator-activated receptor 
alpha expression: influence of pituitary and gonadal hormones. Endocrinology, 2003. 
144(1): p. 101-9.
192. Sundseth, S.S. and D.J. Waxman, Sex-dependent expression and clofibrate inducibility 
of cytochrome P450 4A fatty acid omega-hydroxylases. Male specificity of liver and 
kidney CYP4A2 mRNA and tissue-specific regulation by growth hormone and 
testosterone. J Biol Chem, 1992. 267(6): p. 3915-21.
193. Svoboda, D., D. Azarnoff, and J. Reddy, Microbodies in experimentally altered cells. 
II. The relationship of microbody proliferation to endocrine glands. J Cell Biol, 1969. 
40(3): p. 734-46.
194. Styles, J.A., M. Kelly, and C.R. Elcombe, A cytological comparison between 
regeneration, hyperplasia and early neoplasia in the rat liver. Carcinogenesis, 1987. 
8(3): p. 391-9.
195. Alison, M., et al., Liver regeneration: a comparison of in situ hybridization for histone 
mRNA with bromodeoxyuridine labeling for the detection of S-phase cells. J Histochem 
Cytochem, 1994. 42(12): p. 1603-8.
196. Carthew, P., et al., Method for determining whether the number of hepatocytes in rat 
liver is increased after treatment with the peroxisome proliferator gemfibrozil. J Appl 
Toxicol, 1997. 17(1): p. 47-51.
197. Muskhelishvili, L., et al., Evaluation of cell proliferation in rat tissues with BrdU, 
PCNA, Ki-67(MIB-5) immunohistochemistry and in situ hybridization for histone 
mRNA. J Histochem Cytochem, 2003. 51(12): p. 1681-8.
198. Liu, M.L., et al., Collagenase pretreatment and the mitogenic effects of hepatocyte 
growth factor and transforming growth factor-alpha in adult rat liver. Hepatology, 
1994. 19(6): p. 1521-7.
199. Deitch, A.D., H. Law, and R. deVere White, A stable propidium iodide staining 
procedure for flow cytometry. J Histochem Cytochem, 1982. 30(9): p. 967-72.
200. Miller, R.T., et al., The peroxisome proliferators WY-14,643 and methylclofenapate 
induce hepatocyte ploidy alterations and ploidy-specific DNA synthesis in F344 rats. 
Toxicology and Applied Pharmacology, 1996. 138(2): p. 317-323.
201. Menegazzi, M., et al., Liver cell proliferation induced by nafenopin and cyproterone 
acetate is not associated with increases in activation of transcription factors NF-
kappaB and AP-1 or with expression of tumor necrosis factor alpha. Hepatology, 1997. 
25(3): p. 585-92.
202. Styles, J.A., Detection and quantification of ploidy, nuclearity, and DNA synthesis in 
rat hepatocytes after administration of a peroxisome proliferator. Environ Health 
Perspect, 1993. 101 Suppl 5: p. 225-7.
203. Kacew, S. and M.F.W. Festing, Role of rat strain in the differential sensitivity to 
pharmaceutical agents and naturally occurring substances. Journal of Toxicology and 
Environmental Health, 1996. 47(1): p. 1-30.
Abdullah Al Kholaifi   Section 4.4
Page 145
204. Plant, N.J., et al., The coordinate regulation of DNA synthesis and suppression of 
apoptosis is differentially regulated by the liver growth agents, phenobarbital and 
methylclofenapate. Carcinogenesis, 1998. 19(9): p. 1521-7.
205. Weglarz, T.C. and E.P. Sandgren, Timing of hepatocyte entry into DNA synthesis after
partial hepatectomy is cell autonomous. Proc Natl Acad Sci U S A, 2000. 97(23): p.
12595-600.
206. Ledda-Columbano, G.M., et al., Early increase in cyclin-D1 expression and accelerated
entry of mouse hepatocytes into S phase after administration of the mitogen 1, 4-Bis[2-
(3,5-Dichloropyridyloxy)] benzene. Am J Pathol, 2000. 156(1): p. 91-7.
207. Ledda-Columbano, G.M., et al., Sex difference in the proliferative response of mouse
hepatocytes to treatment with the CAR ligand, TCPOBOP. Carcinogenesis, 2003. 24(6):
p. 1059-65.
208. Vanden Heuvel, J.P., Peroxisome proliferator-activated receptors (PPARS) and car-
cinogenesis. Toxicol Sci, 1999. 47(1): p. 1-8.
209. Lopez-Diazguerrero, N.E., et al., Susceptibility of DNA to oxidative stressors in young
and aging mice. Life Sci, 2005. 77(22): p. 2840-54.
210. Kraupp-Grasl, B., et al., Increased susceptibility of aged rats to hepatocarcinogenesis
by the peroxisome proliferator nafenopin and the possible involvement of altered liver
foci occurring spontaneously. Cancer Res, 1991. 51(2): p. 666-71.
211. Schulte-Hermann, R., et al., Enhanced proliferation of putative preneoplastic cells in rat
liver following treatment with the tumor promoters phenobarbital, hexachlorocyclo-
hexane, steroid compounds, and nafenopin. Cancer Res, 1981. 41(6): p. 2556-62.
212. Li, A.C. and W. Palinski, Peroxisome proliferator-activated receptors: how their effects
on macrophages can lead to the development of a new drug therapy against atheroscle-
rosis. Annu Rev Pharmacol Toxicol, 2006. 46: p. 1-39.
